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1.   Introduction and aim of the work. 
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The Ph.d thesis here described concerns the set-up and application of analytical methods for 
studying compounds effective as inhibitors of the advanced glycation end-products (AGEs) and 
advanced lipoxidation end-products (ALEs), as well as antagonists of the receptors of AGEs 
(RAGE). 
AGEs and ALEs represent a quite complex and heterogeneous class of compounds that are formed 
by different mechanisms, by heterogeneous precursors and can be formed either exogenously or 
endogenously as detailed in the chapter 2.2. of the present thesis. 
AGEs represent a class of covalently modified proteins generated by oxidative and non-oxidative 
pathways, involving sugars or their degradation products. The term ALEs includes a variety of 
covalent adducts which are generated by the non-enzymatic reaction of reactive carbonyl species 
(RCS), produced by lipid peroxidation and lipid metabolism, with the nucleophilic residues of 
macromolecules, especially proteins.  
AGEs and ALEs share some common properties, for example, both consist of non-enzymatic, 
covalently modified proteins and oxidative stress is often (although not always) involved in the 
mechanism of their formation. Moreover some AGEs and ALEs have the same structure, since they 
arise from common precursors, as in the case of carboxymethyllysine (CML) which is generated by 
glyoxal, which in turn is formed by both lipid and sugar oxidative degradation 
pathways [1]. 
Besides being considered as reliable biomarkers of oxidative damage, as well as predictors and 
prognostic factors, more recently, AGEs and ALEs have also been recognized as important 
pathogenetic factors of some oxidative based diseases, as supported by the following facts: 1) a 
strict correlation between the amount of AGEs/ALEs in tissues and fluids and disease states has 
been found, in both animal and human subjects; 2) a substantial amount of literature is now 
available reporting the molecular and cellular pathogenic mechanisms for the AGEs/ALEs 
involvement in the onset and progression of different oxidative-based diseases including diabetes 
[2], chronic renal failure [3], cardiovascular diseases [4] and neurological disorders [5]. The 
AGEs/ALEs damaging effect is mediated by different mechanisms, including the dysfunction of 
the proteins undergoing the oxidative modification, protein polymerization, signal transduction, 
immunoresponse and RAGE activation. Some of the biological effects are due to the loss of 
function of the target proteins undergoing the covalent modification, such as in the case of 
extracellular matrix proteins that lose their elastic and mechanical functions when modified as 
AGEs/ALEs and in particular, when cross-links are involved [6]. Other examples of a direct 
damaging effect of AGEs/ALEs can be ascribed to the covalent modification of enzymes and 
receptors that lose their activity due to the covalent modification involving the catalytic or binding 
site, or following a conformational change of the protein structure. Moreover AGEs and ALEs can 
be immunogenic. 
11 
 
Hence AGEs/ALEs are now considered as promising drug targets and a substantial effort is 
dedicated to delve the molecular strategies aimed at preventing, reducing or removing these protein 
oxidation products.  
The different molecular approaches thus far reported can be grouped by considering at which level 
of the damaging AGEs/ALEs cascade they are effective and in particular if they act by inhibiting 
the AGEs/ALEs formation, accelerating their catabolism or blocking their biological effects as 
summarized in Fig.1 and detailed in the chapter 2.4. 
 
 
 
Fig 1.  Molecular strategies to inhibit AGEs/ALEs formation and damaging response. 
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The first level of action, the inhibition of AGEs/ALEs formation, also consists of different 
approaches, which target the different inducers (ROS, metal ions) and intermediate products 
(mainly reactive carbonyl species, RCS) involved in the AGEs/ALEs formation. Antioxidants, 
radical scavengers, metal-ion chelators and reactive carbonyl compounds quenchers  (RCS 
sequestering agents) represent the most promising approaches so far reported for inhibiting 
AGEs/ALEs formation. In some cases, as found both for natural or synthetic compounds, the 
inhibition of AGEs/ALEs formation does not proceed through a single specific mechanism but 
implicates multiple mechanisms, involving at least two of the following ones: antioxidant, radical-
scavenging, metal ion chelation and RCS trapping. The second level of intervention consists of 
accelerating the catabolism of already formed AGEs/ALEs and this can be achieved by potentiating 
the endogenous proteolytic system or by using xenobiotics able to catalytically degrade 
AGEs/ALEs.  
The third level of intervention, which is also the most innovative, consists of blocking the 
biological response of AGEs/ALEs by inhibiting the activation of the RAGE receptors through 
different classes of antagonists. It should be noted that such an approach permits the blocking of 
the damaging effect induced not only by endogenously formed AGEs/ALEs but also by 
exogenously derived AGEs/ALEs.  
In view of a drug discovery program aim to search bioactive compounds, the first step of the 
research program was to set up analytical methods based on high resolution MS strategies able to 
test the efficacy and selectivity of compounds effective as sequestering agents of RCS and also 
acting as RAGE antagonists. The methods so far reported in the literature to test RCS sequestering 
compounds consist to measure the consumption of the aldehydes when incubated with the test 
compounds by a direct spectrophotometric analysis and depending on the aldehyde, the 
derivatization reaction should also be considered. The main limitations of such approach is that it 
cannot be applied to mixtures or extracts, it cannot be applied to a high throughput screening and 
in several cases the experimental conditions such as the acid condition of the derivatization 
process can dissociate the adducts between the aldehydes and the sequestering agents.  
Therefore, based on the limits above reported, the initial aim of this research project was focused to 
set-up and then apply suitable analytical methods able to screen novel RCS sequestering agents. 
An HPLC method was firstly set-up in order to measure the consumption of RCS (reactivity) and 
of endogenous carbonyls such as pyridoxal (selectivity) when incubated in presence of the tested 
compounds. The method was optimized in order to use a mobile phase buffered at pH 7.4 in order 
to avoid the acid catalyzed degradation  of the formed adducts. 
The work was then addressed to set-up a rapid and accurate method for testing the ability of RCS 
sequestering agents to inhibit protein carbonylation.  
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Fig 2.  HNE-induced modification on ubiquitin: intact protein analysis. A) Multi-charged spectrum 
for HNE-modified ubiquitin, upon 24 h incubation with HNE (1:50 ubiquitin:Hmolar ratio). B) 
Zoom on the m/z region of the [M+11H]
11+
 peaks corresponding to non-modified and HNE-
modified ubiquitin. C) Quantification of the percentage of modified ubiquitin upon incubation with 
increasing concentration of HNE (equal to 0.1, 0.2, 0.5 and 1 mM, corresponding to 10, 20, 50, 
100-fold excess over ubiquitin concentration, equal to 10 µM). D) Quantification of the percentage 
of modified ubiquitin upon incubation with HNE for 3, 6, 24 and 48 hours (1:50 ubiquitin:HNE 
molar ratio). 
 
To set-up the method, HNE, which is one of the most abundant and reactive lipid-derived RCS, 
was used as RCS, and ubiquitin [8] as a model of protein substrate. Going into details, ubiquitin 
was selected as a protein target since it is commercially available at high purity and at a reasonable 
cost and because its molecular weight is suitable for intact protein analysis using a high resolution 
mass spectrometer such as the Orbitrap. Despite lacking cysteine residues, ubiquitin exposes a set 
of reactive lysines and a highly reactive histidine, which make this protein a suitable benchmark to 
test protein carbonylation and its inhibition. The method was firstly validated by using known RCS 
sequestering agents and the results well correlate with those obtained by HPLC analysis. The 
method was found suitable to test mixtures or extracts and to be used for HTS applications. 
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In the second part of the work, the methods set-up were then applied in view to search effective and 
selective RCS sequestering agents. 
Reactivity towards RCS was evaluated by testing the ability of the tested compound to quench 4-
hydroxy-nonenal (HNE) chosen as a model of alfa,beta-unsaturated aldehydes, glyoxal (GO) and 
methylglyoxal (MGO) as di-carbonyl derivatives. Selectivity was tested by measuring the 
consumption of pyridoxal as an endogenous aldehyde. The method was firstly validated by testing 
the reactivity and selectivity of known RCS scavenger compounds such as edaravone (EDA), 
hydralazine (HY), aminoguanidine (AG), and pyridoxamine (PYR). Even though they are very 
effective as RCS detoxifying agents, their usage is limited due to their lack of selectivity because 
they react with physiological aldehydes such as pyridoxal and by a promiscuous activity: ED is a 
neuroprotective compound, HY an antihypertensive drug and AG a NOS inhibitor. The HPLC 
method was then applied to study the reactivity and selectivity of carnosine (CAR) and derivatives 
such as anserine, n-acetyl carnosine and of carnosine analogues designed to be stable to 
carnosinase, a specific metal-ion dependent homodimeric dipeptidase (carnosinase, CN1 
EC.3.4.13.20),.  
The screening permitted to identify carnosinol, a carnosine peptidomimetic characterized by the 
replacement of the carboxyl group with a hydroxyl group, as a selective and reactive RCS 
sequestering agent, characterized by a suitable PK profile since resistant to serum carnosinase and 
recognized by HPEPT1 (patent application: WO2011080139). 
 
 
Fig 3.  Metabolic description pathway of the Carnosine derivation. 
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Beside evaluating the reactivity and the selectivity, the approach was then implemented by an ESI-
MS approach aimed to fully characterize the covalent adducts between RCS and the sequestering 
agents. The investigation of the mechanisms of carbonyl quenching  have so ensued a broad 
understanding of the biochemical mechanisms  in vitro as well as in vivo that occur between 
cytotoxic RCS and the "sweepers" detoxifying agents. 
The method was then applied to test the RCS sequestering activity of proteinogenic histidine-
containing dipeptides with the C-terminus capped by a methyl ester or by a primary amido group so 
as to study dipeptides which should be still recognized by peptide transporters and resistant to 
proteolysis. Moreover, the study considered diastereoisomeric pairs of dipeptides produced by 
alternating the absolute configuration of the histidine residue thus revealing the effect of 
configuration on the quenching activity. 
AGEs and most probably ALEs are ligands and activators of the receptor RAGE whose activation 
is involved in a NF-kB pathway, leading to NADPH oxidase activation, oxidative stress and a 
condition of inflammatory and pro-fibrotic response. 
Since the damaging AGEs-RAGE axis has been associated to the onset and/or progression of many 
chronic and degenerative oxidative based disease and in many metabolic disorders, it has been 
recently hypothesized that the AGE-RAGE axis represents a promising drug target. One approach 
to counteract the AGEs-RAGE axis is represented by the design of RAGE antagonists. It should be 
considered that a drug design approach aimed to screen RAGE antagonists firstly requires a reliable 
analytical method able to test the binding affinity of small molecules and the set-up of such a 
method represents the final aim of the present research program that is based on the following 
steps:  
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Fig 4.  Receptor for Advances Glyco/oxidation End Products(RAGE). 
 
 RAGE expression as recombinant protein in E. coli strain ORIGAMI B (DE3) with 
recombinant plasmid pET-15b VC1; 
 Application of the automated loop injection High Resolution Mass Spectrometry (MS) 
method, based on the High Resolution Mass Spectrometry method developed to study the 
Ubiquitin-RCS interaction, to inquire in vitro non-covalent binding relationship between 
low molecular weight AGEs and recombinant RAGE. 
 
The receptor for advanced glycation end products (RAGE) is a type I transmembrane glycoprotein 
of the immunoglobulin superfamily of cell surface receptors. RAGE extracellular portion is 
involved in ligand binding and contains one “V” –type followed by two “C”-type immunoglobulin-
like domains (V-C1-C2 structure). V-C1 domains form an integrated unit whereas C2 domain is 
attached to V-C1 by a flexible linker but is a fully independent unit. 
As a general strategy, we decided to express the V-C1 portion of the extracellular domain of human 
RAGE (sRAGE) as protein target since it is water soluble and involved in the molecular 
recognition and engagement of the AGEs ligands.  
Therefore, V, V-C1 and s-RAGE expression was focused on the recombinant protein expression 
carried out by the protein studies obtained through the E. coli expression system. 
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Despite a greater facility to handling the microorganism, E. coli in contrast to eukaryotic expression 
system, is not capable to perform post-translational modifications, including glycosylation, which are 
instead present in the human RAGE. 
 
Regardless for the lack of this peculiarity, numerous studies reported in literature, indicate that, post-
translational modifications have not significantly effect on the RAGE properties regarding for 
instance the bind activity toward certain ligands and so that, the bacterial E. coli expression system 
represent one of the most used host for the heterologous proteins expression. 
A great advantage by using E.coli is its peculiarity of  secreting the protein of interest  in the 
medium that it can be easily purified in one-step. This advantage  have avoided the use of tags, 
such as the Poly-His, that could affect the property of sRAGE during  high throughput screening of 
libraries of compounds  and making  unnecessary  the removal step by  specific protease 
treatments.  
 
 
Fig 5.  ESI-MS spectrum of recombinant sRAGE. 
 
The high resolution mass spectrometric (ESI-MS) approach in top-down and bottom-up approach  
was then used in order to verify the identity of the protein. Fig. 5, upper panel, shows the multi-
charged ESI-MS spectrum of the recombinant protein and in lower panel is displayed the 
corresponding deconvoluted MS spectrum showing the MW of  24580 Da which is consistent with 
the theoretical one.  
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GSHMAQNITARIGEPLVLKCKGAPKKPPQRLEWKLNTGRTEAWKVLSPQGGGPWDSVAR
VLPNGSLFLPAVGIQDEGIFRCQAMNRNGKETKSNYRVRVYQIPGKPEIVDSASELTAGVP
NKVGTCVSEGSYPAGTLSWHLDGKPLVPNEKGVSVKEQTRRHPETGLFTLQSELMVTPAR
GGDPRPTFSCSFSPGLPRHRALRTAPIQPRVWEPV-PLEEVQLVVE. 
 
Fig 6.  LC-ESI-MS chromatogram of peptides arising from sRAGE digestion by trypsin. 
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The primary sequence was then identified by a bottom-up approach (Fig. 6) consisting to 
enzymatically digest the protein, separate the peptides by reversed phase capillary column. Eluted 
peptides were then sequenced by MS/MS analyses. The primary structure of the protein is reported 
in Fig. 6  corresponding to the predicted sequence on the bases of the designed nucleotide sequence 
of sRAGE. 
 
After having characterized the protein, a MS approach to  study the non covalent binding of RAGE 
with ligands was set-up. The ligand-binding properties of RAGE was studied by a native MS 
method that is suitable to study the non covalent interactions between ligands and recombinant V-
C1. The advantages of  native MS over other methods is that it does not require labeled target or 
ligands, it is characterized by high sensitivity, low sample consumption,  fully automatation  and 
that ligands can be screened as mixture.  
 
The experiments consist in maintaining the concentration of VC1 constant and increasing the 
ligand concentration. The ligands used are well known low molecular weight sRAGE ligands such 
as carboxymethyl lysine (CML) and carboxyethyl lysine (CEL) derived peptide [9]. 
Unmodified peptides were also used as controls. Validation of the method was obtained by 
comparing the Kd values obtained by native MS analysis in respect to the Kd values determined  
from fluorescence titration experiments. The native MS method  was found accurate and suitable  
to test libraries in order to understand the structure requirements for RAGE recognition as well as 
for searching antagonists. 
 
 
Fig 7.  Automatization method flow scheme. 
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2.1. Oxidative stress 
 
Oxidative stress  is often defined as an imbalance of pro-oxidants and antioxidants in favor of the 
latter, through an impairment of the basal red-ox balance in favor of the oxidation reactions. This 
physiopathological imbalance could be triggered by several factors. The starting factors are mainly 
grouped in endogenous and/or exogenous particles. In both cases the disequilibrium condition is 
reached as a result of an increase of the concentration of pro-oxidant species, or the depletion of the 
endogenous antioxidant. 
Chemically, oxidative stress is associate with increased production of oxidizing species or a 
significant decrease in the effectiveness of antioxidant defenses, such as glutathione[1].  
The effects of oxidative stress depend upon the size of these changes, with a cell being able to 
overcome small perturbations and regain its original state. The extent and the reversibility of the 
molecular damages and the adaptation capability of the biological system involved, are the main 
factors which leads up to a restore of the physiological condition. However, more severe oxidative 
stress can cause cell death and even moderate oxidation can trigger apoptosis, while more intense 
stresses may cause necrosis [2].  
The direct consequence of the oxidative stress is a widespread oxidation of the biological substrates 
(DNA, protein, lipids and sugars)through non-physiological reaction mechanism. 
A massive increase of the basal levels of oxidative stress has been associated in the genesis and/or 
progression of many chronic and degenerative disease and in many metabolic disorders. 
Oxidative stress is suspected to be important as above reported in neurodegerative diseases 
including Lou Gehrig‟s disease (ALS), Parkinson‟s disease (PD), Alzheimer‟s disease (AD), and 
Huntington‟s disease, amyotrophic lateral sclerosis (ALS) [3].   
Indirect evidence via monitoring biomarkers such as reactive oxygen species (ROS) ,and reactive 
nitrogen species production, antioxidant defense indicates oxidative damage may be involved in the 
pathogenesis of these diseases,[4;5], while cumulative oxidative stress with disrupted mitochondrial 
respiration and mitochondrial damage are related with AD, PD, and other neurodegenerative 
diseases[6].  
Oxidative stress is thought to be linked to certain cardiovascular diseases (CVD), since oxidation of 
LDL in the vascular endothelium is a precursor of plaque formation [7].  Oxidative stress also plays 
a role in the ischemic cascade due to oxygen reperfusion injury following hypoxia. This cascade 
includes both strokes and heart attacks[8].  
Oxidative stress also contributes to both tissue and organs injury playing important roles in  
the pathophysiology of type 2 diabetes mellitus (T2DM) and as well in the related diseases[9].   
Furthermore, is it well known the close correlation of oxidative stress and ageing, and it seems 
likely to be involved in several age-related development of cancer. The reactive species produced in 
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oxidative stress can cause direct damage to the DNA and are therefore mutagenic, and it also 
suppress apoptosis and promote proliferation, invasiveness and metastasis[10].    
Up to now it is unclear however, whether the oxidative stress is causal in disease progression or the 
result of the cell death associated with cell dying by necrosis. For instance, if the disease can be 
linked to a prolonged disturbance of redox regulation then oxidative stress can be determined as 
causal. In such instances, pharmacological interventions would be optimal when the corresponding 
redox imbalance are still reversible. This, however, requires detailed knowledge on the biochemical 
mechanisms involved. 
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2.1.a.  Reactive Oxygen species(ROS). 
 
Reactive oxygen species (ROS) represent the main molecular inducers and mediators of oxidative 
stress. ROS are reactive compounds generated in cells by both enzymatic and non-enzymatic 
sources[11], and have been implicated in a magnitude of physiological processes including  ageing 
and immune function, as well as in disease initiation or progression. Oxidative stress occurs when 
the rate of ROS generation during normal/aerobic metabolism exceeds the detoxification abilities of 
the cell, and it has been implicated in many chronic and degenerative diseases[12].  
Besides to act as injurious by-product of cellular metabolism, recent evidences indicate that ROS 
are also essential participants in cell signaling and regulation. Although this role for ROS is a 
relatively novel concept in vertebrates, there is a strong evidence of a physiological role for ROS in 
several non mammalian systems[13]. The apparent paradox in the roles of ROS as essential 
biomolecules in the regulation of cell functions and as a toxic by-product of metabolism may be 
addressed, at least in part, to differences in the concentration of ROS produced[14]. This is 
analogous to the effect of nitric oxide(NO), which has both regulatory functions and cytotoxic effect 
depending on the enzymatic source and relative amount of NO generated[15]. NO functions as a 
signaling molecule mediating vasodilation when produced in low concentrations by the constitutive 
isoform on nitric oxide synthase(NOS) in vascular endothelial cells[16] and as a source of highly 
toxic oxidants utilized for microbicidal killing when produced in high concentration by inducible 
NOS in macrophages[17]. Indeed, all phagocytic cells have a well-characterized O2-.generating 
plasma membrane oxidase capable of producing the large amounts of ROS required for its function 
in host defense[18].  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
26 
 
2.1.b.  Chemistry of Endogenous Reactive Oxygen Species. 
 
Reactive oxygen species (ROS) are chemically reactive molecules containing oxygen. ROS are 
formed as a natural byproduct of the normal metabolism of oxygen but very often they are also 
generated by exogenous sources such as ionization radiation or xenobiotic[19].   
Endogenously ROS are produced intracellulary through multiple mechanisms, the major sources 
being mitochondria, peroxisomes, endoplasmic reticulum, and the NADPH oxidase (NOX) complex 
in the membranes[20].      
For instance, in aerobic organisms the energy needed to fuel biological functions is produced in the 
mitochondria via the electron transport chain which require ROS as physiological intermediates. 
Mitochondria convert energy for the cell into an usable form, adenosine triphosphate (ATP) via 
oxidative phosphorylation, involving the transport of protons across the inner mitochondrial 
membrane by means of the electron transport chain. The different intermediates and ATP are 
carried out athwart a series of oxidation-reduction reactions in which the driving force is obtained 
from a great potential reduction. Ordinarily, during these redox passages,  most of the amount of 
oxygen is reduced to water; however, up to 2% of electrons passing through the chain oxygen is 
instead incompletely reduced to give the superoxide radical(.O2-). This intermediate is not highly 
reactive, but can inactivate specific enzymes or acting as trigger of lipid peroxidation in its 
protonate form H02-[21].   
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Fig 1. Major cellular sources of ROS in living cell(Major cellular sources of ROS in living non-
photosynthetic cells. From a review by Novo and Parola, 2008) 
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As above reported several physiological ROS classified as oxygen ions and peroxides can be 
generated to act in many cellular functions in order to allow a correct cellular signaling or to 
maintain a finely balanced homeostasis. Furthermore, the different classes of ROS are generated 
ubiquitously at different concentrations depending of the cell type: 
Some relevant ROS include: 
 
-  The superoxide anion (•O2-), formed through one-electron reduction of O2: 
O2 + e- > •O2- 
 
- Hydrogen peroxide (H2O2), which has no unpaired electrons, and thus it is not a radical as reported 
by Halliwell and coworker in 1991 
It is formed by several metabolic reactions, for instance the dismutation reaction of •O2- catalyzed 
by superoxide dismutase, and which has as intermediate the hydroperoxyl radical: 
•O2- + H+ > HO2. 
2HO2. > H2O2 + O2 
 
- The hydroxyl radical (•OH) that can be formed from either the superoxide anion through the 
Haber-Weiss reaction or from H2O2: 

O2
-
 -+ H2O2 > O2 + HO
- 
+ •OH –  
 
The reactions leading to hydroxyl radicals(•OH), from Hydrogen peroxide (H2O2) and superoxide 
(•O2-) are very slow, but can be catalyzed catalyze by iron. The first step involves the reduction of 
ferric ion in ferrous 
Fe
3+
 + 

O2
-
 > Fe
2+
 + O2 
 
The second step is the Fenton reaction: 
Fe
2+
 + H2O2 > Fe
3+
 + OH
-
 + •OH 
 
Net reaction: 
•O2- + H2O2 > Fe
3+
 + OH
-
 + O2 
 
The reaction is named by Fritz Haber and his student Joseph Joshua Weiss[22].    
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2.1.c.  Endogenous defenses toward ROS. 
 
Enzymatic antioxidants, i.e. superoxide dismutase (SOD), catalase (CAT) and glutathione 
peroxidase (GPX) and  glutatihione S-transferase, (GSH), together with antioxidant, radical 
scavengers and metal-ion chelators represent  the first defense-line toward ROS[23].   
SOD represent the most powerful and immediate line  of defense against oxidative stress at all cells 
exposed to oxygen. Going into details SOD are a class of enzymes that catalyze the dismutation of 
peroxide into oxygen and hydrogen peroxide. In all the mammals, three form of superoxide 
dismutase are present. SOD1, located primally in the cytoplasm, SOD2 in the mitochondria and 
SOD3 at extracellular level. SOD1 and SOD3 contain copper and zinc ions, while SOD2 has 
manganese ion in its reactive center. 
 
M
(n+1)
 – SOD + O2
- 
> Mn
+
 - SOD + O2 
 
- M
(n+)
 – SOD + O2- + 2H
+
 > m
(n+1)
 – SOD + H2O2 
 
Catalase is another enzyme particularly effective. It is concentrated in peroxisome, located next to 
mitochondria, and reacts with the hydrogen peroxide to catalyze the formation of water and oxygen.  
2 H2O2 > 2 H2O + O2 
Glutathione peroxidase reduces hydrogen peroxide by transferring the energy of the reactive 
peroxides to a very small sulfur-containing protein called glutathione. The metal center (selenium) 
in this enzymes act as reactive center, carrying electrons from the peroxide to the glutathione. 
2GSH + H2O2 > GS-SG + 2H2O 
A further class of ubiquitous enzyme called Peroxiredoxins are able to degrade H2O2 in its basic 
non-cytotoxic components, within mitochondria, cytosol, and nucleus. 
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2.2.  Advanced glycoxidation and lipoxidation end products (AGEs and ALEs): an 
overview of their mechanisms of formation. 
 
 
2.2.a.  Protein Carbonylation and Carbonyl Stress. 
 
As previously described ROS can cause specific protein modifications that may lead to a change in 
the activity or function of the oxidized protein. Several major forms of oxidative modifications can 
occur on amino acid residue side chains including carbonylation.  
Carbonylation of proteins is irreversible and irreparable and may alter the conformation of the 
polypeptide chain, determining the partial or total inactivation of proteins[24;25]. 
Hence the  protein carbonylation induces  widespread cellular dysfunctions which can also reflected 
at the tissue level.  The major alterations can be a loss of functional activity, dysfunction of the 
protein folding processes, accumulation of misfolded proteins, inhibition of the ubiquitin-dependent 
proteosomal function, direct inactivation of proteasome, accumulation of oxidized proteins and 
induction of apoptosis and necrosis[26].    
The carbonyl derivatives, grouped in aldehydes and ketones, can act through direct oxidation of  
proteins binding the amino acid side-chains of Pro, Arg, Lys, and Thr. Protein carbonyl derivatives 
can also be generated through oxidative cleavage of proteins, via the a-amidation pathway or 
through oxidation of glutamine side chains, leading to the formation of a peptide in which the N-
terminal amino acid is blocked by an a-ketoacyl derivative. In addition, carbonyl groups may be 
introduced into proteins by secondary reaction of the nucleophilic side chains of Cys, His, and Lys 
residues with reactive carbonyl species (RCS) produced during lipid peroxidation (mainly α,β-
unsaturated aldehydes), or generated as a consequence of the reaction of reducing sugars, such as 
glyoxal (GO) and methylglyoxal (MGO), or their oxidation products (ketoamines, ketoaldehydes, 
deoxyosones) with Lys residues of proteins (glycation and glycoxidation reactions) [27;28;29].    
Most of the biological effects of intermediate RCS are attributed to their capacity to react with the 
nucleophilic sites of proteins, forming Advanced Lipoxidation End Products (ALEs) and Advanced 
Glycation End-Products (AGEs). 
Glycation is a spontaneous reaction recognized as the initial step of a very complex process, the 
Maillard cascade, which involves the formation of several end-stage products responsible for 
protein modification and is catalyzed by oxidative stress and ROS[30;31].   
Protein modification by lipoxidation-derived RCS is little known, although a large body of evidence 
indicates their involvement in physiological ageing as well as in the onset and/or progression of 
several cardiovascular(e.g., atherosclerosis, long-term complications of diabetes) and 
neurodegenerative diseases[32;33;34].   
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.Accumulation in serum of RCS-derived from lipids and carbohydrates and the subsequent protein 
carbonylation have first been defined as „„carbonyl stress‟‟ by Miyata et al[35]. 
The increased protein carbonylation by lipids and carbohydrates in chronic diseases is the result of 
carbonyl overload on metabolic pathways involved in detoxification of RCS[36;37;38].  
This leads to a general increase in steady-state levels of RCS formed by both oxidative and non-
oxidative reactions. In fact, in both diabetes and uremia, not only glycoxidation and lipoxidation 
products are increased, but also the products of reaction of proteins with dicarbonyl compounds 
formed by non-oxidative mechanisms[39].   
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2.2.b.   ALEs: an introduction. 
 
 
 
Fig 2 .  Structure of the most reactive carbonyl species (RCSs) arising from lipoxidation break-
down and prostaglandin metabolism. 
 
The term ALEs (Advanced Lipoxidation End products) includes a variety of adducts and cross-links 
which are generated by the non-enzymatic reaction of RCS produced by lipid peroxidation and the 
lipid metabolism with the nucleophilic sites of macromolecules such as proteins, DNA, and 
aminophospholipids, leading to their irreversible modification[40]. The most studied ALEs are 
those arising from the reaction of RCS break-down products of the lipid peroxidation cascade with 
the nucleophilic residues of proteins, mainly Cys, Lys, His, and Arg residues.  
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As schematized in Fig 2, the RCS arising from the lipid peroxidation cascade are quite 
heterogeneous and can be divided into three main classes, namely :  
 
(1) the α,β-unsaturated aldehydes, including hydroxylated, such as 4-hydroxy-2-nonenal (HNE) and 
4-hydroxy hexenal (HHE), and nonhydroxylated derivatives, nonenal and acrolein (ACR);  
 
(2) di-aldehyde, including the well-known lipid peroxidation by product malondialdehyde (MDA) 
and glyoxal (GO);  
 
3) cheto-aldehyde such as methylglyoxal (MGO), 4-oxo-nonenal (ONE), and the isoketals also 
called levuglandins (LGD2, as exemplified in Figure x) which are gammaketoaldehydes formed via 
the isoprostane pathway of arachidonic acid peroxidation.  
 
The RCS acting as precursor of ALEs, besides including the short-chain carbonyl derivatives 
generated by the break-down of nonenzymatic lipoxidation-derived hydroperoxides, also include 
the oxidized truncated phospholipids, where the electrophilic moiety remains covalently linked to 
the phospholipid[41].    
Examples of phospholipids-based RCS, as reported in Fig.2, include γ-hydroxy-α,β-unsaturated 
aldehyde, γ-keto-α,β-unsaturated aldehyde phospholipid,γ-hydroxy-α,β-unsaturated carboxylic 
phospholipid and γ-keto-α,β-unsaturated carboxylic phospholipid[42]. As in the case of short-chain 
RCS, also the oxidized phospholipids containing electrophilic moieties are able to covalently react 
with the nucleophilic sites of proteins forming Michael adducts or Schiff bases. Although the ALEs 
formed by short-chain RCS have been much more studied in respect to those generated by oxidized 
phospholipid, some protein and peptide targets of oxidized phospholipid have already been 
identified, such as cathepsin B and angiotensin II[43].  
It should be noted that although the chemical reactions of RCS in free form or bound to 
phospholipid are practically the same and mainly based on the formation of Michael adduct or 
Schiff base as below described, the protein targets might be different since the two classes of 
compounds have a quite different lipophilicity and consequently a different cellular distribution. 
The above-mentioned RCS are generated by a common lipid-peroxidation cascade, which can 
involve free polyunsatured fatty acids (PUFAs) or phospholipids. An additional class of RCS able 
to form protein adducts is represented by electrophilic prostaglandin metabolites, which are 
characterized by an α,β-unsaturated carbonyl moiety (cyclopentenone). Among these RCS, it is 
worth mentioning Prostaglandin 2 (PGA2) generated from the dehydration of Prostaglandin E2 
(PGE2) and 15-deoxy- Δ 12,14 -prostaglandin J2 (15d-PGJ2) which is generated as a consequence 
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of dehydration of PGD2, a principal COX-2 product formed in various cells and tissues during the 
inflammatory processes[44,45]. 
It should be stressed that some RCS such as glyoxal and methylglyoxal are generated by the 
oxidative pathways involving both lipids and sugars, thus the corresponding reaction products with 
proteins can be named both as ALEs and AGEs or as EAGLEs (either advanced glycation or 
lipoxidation endproducts). 
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2.2.c.    α,β-unsaturated carbonyls. 
 
2.2.c.1.  Exogenous and endogenous sources. 
 
Regarding the endogenous sources of α,β-unsaturated carbonyls, lipid peroxidation represent the 
major mechanism by which they can be generated in vivo[46;47].    
Lipid peroxidation is initiated by the generation of free radicals close to cellular membranes, which 
represent rich source of PUFAs. Hence, the levels of α,β-unsaturated carbonyls is strictly related to 
radical formation and spontaneously but is one hundred times faster when catalyzed by glutathione-
S-transferases (GSTs) [48].  
Other metabolic reactions can involve the carbonyl function that can be either reduced into alcohol 
or oxidized into acid, involving alcohol dehydrogenase or aldo/keto reductase (AKR) and aldehyde 
dehydrogenase, respectively[49]. 
While HNE (Fig.2), (which is the most abundant and toxicα,β-unsaturated aldehyde and generated 
through the β-cleavage of hydroperoxides from ω-6 PUFAs  containing ω -six chains, such as 
linoleic acid and arachidonic acid [50] is almost exclusively formed endogenously, acrolein (ACR)  
is ubiquitously present in foods and in the environment, which might help understanding of the 
mostly cytotoxic effect of ACR on the one hand and cytotoxic and regulatory effect on the 
other[51;52].  
Acrolein is generated by heat-induced dehydration and decomposition reactions of sugars, lipids, 
and amino acids during food cooking[53;54], but, nonetheless, smoking of tobacco products 
represent the major source of the total human exposure to ACR [54] as demonstrated by the level of 
its main metabolite, namely 3-hydroxypropyl mercapturic acid, in urine of smokers, which is about 
twice than that of non-smokers[55].  
ACR is the strongest electrophilic α,β-unsaturated aldehydes, showing the highest reactivity with 
thiols and amines reacting more than 100 times faster with GSH than HNE. The thiol adducts of 
ACR formed by the same mechanism of reaction of HNE but without the cyclization rearrangement 
are considerably more stable than those formed by other α,β-unsaturated aldehydes with 
dissociation constants 10-10,000 times lower[56]. 
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2.2.c.2.  ALEs formed by α,β-unsaturated carbonyls. 
 
Most of the lipid-derived RCS are characterized by a carbonyl group (a keto or an aldehyde 
function) which is conjugated to a double bond and which regulates the electrophilic reactivity 
toward the nucleophilic moieties.  
In particular, the carbonyl group acts as an electronwithdrawing group, which decreases the 
electron-richness of the conjugated alkene group. The combination of polarizable mobile electrons 
and the electron-withdrawing capacity of the carbonyl group thus creates an area of electron 
deficiency at the alkene β-carbon atom of the α,β-unsaturated carbonyl derivatives[57].  
Hence, the β-carbon atom shows an electrophilic character, which in the case of γ-hydroxylated 
derivatives, such as HNE and HHE is further enhanced by the inductive effect of the vicinal 
hydroxyl group. It covalently reacts with the nucleophilic (electron-rich species) side chains on 
amino acid residues of proteins, such as the thiol group of cysteine, the imidazolic nitrogen of 
histidine, and the epsilon amino group of Lys, forming the corresponding Michael adduct. However, 
although the Michael adducts formed with Cys and His are stable in isolation, Michael adducts to 
Lys ε -amino groups are formed reversibly and can be isolated only following reductive trapping 
with NaBH4[58;59].   
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Fig 3.  General reaction mechanisms of ALEs formation for hydroxylated and nonhydroxylated α,β-
unsaturated aldehydes with specific focus to HNE-derived ALEs. 
 
If the resulting Michael adduct contains an γ-hydroxyaldehyde, it can further react intra-molecularly 
forming cyclic hemiacetals (Fig 3). Another general reaction involving α,β-unsaturated aldehydes 
consists of the reaction of the aldehydic carbonyl group with the primary amino group of Lys or 
with the terminal amino group, forming the corresponding Schiff base. In more detail, the reaction 
starts with the formation of a carbinolamine intermediate that rearranges and loses water to yield a 
Schiff base. 
The Schiff base is a reversible adduct which undergoes a hydrolytic cleavage and hence 
it is more stable when the reaction involves the Lys residues embedded in lipophilic and anhydrous 
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protein pockets. The right side of the figure 10 summarizes the general reaction mechanisms for 
hydroxylate and nonhydroxylated α,β-unsaturated aldehydes. 
The Michael adducts and Schiff bases are the early reaction products of α,β-unsaturated carbonyl 
that for most of the RCS further react and rearrange forming additional reaction products such as 
cross-links and which are specific for each RCS. 
For example, the upper left side of Fig 3 shows that HNE besides forming Michael adduct reaction 
products with His, Cys, and Lys residues as well as Schiff bases with Lys residues, also forms other 
different ALEs, such as the HNE-derived 2-pentylpyrroles and the fluorescent four-electron 
oxidation product, 2-hydroxy-2-pentyl-1,2-dihydropyrrol-3-one iminium[60]. 
HNE, since possessing both an aldehyde and an electrophilic carbon, can form cross-links, 
involving condensation with Lys at carbonyl carbon atom (Schiff base) and the Michael adduct at β 
-carbon atom with nucleophilic residues. As shown in the bottom left side of the figure 3 this adduct 
can then dehydrate yielding the cyclic carbinolamine[61].  
The 4-keto derivative of HNE, 4-oxo-nonenal (ONE, figure 3), has been demonstrated to be a direct 
product of lipid oxidation[62], arising independently and not from oxidation of HNE, and more 
reactive that HNE (it reacts with protein nucleophiles through conjugate addition at a rate 6 – 31 
times faster than does HNE) [63]. 
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Fig 4.  Reaction mechanisms of formation for the ONE-based adducts with nucleophilic sites. 
 
As depicted in Fig 4, ONE forms simple 4-ketoaldehyde Michael adducts by the reaction of C2 and 
C3 with His, Lys, and Cys that can exist as such or undergo ring-closure to furans forming the furan 
derivatives. 
ONE reacts also with the amino group of Lys forming the corresponding Schiff base, which then 
reacts with a second amine moiety at C3, followed by tautomerization and then a second two-
electron autoxidation to give the fluorophore pyrrolium Lys – Lys cross link which is also formed 
by HNE. More recently Zhu and Sayre[64] reported that apparent long-lived Lys adducts with the 
mass expected of a Michael adduct are actually the isomeric 4-ketoamide  which together with Lys-
derived pyrrolinone and Lys–His imidazolylpyrrole cross-links are all major products that form on 
proteins from ONE. 
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Notably, Lys-derived pyrrolinone which is inequilibrium with its corresponding hydroxy pyrrole 
tautomer, can dimerize generating the 2:2 ONE-Lys adduct.  
It should be noted that unlike HNE and other α , β -unsaturated aldehydes, ONE reacts also with 
Arg residues to give stable covalent adducts. Preference for the reaction of amino acid nucleophiles 
with ONE was determined to have the following order: Cys >>His >>Lys >Arg[64].  
 
 
 
Fig 5.  Reaction mechanism of formation for the acrolein-based adducts with nucleophilic sites. 
 
Another well-studied α,β-unsaturated aldehyde is represented by ACR (Fig 5) which has several 
sources other than peroxidation of PUFAs including the metabolism of amino acids, polyamines 
and drugs as well as the environment and food[65].  
Among the α,β-unsaturated aldehydes, ACR is by far the strongest electrophile and therefore shows 
the highest reactivity with protein nucleophiles, the order of reactivity (Cys >His> Lys) being the 
same as that established for HNE. As illustrated in Fig 5 and among these sites, the preferential 
formation of Michael-type adducts on cysteine residues is believed to be the predominant way for 
ACR to exert its reactivity in biological systems. 
Besides a simple Michael adduct, ACR forms additional ALEs as studied by Uchida et al.  
In particular they identified an ACR – lysine adduct, N ε -(3-formyl-3,4-dehydropiperidino) lysine 
(FDP-lysine). The mechanism proposed for FDP-Lys formation involves Michael addition of the 
Lys amino group to the ACR β-carbon atom to give a secondary amine with retention of the 
aldehyde group (Lys-Michael adduct). This intermediate reacts with another ACR molecule via a 
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Michael addition forming an unstable derivative that, after aldol condensation and dehydration, 
gives the FDP-Lys adduct[66]. 
Later Uchida et al. identified another ACR-dependent ALE, the Nε-(3-methylpyridinium)-lysine 
(MP-lysine), resulting from the initial Schiff base formation of ACR with theε-amino group of 
lysine, which further reacts with a second ACR molecule via a Michael addition to generate an 
imine derivative. The subsequent conversion of this imine derivative to the final product (MP-
lysine) requires two oxidation steps and intramolecular cyclization, but its detailed mechanism has 
not yet been clarified[67].  
More recently the same research group, by using a reductive amination-based method, analyzed the 
ACR-specific adducts with a carbonyl function and found that ACR modifcation of the protein 
produced a number of carbonylated amino acids, including an ACR _ histidine adduct. 
On the basis of the chemical and spectroscopic evidence, this adduct was identified as N τ -(3-
propanal) histidine which appeared to be one of the major adducts generated in the oxidized 
LDL[68].  
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2.2.d.  Di-carbonyls. 
 
 
2.2.d.1.  Exogenous and endogenous sources. 
 
In this section the attention is focused on those of malodialdeyde (MDA) and isoketals. 
The former has endogenous sources almost identical to those of α,β -unsaturated carbonyls since its 
main in vivo source is represented by peroxidation of poly unsaturated fatty acids with two or more 
methylene interrupted double bonds[69]. 
Isoketals, also called LGs and isolevuglandins (isoLGs), are formed by the rearrangement of 
endoperoxide intermediates generated through the cyclooxygenase and free radical-induced 
oxidation of arachidonates[70].  
While isoketals are generated almost only endogenously, malondialdeyde can be present in foods 
arising from lipid peroxidation induced by heating. Indeed, it has been found in heated edible oils 
such as sun flower and palm oils and is contained at high levels in many rancid foods[71]. 
 
 
2.2.d.2.  ALEs formed by di-carbonyls. 
 
Different ALEs are generated by the reaction of dicarbonyls (di-aldehydes and cheto-aldehydes) 
with proteins. 
Some of these RCS, such as GO and MGO, besides being generated by a lipid 
oxidation/metabolism, are also formed by different enzymatic and nonenzymatic pathways 
involving sugars and their reactivity and formation of AGEs adducts will be discussed under the 
AGEs section. 
It should firstly be noted that the ability of the dicarbonyls to form stable and irreversible ALEs in 
relatively short periods is due to the presence of both the electron-withdrawing carbonyl groups, the 
chemical reactivity of which is further enhanced by the activation of one carbonyl group on the 
other. Indeed, the presence of only one carbonyl function can only give reversible Schiff bases that 
to be analytically detected require stabilization by a chemical reduction (reductive amination) using, 
for example, sodium borohydride. 
The reaction of the lipid-derived di-carbonyls usually involves the formation of a carbinolamine as 
a first step, followed by different rearrangement reactions leading to, in most cases, heterocylic 
cross-links as in the cases of glyoxal and methylglyoxal. Isoketals is another example of di-
carbonyls forming irreversible ALEs, which include heterocyclic cross-links.  
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Fig 6.  Reaction mechanism of formation for the isoketal-based adducts with nucleophilic sites. 
 
Isoketals are highly reactive γ-ketoaldehydes formed by free radical-mediated lipid peroxidation of 
H2-isoprostanes. 
Unlike the F2-isoprostanes, the biological effect of these products is due to their ability to modify 
proteins rather than through activation of specific receptors[72]. 
Fig 6 reports the reaction of isoketals with the amino group of Lys which is based on the formation 
of a carbinolamine intermediate that is in equilibrium with the corresponding reversible Schiff base 
or the remaining carbonyl of hemiaminal can undergo an intramolecular nucleophilic attack by the 
ε-amino group of a second Lys residue to yield a highly unstable pyrrolidine adduct  which 
undergoes a rapid dehydration to form a pyrrole adduct[73].  
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Fig 7.  Reaction mechanisms of formation for the MDA-based adduct with nucleophilic sites. 
 
Malondialdehyde is often the most abundant individual aldehyde resulting from lipid peroxidation 
and occurs in biological materials in various covalently bound forms[74]. 
As shown in Fig 7 and compared with other RCS, MDA is relatively less reactive at neutral pH and 
this is explained by considering that it enolizes rapidly and then loses a proton at neutral pH 
forming the enolate salt which is stabilized by a conjugated π -bond system. The reactivity of MDA 
is due to the nondissociated enolate (the β-hydroxyacrolein) which is able to react with the ε -amino 
group of Lys forming the semistable N ε -(2-propenal)lysine (N-propenal-Lys).  N-propenal-Lys 
can further react with another molecule of MDA and a molecule of acetaldehyde (derived from 
MDA breakdown) to form a stable fluorescent product containing a dihydropyridine moiety (DHP-
Lys) or with an additional Lys residue to form a Lys – Lys-diimine which would exist as its 
resonance-stabilized enamine[75].  
Thealdehyde side chains on the stable dihydropyridine ringcan further react with Lys residues to 
form a reversible cross-link[76]. 
MDA protein adducts and, in particular, N-propenal-Lys and the dihydropyridine cross-links have 
been more recently characterized by MS approaches and using insulin and albumin as target 
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proteins[77;78]. Beside Lys, MDA reacts with other nucleophilic residues such as Arg, as shown in 
the bottom side of the Fig 7, forming the stable N δ-(2-pirimidyl)-Lornitine[79] and  recently the 
cross-linking of MDA involving Lys and Arg residues, 2-ornithinyl-4-methyl-1,3-imidazole has 
been elucidated by NMR and MS and identified in diabetic patients[80]. 
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2.2.d.3.  AGEs: an introduction. 
 
The browning process, that occurs during food heating, is a well-known phenomenon which 
characterizes several cooked dishes and is caused by the so-called Maillard reaction, a 
nonenzymatic process firstly described by Maillard in 1912 (Louis Camille Maillard, 1878 – 1936) 
[81].  
It generates yellowish-brown colored products and involves a complex series of degradative 
reactions between sugars and proteins, whose chemical mechanisms were first described by Hodge 
40 years later[82].  
For many years, studies on the Maillard reaction were focused on foods and food-like systems 
where it occurs during heating, processing, and storage, and plays key roles in determining color, 
flavor, and nutritional quality. 
Other studies concerned the effects of the Maillard reaction when it occurs in paper, textile, soil, 
and biopharmaceutical products. 
Even though the first glycated protein was discovered by Kunkel and Wallenius in 1955 (a glycated 
HbA1C hemoglobin) [83] increasing attention has been shifted to the human body only in the last 
three decades, namely since the pathological role of in vivo posttranslational protein glycation has 
become clearly evident in all its detrimental consequences. In vivo, the process can occur in tissue 
and body fluids, is usually associated with hyperglycemic pathophysiological conditions, and 
involves the generation of irreversible protein adducts and cross-links known as AGEs.  
In vivo , several disorders appear to be exacerbated by such damaging protein adducts, especially 
when they involve long-lived proteins. A paradigmatic example is offered by collagen[84], the 
glycation of which induces vascular thickening with detrimental consequences including decreased 
elasticity, hypertension, and endothelial dysfunctions, and induces marked accelerating effects on 
disorders such as atherosclerosis, nephropathy, and retinal pathologies[85;86].  
Moreover, glycation can also affect short lived peptides causing detrimental changes in their 
biological functions as demonstrated by the accumulation of glycated insulin in the pancreatic β -
cells of diabetic animal models[87].  
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2.2.d.4  Maillard reaction. 
 
Fig 8.  Major steps in the Maillard reaction of reducing sugars following the well-known Hodge 
scheme. 
 
As shown in Fig 8 and following the well-known Hodge‟s scheme[88], the first step in the Maillard 
reaction involves condensation between a carbonyl group from a reducing sugar (e.g. D-glucose) 
and a primary amino group belonging, for example, to the lysine side chain or to the protein N-
terminus. The condensation yields a carbinolamine intermediate, which dehydrates to give an 
unstable imine adduct which can, in turn, cyclize to generate N-substituted D-glucosylamine (D-
Glucosylamine) [89].  
At physiological pH and room temperature, the imine derivative spontaneously undergoes the acid-
catalyzed Amadori rearrangement (Mario Amadori, 1886 – 1941) and gives the corresponding N-
substituted 1-amino-2-desoxy-2-ketose, which can cyclize yielding very stable derivatives called 
Amadori products which are more stable compared to that of the N-substituted  
D-glucosylamine[90] even though all these products can react with amino acids to produce brown 
melanoidins[91].   
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Formation of the Amadori products is favored at alkaline pH values and in the presence of 
phosphate ions. Despite being relatively stable, the Amadori products can react following two major 
routes. At low pH values, they undergo enolization yielding 1,2-dicarbonyls, which then dehydrate 
to give furfural derivatives[92].  
At higher pH values, enolization produces 2,3-dicarbonyls which then dehydrate to give 
reductones[93].  
These conjugated enediols have a moderate reducing power and can contribute to antioxidant 
activity. In the presence of amino acids they can generate brown melanoidins. 
The cyclization of 2,3 dicarbonyl intermediates can also give furanones and pyranones which 
include important flavor compounds with very low aroma threshold values[94].  
By following different pathways, Amadori products can generate α-dicarbonyls mainly through 
oxidative fission[95] or retro-aldol fragmentation[96], the former being markedly catalyzed by the 
presence of transition metal ions. Sugar fragmentation can also occur via a free radical-based 
mechanism according to the so-called Namiki pathway[97].  
 
 
 
Fig 9.  Relevant molecules involved in Maillard reaction. The first row includes α-dicarbonyls, the 
second row collect cyclization producrs, and the third row shows carbonyl derivatives generated by 
sugar fragmentation. 
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Di-carbonyl compounds are very reactive products and their critical relevance in AGEs generation 
will be discussed in-depth in this introduction. 
Besides di-carbonyls, sugar fragmentation can also generate hydroxyl aldehydes and the 
corresponding oxidized acid analogues as depicted in Fig 9. Di-carbonyl compounds can react with 
amino acids through the so-called Strecker degradation, in which the amino acid is transformed into 
the corresponding aldehyde liberating CO2 and the remaining α-aminocarbonyl compound, which 
can then condense to yield pyrazine derivatives, typical aroma components in heated foods[98].  
The relationship between sugar structure and susceptibility to Maillard reaction has been 
extensively studied both in vivo and in foodstuffs[99]. 
Although in all sugars the cyclic form is thermodynamically favored, the reactivity of 
monosaccharides is directly related to the abundance of their open chain form[100].  
This easily explains why glucose, due to the stability of its pyranose ring, is the least reactive sugar, 
while fructose whose furanosic cyclic form is somewhat less stable is about 7.5-fold more reactive 
than glucose[101].  
Notably, the Maillard reaction can also involve fructose metabolites, such as fructose-6-phosphate 
or glyceraldehyde-3-phosphate, which show an extraordinary reactivity up to 200-fold compared to 
that of glucose. The resulting critical role of fructose in protein glycation leads to the term  
“ fructosylation ”, and the fructose effects are further exacerbated by its widespread diffusion[102].   
Despite its low reactivity, even glucose, which is present in millimolar concentration in several 
tissues, markedly contributes to protein glycation also because it can be converted into fructose via 
the Polyol pathway[103].  Besides the abundance of open chain forms, other factors governing 
susceptibility to the Maillard reaction include the sugar length and the intrinsic reactivity of the 
functional groups. Thus, 
aldoses are more reactive than ketoses, because aldehydes are more accessible and more 
electrophilic than ketones[103].  
Figure 9 illustrates some relevant players involved in the above-described Maillard reaction. The 
first row collects the major α -dicarbonyls including both short-chain derivatives (e.g. glyoxal and 
methylglyoxal) and longer polyol dicarbonyls (e.g. glucosone analogues such as 3-deoxyglucosone 
and 1-deoxyglucosone).  
The second row shows the main cyclization products. Beside the already-mentioned 5-
hydroxymethyl furfural, it is worth mentioning furaneol (2,5-dimethyl-4-hydroxy-3(2H)-furanone) 
[104], which represents an illustrative example of reductones. 
Cyclization of 2,3-dicarbonyls can also afford flavored and colored furanones (e.g. Maple furanone, 
5-Ethyl-3-hydroxy-4-methyl-2(5H)-furanone) [105], pyranones (maltol, 3-Hydroxy-2-methyl-4- 
pyrone) [106], and isomaltol (1-(3-hydroxy-2-furanyl)-ethanone) [107].  
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The last row includes examples of hydroxyl carbonyl compounds arising from sugar fragmentation. 
They include aldehydes (glycolaldehyde, glyceraldehyde, aldol), ketones (aceton, acetoin), and 
oxidized derivatives as in the case of levulinic acid which arises from the acid-catalyzed ring 
opening of the 5-hydroxymethylfurfural[108].  
Notably, the chemical reactivity of these last compounds decreases from left to right. 
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2.2.d.5.  AGEs and their reactive precursors. 
 
AGE formation involves complex sequential and parallel reactions, whose precise mechanism is 
still debated even though at least two main pathways by which AGE can be generated are well 
established[109]. The first route involves irreversible rearrangements of the Amadori products 
following both oxidative and nonoxidative pathways. The second route involves condensation 
between the side-chain of lysine, cysteine and arginine residues, and di-carbonyls, which can be 
generated by enolization of Amadori products as well as by the direct degradation of aldoses and 
ketoses. 
Through multiple mechanisms, a large variety of AGE structures can be generated, some of which 
conserve completely the sugar carbon skeleton even though condensed to form aromatic rings, as in 
the case of crossline, while other AGEs involve oxidative degradation with loss of sugar carbon 
atoms. The analysis of the valence of carbon atoms shows that oxidative reactions are not 
necessarily required in AGE formation and, in some cases, non-oxidative pathways can be involved 
depending also on the considered precursors. For this reason, the term glycation is preferable to 
glycoxidation, which would not be broadly applied to all AGEs. 
Although the following sections are clearly focused on endogenously formed AGEs, the dietary 
intake of food derived AGEs may significantly contribute to the total body AGEs load[110;111]. 
Several AGEs have so far been identified in heated foods, and indeed preclinical and clinical studies 
have demonstrated that an elevated intake of thermally processed foods might induce diabetogenic 
and nephrotoxic effects, low-grade inflammation, enhance oxidative stress, and promote 
atherosclerosis[112].  
Besides the AGEs which are also endogenously generated (e.g., carboxymethyllysine, pyrraline, 
pentosidine) [113;114], some adducts are typically found only in heated foods since they derive by 
thermal degradation of AGEs. A well-known example is represented by furosine(N6-(2-(2-Furanyl-
2-oxoethyl))-L-lysine), which arises from the heating of fuctosyl lysine in weakly acid 
conditions[115].  
Finally, di-carbonyls and AGEs can react with specific residues producing several nitrogen-, 
sulphur-, and oxygen-containing heterocyclic derivatives, which are potent aroma compounds. They 
include alkylpyrazines, oxazoles, oxazolines, tetrahydropyridine, pyrroline, thiazoles, thiazolines, 
and pyrazinones, which are generated at high temperature via Strecker degradation followed by 
decarboxylation and rearrangement reactions[116].  
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2.2.e.  Glyoxal. 
 
 
2.2.e.1.  Exogenous and endogenous sources. 
 
Glyoxal is the smallest dialdehyde and appears as a yellow liquid, which forms hydrates in water 
solution. The hydrates tend spontaneously to condense to yield oligomeric species, the exact 
structures of which remain unclear[117].  
Sources of glyoxal can involve both exogenous and endogenous pathways. The former include 
dietary and environmental sources, while the latter include various metabolic and oxidative 
reactions all of which are able to induce cellular damage[118].  
Environmental sources include all products arising from combustion processes such as cigarette 
smoke and vehicle exhaust, while detectable amounts of glyoxal are also found in soil, groundwater, 
seawater, and sediment[119].   
With regard to endogenous production mechanisms, glyoxal can be essentially generated starting 
from sugars and lipids (plus their metabolites) [120]. Sugars can produce glyoxal through two major 
pathways. The first includes direct autoxidation reactions, which appear to be promoted by the 
presence of phosphates and transition metal ions, although the direct conversion of sugars in glyoxal 
can also involve retroaldol fragmentation[121;122]. 
The second pathway involves the Maillard reaction and occurs via Amadori products, which can be 
transformed into glyoxal by enolization as described above. 
Although sugars are often seen as the main source, glyoxal can also arise from lipid peroxidation. 
Indeed, the nonenzymatic peroxidation of polyunsaturated fatty acids, such as linoleic and linolenic 
acids, generates peroxide intermediates, which then degrade to yield a variety of oxidative products 
including glyoxal[123]. Lastly, ascorbate can also spontaneously hydrolyze into glyoxal through an 
unknown mechanism[124]. Concerning the metabolic fate of glyoxal, the large majority is 
enzymatically converted in glycolate by GSH dependent glyoxalase system, which comprises two 
isozymes differing for tissue and subcellular localization[125]. When GSH is depleted, as happens 
in many oxidative-based disorders, other enzymes including aldehyde reductase, aldose reductase, 
carbonyl reductase, aldehyde dehydrogenase, and 2-oxoaldehyde dehydrogenase can contribute to 
the glyoxal metabolism[126].  
Finally, several lines of evidence have revealed that glyoxal catabolism could be involved in oxalate 
formation as suggested, for example, by studies on diabetics showing that they have increased 
levels of both plasma glyoxal and urinary oxalate[127].  
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2.2.e.2.  Glyoxal-derived AGE. 
 
The remarkable activity of glyoxal is clearly evidenced by the observation that more than 90% of 
glyoxal present in biological matrices is covalently bound to Cys, Lys, and Arg residues thus 
having a key role in protein glycation[128;129].  
 
 
Fig 10.  Schematized pathways for Glyoxal-derived AGEs formation. 
 
As depicted by Figure 10, glyoxal can react with the lysine side chain to yield   
N
ԑ
-(carboxymethyl)lysine(CML) through an aldimine intermediate, and with the cysteine thiol 
group to give an irreversible end product, S-(carboxymethyl)cysteine(CMC), the formation of 
which involves a Cannizzaro-like rearrangement of the corresponding thioacetal intermediate[130]. 
Notably, the single modified CMC amino acid has long been known as a mucolytic agent, and has 
attracted recent interest in the long-term treatment of chronic obstructive pulmonary disease 
(COPD) for its capacity to decrease the adhesion of bacteria to the upper respiratory tract[131].  
Fig 10 shows that the in vivo reactions between the arginine side chain and glyoxal are clearly more 
complex[132], since they involve the formation of two possible dihydroxyimidazolidine 
intermediates: G-DH1, N
δ
-(3,4-dihydroxy-1-imidazolidin-2-yl) (ornithine) and its isomer G-DH2, 
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(5-(4,5-dihydroxy-2-imino-1-imidazolidinyl) (norvaline). Both intermediates can (1) open to give 
the N
7
-(carboxymethyl) arginine(CMA)adduct [133] or (2) dehydrate to yield three different 
imidazolone derivatives, that is, N
δ
-(5-hydro-4-imidazolon-2-yl) ornithine, G-H1, and its isomers 5-
(2-amino-5-hydro-4-imidazolon-1-yl) norvaline G-H2and5-(2-amino-4-hydro-5-imidazolon-1-yl) 
norvaline, G-H3. Among the possible arginine adducts, the dihydroxyimidazolidines, despite acting 
as intermediates, are the most abundant followed by the imidazolones and CMA[133].  
While considering that each protein residue possesses a specific reactivity depending on its 
microenvironment, comparison of the possible adducts of lysine and arginine residues shows that 
the latter are usually more abundant thus emphasizing the greater susceptibility of arginine residues 
in producing AGEs[134].  
Due to its dicarbonyl structure, glyoxal can also react with two lysine or arginine residues yielding 
imidazol cross-linked adducts. As represented in Fig 10, glyoxal can react with two lysine residues 
giving the corresponding glyoxal–lysine dimer (GOLD, 6-{1-[(5S)-5-ammonio-6-oxido-6-
oxohexyl]imidazolium-3-yl}-L-norleucine) whose mechanism of formation is common to the 
corresponding methylglyoxal containing dimer and involves an initial bis lysyl diimine 
intermediate, which reacts with a second glyoxal molecule through a Cannizzaro-type reaction, and, 
after dehydration, condenses to give the final imidazolium dimer[135].  
The cross-linking reaction between arginine, lysine, and glyoxal gives the GODIC product (N6-(2- 
{[(4S)-4-ammonio-5-oxido-5-oxopentyl]amino}-3,5-dihydro-4H-imidazol-4-ylidene)-L-lysine).   
Lastly, two lysine residues can react with glyoxal via Strecker degradation to yield the amide 
adduct, GOLA (N6-(2-{[(5S)-5-ammonio-6-oxido-6-oxohexyl] amino}-2-oxoethyl)-L-lysine) which 
can be derived also through oxidative fragmentation of the Amadori products and which appears to 
be favored with increased glyoxal concentrations[136;137].  
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2.2.e.3.  Exogenous and endogenous sources. 
 
Methylglyoxal, also called pyruvaldehyde or 2-oxopropanal (CH3- CO–CHO or C3H4O2 ), is a 
yellow liquid ubiquitous in living cells and therefore almost all foods contain methylglyoxal, the 
concentration of which is increased by processes such as cooking, fermentation, and prolonged 
storage[138].  
In foods and beverages, the main sources of methylglyoxal are represented by sugars and 
lipids[139].  
Sugars can generate methylglyoxal through retro-aldol reaction or auto-oxidative fragmentation 
and, although these processes are greatly favored by alkaline conditions, they can also occur during 
caramelization by the heating of mono-, oligo-, and polysaccharides[140;141].  
Besides heating processes, also prolonged storage can degrade sugars to generate methylglyoxal 
through a process which is especially favored in foods with a high content of simple 
carbohydrates[142].  
Regarding environmental sources and similarly, combustion processes can generate methylglyoxal, 
as in the case of cigarette smoke, which indeed is one of the major sources of air contamination by 
this toxic dicarbonyl compound[143].  
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Fig 11.  Schematized pathways for MGO formation and catabolism (dotted line indicate 
nonenzymatic MGO formation). 
 
Endogenous sources of methylglyoxal involve manypathways that can be subdivided into enzymatic 
or nonenzymatic reactions[144;145].  As represented by Fig 11, the former includes reactions 
catalyzed by methylglyoxal synthase, cytochrome P450 2E1, myeloperoxidase, and amino oxidase, 
whereas the latter include the spontaneous decomposition of dihydroxyacetone-phosphate, the 
Maillard reaction, the oxidation of acetol, and lipid peroxidation[146]. In more detail, the main 
route leading to methylglyoxal involves the enzymatic or nonenzymatic degradation of the triose 
phosphate intermediates originating from the glycolytic processes[147]. The intermediates include 
glyceraldehyde 3-phosphate and dihydroxyacetone-phosphate, which are in equilibrium due to the 
activity of triosephosphate isomerase[148].  
Thus, dihydroxyacetone-phosphate can yield methylglyoxal by both spontaneous nonenzymatic 
elimination of the phosphate group and by the effect of methylglyoxal synthase, an mammalian 
enzyme system[146;147].  
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Similarly to what was observed during food cooking, methylglyoxal can also derive via the Maillard 
reaction in vivo under physiological conditions. 
Lipids can take part in the methylglyoxal generation through the acetone metabolism[149]. In detail, 
acetonederives from acetoacetate by myeloperoxidase activity and is converted to methylglyoxal by 
the cytochrome P450 2E1 via acetol as intermediate[150].  
Particular pathophysiological conditions, such as ketosisand diabetic ketoacidosis, significantly 
increase methylglyoxal generation from acetone[151].  
Yet again, glycerol resulting from triacylglycerol hydrolysis can be transformed into methylglyoxal 
through the glycerolphosphate intermediate which is produced by a specific glycerol kinase[152].  
Threonine and glycine can also generate methylglyoxal through the aminoacetone 
intermediate[153]. This metabolic pathway is mediated by semi carbazide sensitive amine oxidase 
(SSAO) and appears to be exacerbated in low coenzyme A states[154;155]. 
Different enzymes contribute to methylglyoxal detoxification among which the glyoxalase system, 
aldose reductase (ALR), betaine aldehyde dehydrogenase, and2-oxoaldehyde dehydrogenase play a 
key role[156;157;158]. 
 The above-described glyoxalase system catalyzes the biotransformation of methylglyoxal to D-
lactate, which in turn is converted into pyruvate by D-lactate dehydrogenase. Aldose reductase 
(ALR2,AKR1B1) catalyzes the NADPH-dependent reduction of methylglyoxal into lactalde hyde 
or into acetol when GSH is depleted[159].  
Nonspecific aldehyde dehydrogenases can recognize substrates only in their anhydrate forms 
and thus they cannot detoxify methylglyoxal and other α-oxoaldehydes, which are completely 
hydrated under physiological conditions[160]. However, methylglyoxalis substrate for betaine 
aldehyde dehydrogenase (ALDH9or E3) which indeed contributes to its detoxification[161].  
Moreover, the missing activity of nonspecific aldehyde dehydrogenases is counterbalanced by the 
specific2-oxoaldehyde dehydrogenase (2-ODH) which catalyzes the NAD/NADPH-dependent 
oxidation of methylglyoxal into pyruvate. The enzyme also requires an activator: Vicinal 
aminoalcohols, aminothioles, and glycine were found to act as activators even though the 
physiological activator is still unknown[162]. 
 
 
 
 
 
58 
 
2.2.e.4.  Methylglyoxal-derived AGEs. 
 
It has long been known that methylglyoxal is able to induce irreversible modifications in proteins 
under physiological conditions[163;164].  
 
 
 
Fig 12.  Major pathways for formation of the methylglyoxal-derived AGEs in vivo. 
 
 
The formed adducts can be grouped into fluorescent and non fluorescent products. Specifically and 
as schematize by Fig 12, methylglyoxal reacts primarily with arginine residues yielding cyclic 
imidazolone adducts[165], whose formation mechanism involves firstly the condensation between a 
carbonyl group and the N
7
 guanidino atom to give the corresponding carbinolamine which then 
cyclizes to form the diol intermediates and to yield the final adducts through two successive 
dehydrations[166].  
Depending on the nitrogen atoms involved in the cyclization and on environmental pH value, three 
different adducts are possible, as represented in Figure x, namely Nδ-(5-methyl-4-imidazolon-2-yl)-
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Lornithine (MG-H1), 2-amino-5-(2-amino-5-hydro-5-methyl-4-imidazolon-1-yl)pentanoic acid 
(MG-H2), 2-amino-5-(2-amino-4-hydro-4-methyl-5-imidazolon-1-yl)pentanoic acid (MG-H3).  
 
These three imidazolone adducts are in equilibrium since they can open giving the 
carboxyethylarginine(CEA) adduct which in turn re-cyclizes allowing mutual interconversion 
between the imidazolone adducts[167]. 
Besides the mentioned ring opening, the imidazolone adducts can undergo other reactions as 
depicted by Figure 12. In more detail, they can add a second methylglyoxal molecule yielding either 
THP(N
δ
-(4-carboxy-4,6-dimethyl-5,6-dihydroxy-1,4,5,6-tetrahydropyrimidine-2-yl)-L-ornithine) 
through an open intermediate [168] and a final re-cyclization reaction or argpyrimidine, (N
δ
-(5-
hydroxy-4,6-dimethylpyrimidine-2-yl)-l-ornithine), a fluorescent derivative via decarboxylation and 
dehydration[169]. 
Methylglyoxal can react with lysine residues generating the carboxylethyllysine(CEL) adduct 
through a mechanism, which involves an aldimine intermediate and brings to mind the already 
mentioned pathway for the formation of the nor-analogue carboxymethyl lysine[170].  
As already seen for glyoxal, the aldimine intermediate can react with the arginine guanidine group 
yielding a cyclic intermediate that, after dehydration and rearrangement, produces the final cross-
link imidazol MODIC adduct (2-ammonio-6-({2–[4-ammonio-5-oxido-5-oxopently)amino]-4-
methyl-4,5-dihydro-1H-imidazol-5-ylidene}amino)hexanoate) with an overall mechanism almost 
identical to that described for GODIC formation[171;172].  
Yet again, similarly to what was described for glyoxal, methylglyoxal can react with two lysine 
residues forming an initial diimine intermediate, which then adds a second methylglyoxal molecule 
and, via an intermolecular Cannizzaro-type reaction, yields the final imidazolium MOLD adduct 
(6{1-[(5S)-5-ammonio-6-oxido-6-oxohexyl]-4-methyl- imidazolium-3-yl}-L-norleucine) [173].  
This cross-link reaction occurs more efficiently with methylglyoxal compared to glyoxal and this 
difference is in agreement with the proposed mechanism since the required fragmentation reaction 
is more favorable for methylglyoxal, due to increased relative stability of the leaving group[174]. 
Lastly, methylglyoxal can react with cysteine residues giving reversible hemithioacetal [166] and 
with tryptophan residues yielding βcarboline derivatives, a particularly common reaction during 
prolonged food storage[175;176].  
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2.3.  The receptor for AGEs (RAGE) and its involvement in the inflammation. 
 
Studies of the last decades have demonstrated that the oxidative stress of cells exposed to products 
of glycoxidation is partially due to the stimulation of specific receptors present on cell surface, 
namely RAGE. 
Several lines of evidence have shown a key role of RAGE in many pathologic pathways and that it 
is involved in the inflammatory events involved in different pathological conditions such as 
atherosclerosis[177], severe diabetes complications[178], chronic inflammation[179], 
neurodegenerative disorders such as muscular dystrophy, alzheimer‟s , parkinson‟s[180].   
In healthy animals and humans, the constitutive expression of RAGE in physiological conditions is 
very low in most cell types including smooth muscle cells, endothelial, and neurons and tissues. On 
the contrary, in different disease states but also during embryonic development, elevated levels of 
expression are observed afterwards the receptor engagement. Such changes in RAGE expression 
elicit concurrent increases in the expression of RAGE ligands, which themselves are also disease-
associated[181].  
As before mentioned the receptor expression in increased also during embryonic development 
suggesting that RAGE signaling has an important role during this growth phase[182;183].  
Moreover, several lines of evidence suggest that RAGE is also involved in tissue homeostasis and 
regeneration/repair upon acute injury, and in resolution of inflammation highlighting the fact that 
the activation of the receptor  not only has negative implications[184;185].  
However AGEs accumulation and RAGE overexpression are enhanced  in the presence of 
hyperglycemia and oxidative stress, typical characteristics of diabetes.  
The final effect of RAGE axis hyper-activation includes endothelial dysfunction, activation of 
coagulation, and increase in activity of the renin-angiotensin system as a result ofthe trigger of an 
intracellular pathway ended by the release of many signal transduction that culminates in gene 
expression[186]. 
RAGE activation and the release of second messengers leads the onset of numerous diseases-
correlated characterized primarily by inflammationsuch as diabetes and atherosclerosis that in turn 
lead to overexpression of RAGE[187].  
RAGE-overexpressing diabetic in mice show in fact progressive glomerulosclerosis with renal 
dysfunction, compared with diabetic mice lacking of the RAGE transgene. Diabetic homozygous 
RAGE null mice fail to develop significantly increased mesangial matrix expansion or thickening of 
the glomerular basement membrane. 
Taken together, these findings suggest that the activation of AGE–RAGE axis contributes to the 
expression of VEGF and enhanced attraction/activation of inflammatory cells in the diabetic 
glomerulus, thereby setting the stage for mesangial activation and TGF-beta production[188]. 
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RAGE has also a pro-adipogenic function in senescent pre adipocytes by suppressing p53 function, 
which may contribute to aging-dependent adiposity by glycated, proteins derived from the diet 
and/or chronically dysregulated metabolic conditions such as hyperglycemia[189].  
The receptor for advanced glycation end products (RAGE)  is a multiligand transmembrane receptor 
member of the immunoglobulin (Ig) superfamily of cell surface receptors acting as a pattern 
recognition receptor, able to recognize a common pattern within its different ligands[190;191].  
AGEs represent the first ligand of RAGE to be identified which derive from non-enzymatic 
glycation of proteins and lipids as above described[192]. 
RAGE is a pattern recognition receptor not only for ligands such as Advanced Glycation 
Endproducts (AGE) but also for members of  S100 proteins family[193], the β-amyloid peptide and 
its fibrillar  protein aggregates[194] and the high  mobility group  protein box-1 (HMGB1) [180].   
RAGE ligands do not seem to share much similarity, nonetheless, all of them have a net negative 
charge at neutral pH: S100 proteins are very acidic, AGE modified proteins accumulate negative 
surface charge during their transformation by glycation and oxidation, amyloid β-peptide has a net 
negative charge, and amyloid fibrils expose a regular pattern of negative charges on their surface, 
while HMGB1 contains a highly acidic domain.  
The second common feature is the tendency of most RAGE ligands to oligomerize[195]. The 
hydrophobic regions of the not-charged and lipophilic AGEs also contribute to the RAGE 
engagement. AGEs are negatively charged as the result of the Maillard formation reaction, by 
which reducing sugars or aldehydes. Modify arginines and lysines to produce glycated proteins, 
adding a net negative charge on the proteins at physiological pH. AGE binding to the V region of 
RAGE is initially facilitated by the ionic attraction between the positive charges of RAGE and the 
negative charges of AGE. The binding complex is then stabilized with hydrophobic interaction after 
conformational changes. However, it is not still well understood, which, among the different AGEs 
products so far identified, act as a binder of RAGE, nor whether ALEs, such as HNE or MDA 
protein adducts also bind RAGEs. In fact, with the exception of CML and CEL generated in a 
peptide or protein environment, most of the studies so far reported on RAGE activation by AGEs 
are based on not structurally resolved AGEs which are usually generated by incubating proteins 
(very often albumin) with glucose or fructose or with GO/MG resulting in the formation of a 
different set of glycoxidation products, spanning from either early glycation to cross-linking 
products, depending on the incubation times[196]. 
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2.3.a.  Structure of the receptor for Advanced Glycation Endproducts (RAGE). 
 
RAGE is a type I transmembrane with a variable weight ranging between 45 and 55 kDa depending 
on the different states of glycosylation. Originally, the first isoform of RAGE have been isolated 
from the endothelium of lung cattle and this to mean that the protein is highly conserved and highly 
expressed in all mammals, including humans.  
The Receptor for Advanced Glycation End Products is a transmembrane glycoprotein belonging to 
the receptor protein-activation immunoglobulins superfamily[197]. 
RAGE is encoded by a single gene (AGER) extended in humans for 3080 bp and located on 
chromosome 6, within the class III of the histocompatibility major complex and positioned in the 
proximity of the junction area with the class II. 
Several transcription factors controlled the gene transcription of AGER gene, including the 
multipurpose factors as SP-1, AP-2, NF-kB and NF-IL6. 
At different stage of development is possible to come up against different levels expression of 
RAGE that could be constitutive or inducible depending on the cell type and on the stage of 
development. In fact, while RAGE is constitutively expressed during the embryonic development, 
during the earliest stages of childhood its expression is inhibited with the exception of the lung in 
which AGER keeps the constitutive expression. 
Furthermore, in other cell types, the constitutive expression RAGE is detectable only at very low 
levels in physiological conditions as for example in lymphocytes, endothelial cells, smooth muscle 
cells, phagocytesmononuclear cells, neurons, cardiac myocytes, hepatocytes, bipolar ganglion cells 
of the  retina. The receptor expression can be triggered as a response to high levels of own ligands 
and/or following the activation of its transcription factor by specific signals inducing upregulation. 
The Human-RAGE mature form is composed of 404 amino acids characterizing three different 
functional portions: 
1) starting from the N-terminus it is possible to distinguish, in addition to the signal peptide 
of 22 amino acids, an extensive extracellular domain required for the ligand recognition and for the 
binding activity. The extracellular portion is in turn formed by three subdomains with a highly 
conserved sequence structurally similar to those of Immunoglobulin G and for this reason named 
according to the same nomenclature.  
The first subdomain, domain V (variable), is appointed by the acronym of the letter V which 
indicates the own hypervariability, and also of  two consequential C domains (constants) defined C1 
and C2. 
2) The single transmembrane portion is formed by an α-helix followed by a cytoplasmic domain 
characterized by extreme acidity essential for the signal transduction and distinguished by the loss 
of homologous to any tyrosine or serine / threonine kinases motif. 
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Fig 13.  Schematic representation  of the RAGE protein[198]. 
 
More recently it has been found that at the level of  V domain there are two potential N-
glycosylation sites located  in correspondence of the asparagine residues 25 and 81. 
 
 
Fig 14.  Regulation of human RAGE gene expression and the splice variants[199]. 
 
Three major variants were identified: the known full-length membrane bound form, a novel N-
terminally truncated membrane-bound form, and a novel C-terminally truncated soluble form. The 
first main product is the full-length form anchored to the membrane, ant the other forms are 
represented by the  soluble forms lacking of the transmembrane domain (TMD). The production of 
sRAGE (soluble RAGE portion) can be achieved either by proteolytic  cutting (for instance through  
ADAM10 membrane metalloproteinases) 
 
Soluble RAGE portion (s-RAGE) 
Binding site 
Glycosylation site 1 
Glycosylationsite 2 
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or through the alternative splicing phenomenon and in this case the corresponding product of the 
enzymatic activity takes the name of esRAGE (endogenous secretory RAGE).  
The soluble isoforms include the extracellular domains but not the cytoplasmic and transmembrane 
portions. An additional product resulting to alternative splicing, appointed as DN-RAGE (dominant 
negative RAGE), is characterized by the lack of the intracellular region and hence, even if being 
expressed on the membrane, is not able to transduce  an effective intracellular signal (Figure 14). 
 
 
Fig 15. esRAGE[199]. 
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2.3.b.  The RAGE structure. 
 
The circular dichroism and NMR were used to characterize the secondary and tertiary sRAGE 
structure[200]. Going into the details the soluble isoform of RAGE is mainly composed by β-sheet 
and random coil subunits. In particular, the V-domain, whose folding is homologous to that of the 
V-type domain of immunoglobulins, is composed of seven β-strands linked by six hairpin loops, 
which after assembly, form two complete β-sheets structures.  
The disulfide bridge formation between the cysteine 38 and cysteine 99 allows the connection of the 
two β-sheets acquiescing the β-sandwich structure formation (Fig 16).  
The secondary structure elements were labeled in agreement with the immunoglobulins  
nomenclature in use.  
 
 
Fig 16.  Computational representation of V domain . The α-helix is colored orange. The β-sheets 
are colored in blue (β-sheet 1) and purple (β-sheet 2) and named, by convention, A, B, C, D, E, F 
and G while the six loops are called L1, L2, L3, L4, L5 and L6 starting at the N-terminus[201]. 
 
Compared to the traditional structure of immunoglobulins, however, recent evidence from 
molecular modeling analysis have highlighted at the V domain level , two main differences with 
respect to the reference structure. The first one is represented by an α-helix  structure located after 
L3 (reported in orange in Fig 16) included between Trp72-Ala76 residues and also by  two β-strand 
lost, called C 'and C''. In replacement of these structures take place another region characterize by a 
not defined secondary structure, but forming a long extended loop called L3. All these information 
permit to  extensively describe the structural characteristics of soluble RAGE and are essential to 
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carry out a massive structure comprehension as well as to better understand the relationships 
between the three domains V, C1 and C2[201]. 
In addition to the above results, more detailed experiment based on proteolysis digestions and 
heteronuclear-NMR, permitted to conclude that the C2 domain shows the characteristics of an 
independent and well-folded stable domain, while V and C1 domains do not behave as independent 
domains, forming, instead, a single structural unit.  
In particular the C1 domain appears to be the most unstable domain that in the absence of the V 
domain increase its instability, while the latter, albeit in limited manner, is more stable and even if 
isolated is better structured.  The instability of the C1 domain mentioned above is due to three 
residues located within the domain which (Tyr150, Arg179, Phe186) that usually interact with V 
domain and when  exposed to an aqueous solvent, make C1 particularly unstable. 
Actually, the structural configuration of the VC1 region which joins the domains V and C1 is 
supported by  hydrogen-hydrogen bond and hydrophobic interactions bonds and hydrophobic 
interactions[202;203].   
In more details, the aminoacid Gln119 located into the V domain forms a hydrogen bond 
with the C1 subunit through the residual Tyr150 that in turn interacts with Glu94[204] Regarding  
the hydrophobic interactions between C1 and V, several aminoacids belonging to the lateral chain 
are involved, such as the Pro215 of C1 tied whit Tyr118 of V and also through Tyr150 of C1 and 
Ile91 of V[204].   
Consequently, compared to isolated forms, these two regions strongly are anchored to each other 
thus to be more resistant to the trypsin digestions and also more structurally homogeneous. 
The studies conducted by Dattilo[205] permitted to establish the dividend points of the various 
domains. The V-domain starts with the asparagine 25 and ends with the tyrosine 118 (important to 
notice that the heterologous expression of this region just involves the stretch from alanine 23 to 
proline 121), while the C1 domain starts from glycine 122 to tyrosine 222. 
It can be assumed that the linker between V and C1 domains consist of only one tripeptide (Gln119-
Pro121), because Tyr118 forms a single hydrogen bond which is involved in the β-strand of the V-
domain and in addiction the Gly122 forms an equivalent type of bond with a β-strand of C1 domain. 
Instead, the link jointing C1 domain with C2 result to be longer with respect to the link between C1 
and V, being formed by 14 residues (Ala123-Glu236).  The greater length of this region is in 
agreement with the experimental observations which show high possibility of flexibility between 
C1 and C2. This observation further confirm confirms the complete independence of C1 and V with 
respect of C2. 
 
 
67 
 
 
Fig 17.  Structure of the Tandem VC1 Domains of RAGE (A) Stereo ribbon diagram VC1 with the V 
domain in green and the C1 domain in magenta. The two Ig domains adopt a fixed orientation that 
is stabilized by hydrogen bonds and hydrophobic contacts. 
(B) Topology diagram of VC1 with the strands colored as in (A). The structure of the V domain 
shows it belongs to the I-set of Ig domains, whereas C1 remains in the C1 set. Note that a 
unique parallel b sheet is formed by strands A0 and G0 , which stabilizes the C terminus of the C1 
domain[204]. 
 
 
Fig 18.  Computational representation of the VC1 domain model. The V domain(25-118) is red 
colored, the linker (119-121) in black and the C1 domain (122-222) in blue. The side chains of 
residues of the linker are shown in black, through "wire" representation. The side chains of the 
VresiduesandC1involved in the interaction between the two domains are represented in mode "fill 
space" using the respective colors of the belonging  domains. 
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2.3.c.  AGE-RAGE interaction. 
 
The modular structure of sRAGE confirms that the three extracellular domains do not act 
independently (V, C1 and C2). Despite initial consideration, several lines of evidence have showed 
that during the course of evolution, the Ig-like protein superfamily has developed a scheme that 
includes the assembling of the domains. It follows that each domain cannot be considered as a 
single independent module, but as a multifunctional unit able to responding to a multiple ligands. 
RAGE, in fact, seems to adapt to this paradigm since the various ligands identifies so far appear to 
differently interact with the three individual components of the extracellular portion, although the 
most important link is regarded to be the V-domain[205].  
The V domain is characterized by the presence of a large hydrophobic cavity between the loops L2, 
L3 and L4 and in addition, the molecular surface is entirely covered with positive charges. Within 
this area it is possible to distinguish an area in which these charges are condensed forming a 
cationic center. The residues involved are Lys39, Lys43, Lys44 e l' Arg48 on the loop L2, Lys52 on 
the C-strand, Arg98 on the strand F e Lys104, Arg107 and Lys110 on the loop L6[206].  
 
 
 
Fig 18.   A Distribution of the electrostatic potential on the domain V surface(Blue color indicates a 
positive potential and red a negative one). .B Representation of the V domain molecular surface 
characterized by the hydrophobic cavity (yellow portion). 
 
The positive charges located on the V-domain surface provide an essential support regarding the 
AGE-RAGE interactions. In fact, given that AGE are negatively charged due to the glycation of the 
positive residues of the protein, it can be deduced the essential role of the surface charges in the 
ligand-receptor interactions. Moreover, mutagenesis studies focused on the substitution of the nine 
basic amino acids forming the cationic center with the same number of alanines, allowed to classify 
these residues in two groups: the group 1 residues, in which the amino acids replacement brings 
A B 
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high reduction of the binding ability on AGE-RAGE axis (amino acids located around the 
hydrophobic cavity) and the group 2 in which the amino acids substitution (amino acids located on 
the opposite side with respect to the cavity) causes only a small effect on the binding capacity[206].  
 
 
 
Fig 19.  CPK representation of the replaced residues with alanine in site-specific mutagenesis 
studies. B Arrangement of the substituted residues with respect to the hydrophobic cavity. Residues 
belonging to the group 1 and2 are respectively yellow and blue colored. The side chain forming the 
hydrophobic cavity are showed in orange, while the two potential sites of N-glycosilation are 
pointed out in purple. 
 
Moreover, considering the interaction BSA-AGE and Lys-AGE it has been observed that  the 
complexes formed after receptor binding appear more stable with respect the AGE-RAGE 
interaction.  Moreover, the complex between BSA-AGE and domain V requires  the use of 
“extreme” condition, stronger in respect to those used to dissociate  the Lys-AGE complex[206]. 
These results suggest AGEs bind to domain V not only through electrostatic interactions, but also 
through interactions of other types, including the hydrophobic ones. The hydrophobic cavity located 
closed to the basic residues (group 1) in the cationic center, forms a pocket essential in the AGE-
RAGE interaction. The proposed mechanism consists of the following steps: as a first step, the ionic 
attraction between the positive charges of the receptor and the negative ones located on the ligands 
cause a narrowing of the pocket. Is the narrowing of the pocket (second step) that induces the 
formation of internal hydrophobic interactions which stabilize the complex[206]. This hypothesis 
supports the fact that the replacement of the basic residues belonging to the first group exhibit a 
drastic reduction in the formation of the complex. Thus, although several AGEs may have equal 
access to basic residues of the cationic center on the V domain, probably only those that interact 
with the amino acids of group 1 can easily move into the hydrophobic cavity, remaining trapped. 
A B 
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2.4.  AGEs and ALEs: physiopathology and molecular strategies for their inhibition. 
 
Considering the emerging deleterious role of aldehyde/protein adducts in several human diseases, as 
well as the complexity of reactions involved in ALEs, AGEs, and EAGLEs formation, the 
therapeutic approaches to inhibit and degrade AGEs and ALEs formation as well as RAGE 
activation should be mainly based on the efficient control of the sequence of events at the earliest 
possible stage. 
By considering RCS,ALE/AGE-RAGE axis activation as drug-targets, different molecular 
strategies can be considered: 
 
 Inhibition of the lipid-peroxidation chain-reaction (the primary source of RCS) by a direct 
(radical scavenging), indirect (metal-ion chelating) mechanism, or both. Regarding the 
radical-scavenging approach, different target radicals should be considered: 1) ROS, such 
as HO• and its radical precursor O2
•-
 (through the formation of H2O2), which are responsible 
for initiating the lipid-peroxidation process, or 2) lipid radicals, which propagate the chain-
reaction. The indirect antioxidant mechanism is based on targeting the pro-oxidant. 
 
 Inactivation of the unstable intermediate products of  sugar-degradation and lipid-
peroxidation, whose breakdown leads to the formation of RCS. 
 
 RCS entrapping and scavenging (forming nonreactive, non cytotoxic and with more 
hydrophilic characteristic reaction products). 
 
 Induction of the enzymatic or non enzymatic degradation of accumulated ALEs and AGEs, 
and generally of undigested oxidation reaction products. 
 
 Another therapeutic approach consist in inactivating RAGE . The receptor can be 
inactivated by high-molecular-weight substrates analogues, low-molecular-weight 
substrates analogues inhibitors, or anti-RAGE antibodies, neutralizing the receptor. 
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2.4.a.  Antioxidants interventions.  
 
The intervention strategy based on a direct radical-scavenging (antioxidant) approach that provides 
a first line of defence against free radicals, such as vitamin E and vitamin C, has failed to show 
beneficial effects in RCS-dependent diseases. There is limited evidence, from humans and animal 
models of atherosclerosis, that antioxidant therapy alone or given as diet supplementation can 
provide protection[207;208]. Several clinical trials have failed to provide a clear evidence for the 
efficacy of the antioxidant treatment in diabetic subjects[209] although a growing evidence shows 
that ROS and RCS production is increased in diabetes and that oxidative stress is associated with 
long-term complications. Some of these trials have been criticised in terms of insufficient dosing 
regimens or duration of antioxidant therapy, harmful interactions between the antioxidant 
compounds, or flaws in enrolling or excluding subjects. 
Neurodegenerative disorders, including PD, AD, and ALS, clearly display increased indices of ROS 
and RCS (especially ACR and HNE) in affected brain regions. The antioxidant treatments have 
sorted different effects in these diseases: for example, whereas vitamin E has displayed some 
efficacy for the treatment of AD, it has not proved useful so far for the treatment of PD[210].  
One possible limitation of the antioxidant therapy is that significant damage to macromolecules and 
tissue injury, which ultimately leads to cell death, will already have occurred by the time overt 
symptomatology of the disease is observed. Hence, antioxidant therapy, at best, can only rescue 
undamaged macromolecules and surviving cells, an effect that might not be sufficient to attenuate 
symptomatology[211].  
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2.4.a.1.  Metal chelation intervention. 
 
Several therapeutic approaches based on chelation of transition metals and in particular copper and 
iron have been recently proposed. It has been hypothesized that metal chelators could have dual 
inhibitory function on redox activity, restraining ROS generation as well as indirect inhibition of 
dialdeydes such as glyoxal. Furthermore, AGEs can be generated by oxidative and non-oxidative 
pathways, that appear to be accelerated by transition metals. Hence, chelation of transition metals 
inhibits  several oxidative steps in glycoxidation. 
This aspect results particularly important in neurodegenerative diseases where the dyshomeostasis 
of copper, iron and zinc has been detected, inducing for instance, metal hyper concentration, which 
can act as catalyst for detrimental oxidative reactions within the subtantia nigra in PD[212]. This 
might explain the growing interest in the development of metal chelation therapy as a potential 
promise for preventing or delaying disease progression in PD and other related neurodegenerative 
disorders. 
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2.4.b.  RCS sequestering agents and AGEs detoxification compounds. 
 
Among the molecular approaches up to now described, the most promising in terms of preventing 
or inhibiting carbonyl stress-related diseases is based on those compounds able to deactivate the 
intermediate products of lipid peroxidation or to scavenge RCS. Although several studies have 
already been conducted to develop AGE breakers, no study on compounds inducing enzymatic or 
non enzymatic degradation of ALEs has been reported, although this is an emerging field. 
 
 
Fig 20.  Endogenous and synthetic RCS sequestering agents. 
 
Compounds described in the literature as RCS scavengers(small molecules able to detoxify RCS) 
can be divided into two groups: 
Endogenous or naturally occurring compounds, such as the endogenous dipeptide L-carnosine (L-
CAR) and derivatives such as N-acetil-carnosine (NA-CAR)and homocarnosine (H-CAR),  anserine 
(ANS), the amino acid glycine (Gly), carcinine and finally the vitamer pyridoxamine (PYR). 
Synthetic compounds initially described by their pharmacological or biological activities, such as 
the vasodilating antihypertensive drugs hydralazine (HYD), the iNOS inhibitor aminoguanidine 
(AG), and the oral hypoglycaemic agent metformin (MEF) , carnosinamide (CAR-NH2) and the 
carnosine derivative designed by us carnosinol (CAROH). 
Originally, most of these compound were initially employed as pharmacological treatment for many 
diseases and only subsequently ware identified as RCS scavengers. 
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2.4.b.1.  Pyridoxamin (PYR). 
 
For instance PYR, which is a vitamer in the vitamin B6  acting as an enzyme cofactor in a variety of 
metabolic processes[213],  was initially employed as a novel and effective post-Amadori inhibitor. 
Then it was described as a RCS trapping agent able to inhibit the chemical modification of proteins 
acting mainly on Lys residues during lipid peroxidation reactions in vitro and during copper-
catalysed oxidation of low-density lipoproteins[214].  
 
 
2.4.b.2.  Aminoguanidine (AG). 
 
AG (hydrazinecarboximidamide) is considered to be a prototype scavenging agent of  dicarbonyls, 
able to prevent the AGEs formation. In particular AG was found to detoxify α,β-dicarbonyls  such 
as glyoxal (GO), methylglyoxal (MGO) and α,β-dicarbonyls, forming the corresponding  3-amino-
1,2,4-triazine derivatives[215].  
Moreover, AG is an efficient scavenger of  α,β-unsaturated aldehydes when compared to 
nucleophilic amino acids (Cys, Lys, His). In particular AG react with HNE to yield a stable adduct 
through the well stabilized Schiff base[216]. AG was found to reduce tissue levels of AGEs in 
experimental models of diabetes as well as to retard the development of several pathologies 
including neuropathy, retinopathy, nephropathy and cataract[217;218;219]. However, due to its 
high reactivity , AG does not possess a suitable selectivity because it traps also physiological 
carbonyls[220] and physiological aldehydes. The lack of  selectivity of aminoguanidine, 
causingvitamin B6 deficiency, was the reason for its withdrawn form phase III clinical trials[221].  
 
 
2.4.b.3.  Hydralazine (HYD). 
 
HYD (1-hydrazinylphthalazine) is a direct-acting smooth muscle relaxant characterizes by 
a nitrogen atom containing electron rich function represented by hydrazine group[222]. HyD was 
used to treat hypertension by acting as a vasodilator primarily in arteries and arterioles[223]. 
Furthermore HYD, was tested in the treatment of  multiple sclerosis due tothe fact that this disease 
in characterized by an increase of acrolein that is effeciently quenched by HyD[224].  
Up to now HYD is the lead compound of a series of hydrazine derivatives endowed by a marked 
scavenging ability toward both ALE and AGE precursors. However HYD as RCS scavenging 
compound is limited by two main issues: the lack of selectivity and the promiscuos activity.  
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Regarding the promiscuous activity HYD are well-known vasodilator agents which have been used 
for the treatment of essential hypertension since the 1950's. 
As previously described for AG, also HYD, besides being characterizedby a promiscuos activity,it  
is also characterized by a lack of selectivity,since able to trapalso physiological carbonyls due to the   
hydrazine moietyable to form stable imine derivatives[220].  
 
 
2.4.b.4.  Metformin(MET). 
 
MET (1,1-dimethylbiguadine) is an oral drug used as antidiabetic drug and belonging to the 
biguadine class. Nevertheless the adverse effects due to its use such as lactic acidosis and 
gastrointestinal complication, MET is considered the first-line drug of choice for the treatment of 
type 2 diabetes, in particular, in overweight and obese people and those with normal kidney 
function[225;226]. 
MET was also reported to decrease AGE formation in vitro, most likely by eliminating reactive 
carbonyl precursors[227;228]. In clinical studies, MET reduce levels of reactive dicarbonyls and 
AGEs[229] such an effect would contribute to the positive effects of MET beyond the benefits 
expected from the antihyperglycemic effect. 
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2.4.b.5.  Carnosine (CAR) and the peptidomimetic derivative, Carnosinol (CAROH). 
 
 
Fig 21.  Chemical fate of  suitable β-alanin-histidine CAR derived from dietary sources.  
 
In humans, diet represent the main sources of carnosine (CAR) and histidine derivatives (HD), 
which are contained in significant amount in red and white meats. Dietary CAR is readily absorbed 
intact, primarily in the jejunum by a carrier-mediated transport system (hPEPT1) [230]. The 
enzymatic hydrolysis of the peptide bond represents the main metabolic fate of CAR, and in 
humans, it mainly occurs in the plasma by a specific serum hydrolase (carnosinase) that cleaves the 
b-alanine–histidine peptidic bond. The two hydrolyzed amino acids are then delivered to tissues and 
then again synthetized to carnosinein those tissues characterized by the presence of carnosine 
synthetase[231]. Hence CAR, which is also, an endogenous compound is present in millmolar 
concentration in some tissues as the skeletal muscle, heart and in some regions of the CNS and 
whose multi-step mechanism, mainly based on the ability of imidazole ring to yield Micheal 
addiction on the unsaturated imine intermediate, renders it markedly selective toward 
RCS[232;233].  
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Fig. 22.  Functional group of carnosine and carnosinol involved on endogenous recognition and 
serum carnosinases resistance. 
 
Carnosine (β-Alanyl-L-histidine, L-CAR) is able to react with HNE through a two-step mechanism 
and based on the formation of a reversible Schiff base followed by an intra-molecular Michael 
adduction, leading to the formation of the Michael adduct stabilized in the hemiacetal form[234]. 
Such a concerted mechanism involving both the reactive centers of HNE to form a stable adduct 
makes the sequestering activity of L-CAR and derivatives more selective towards HNE and α,β-
unsaturated aldehydes in respect to the other RCS. By using an HPLC method able to monitor the 
formation of HNE-quencher adducts together with a mass spectrometric approach able to measure 
the formation of covalent adducts of ubiquitin (protein target) induced by HNE incubation and its 
inhibition by the sequestering compounds, we recently compared the quenching activity of the 
known RCS scavengers which was as follows: 
carnosine>hydralazine>>aminoguandine>pyridoxamine.  
By contrast when GO or MGO were used as carbonylating agent, L-CAR was the less efficient thus 
demonstrating that the RCS sequestering efficacy for this class of compounds is quite selective for 
α,β-unsaturated carbonyls[235].         
Moreover, L-CAR was not found able to form stable adducts with the carbonyl function due to the 
fact its primary amino group is too basic (pK = 9.31) [236], since the stability of Schiff bases and 
the basicity of the primary amino group are inversely related. This lack of reactivity is very 
important because it avoids any reactivity towards endogenous and physiological carbonyl 
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compounds such as pyridoxal, so making carnosine a selective compound towards activated and 
cytotoxic RCS. 
The HNE sequestering activity of L-CAR was then demonstrated in more complex biological 
matrices. Spiking HNE in rat skeletal muscle containing up to 5 mM of L-CAR and its methylated 
derivative (anserine) as endogenous components, resulted in the formation of the HNE Michael 
adducts of both the histidine compounds as determined by LC-ESI-MS/MS[234]. Moreover, the 
HNE Michael adducts of carnosine and anserine were both easily detected in the skeletal muscle 
undergoing a spontaneous oxidation and the amount of both the adducts significantly increased by 
depleting GSH thus demonstrating that carnosine participates in the endogenous detoxification of 
HNE together with GSH. Furthermore, carnosine-HNE Michal adduct and its metabolites, namely 
His-1,4-dihydroxynonane (His-DHN), His-4-hydroxynonanoic acid were identified by a mass 
spectrometric approach in the urine of obese Zucker rats and this is the first evidence of carnosine 
acting as a detoxifying agent of HNE in ex vivo conditions[237]. 
Very recently, the ability of L-CAR to act as an endogenous detoxifying agent of RCS was 
confirmed and extended in human samples. Conjugates of HNE with carnosine and metabolites 
such as His-HNE  and His-DHN were detected by MS in human and mice urine although to a 
significantly lesser extent in respect to carnosine-acrolein conjugates[238]. 
However, the major limit of CAR and derivatives as RCS scavenger drug compound is the low 
bioavailability in humans due to the presence of  human serum carnosinase that catalyses its 
hydrolysis. In order to overcome this limit our research group has designed a derivative in which the 
carboxylic group required for carnosinases recognition is replaced by an hydroxyl group . This 
compound, named  carnosinol, was found to be bioavailable in rats thanks to the resistance to the 
endogenous carnosinases and to the fact that it is correctly recognised by carrier PEPT1. In addition, 
in  animal models it has been found that carnosinol is able to inhibit AGEs formation and RAGE 
expression and activation nevertheless the reaction mechanisms through which these positive effects 
occur have not yet been elucidated.  
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2.4.c.  Blocking AGEs-RAGE damaging axis. 
 
RAGE is a pattern recognition receptor for many ligands such as AGEs, the s100 protein family, 
amyloid-β peptide. Several studies of the last decade have demonstrated that a significant part of 
cellular oxidative stress is due to the stimulation of this special receptor . The activation of RAGE 
by these compounds triggers an intracellular pathway resulting in a release of proinflammatory 
molecules. Hence, RAGE receptor has recently been identified as a possible drug target through its 
inactivation. 
Different strategies has been developed  in order block the AGEs-RAGE damaging axis. 1) 
Inactivating ligands, 2) low-molecular-weight antagonists of RAGE or 3) peptides and 
polysaccharides 4)downregulating RAGE expression 5) antibodies 
 
 
2.4.c.1.  Inactivating ligand. 
 
The most abundant RAGE in blood and body fluids is represented by a population of shortened and 
soluble RAGE (sRAGE) which lacks the intracellular signalling domain. sRAGE competes with 
RAGE towards ligands since its affinity is maintained. However the  sRAGE engagement with 
ligands does not trigger signal transduction an hence it does not evoke the inflammatory response. 
A possible molecular strategy is based on the protective role of sRAGE to block RAGE activation 
by competing with the ligands. sRAGE overexpression can be induced by small molecules. 
Interestingly, traditional cardiovascular drugs (statins, thiazolidinediones,  ACE inhibitors) were 
found to be able to affect RAGE expression and circulating sRAGE levels in cardiovascular disease 
states characterized by enhanced RAGE activation, which may represent a novel mechanism of 
their action[239].  
Introduction of recombinant sRAGE may be expected to become a new way of therapy to prevent 
the activation of RAGE by proinflammatory ligands. For instance, RAGE blockade by genetically 
engineered sRAGE was found to reduce vascular complications in a diabetic animal model[240].  
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2.4.c.2.  Low-molecular-weight antagonists of RAGE. 
 
Probably due to the complexity of the molecular interactions between AGEs-RAGE, only few 
studies on AGEs antagonists have so far been reported. Most of the studies on the rational design of 
RAGE antagonists have been carried out by considering amyloid -peptide (A) as a ligand [241]. 
Also in this case, the molecular interaction between A and RAGE is not completely elucidated: by 
using fluorescence and MS it has been found that the major V-RAGE binding region of A 
involves a highly hydrophobic stretch, 17LVFFAED21 and a flanked negatively charged residue 
D22E23 at the C terminus. The interest of A as RAGE ligand is due to the fact that the A-RAGE 
axis is involved in the Alzheimer‟s disease and represents an emerging drug target. In particular, in 
brain endothelium, RAGE mediates the influx of circulating A into the brain while in neurons, it 
mediates A-induced oxidant stress and A intraneuronal transport, causing mitochondrial 
dysfunction. A-RAGE interaction also activates nuclear factor-B (NF-B) which plays a crucial 
role in various inflammatory responses.  
Zlokovic et al. reported the structure of RAGE antagonist with a Kd in a nanomolar range. The lead 
compounds from the first screening shared common structural moieties such as a tertiary amide 
moiety substituted with a hydrophobic moiety and a monosubstitued aromatic group. A second-
generation library of compounds was then synthesized on the basis of the chemical features 
retrieved from the first library. From the second library a compound coded as FPS-ZM1 was 
identified and characterized by a favorable inhibitory and dissociation constants (Ki/Kd= 0.66) as 
well as suitable pK and bioavailability properties. Structure-activity relationship studies revealed 
that the tertiary amide and aromatic rings are essential for activity and that the chlorine atom on the 
electron poor aromatic group may enhance its binding to the receptor [242]. Besides in vitro 
studies, FPS-ZM1 was also found effective in a mouse model of AD inhibiting the RAGE-
mediated influx of circulating A40 and A42 into the brain, -secretase activity, A production 
and microglia activation and neuroinflammation, and normalizing cognitive performance and 
cerebral blood flow responses [241].  
PF-04494700 (previously known as TTP488), an orally bioavailable low-molecular weight 
inhibitor of RAGE, which inhibits sRAGE from binding to RAGE ligands, S100B, amphoterin and 
CML has been developed as a potential treatment for AD (as well as diabetic nephropathy) and has 
reached a phase II clinical trial [243] but was discontinued in 2011 due to a poor efficacy. Feng et 
al. demonstrated that CM-1, a cell protecting agent able to prevent AGEs-induced endothelial 
dysfunction, blocks the interaction of MGH-1 with RAGE by acting as a competitive high-affinity 
antagonist, with IC₅₀ values in the nanomolar range [244]. A screen of 50 compounds for their 
ability to prevent binding to RAGE of a fluorescent AGE-BSA derivative in RAGE-overexpressing 
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cells demonstrated that genistein inhibits this binding in a dose-dependent manner at nM 
concentrations [245]. Thiazolidinediones, calcium channel blockers, angiotensin-converting 
enzyme inhibitors, angiotensin II receptor blockers, and statins are reported to suppress RAGE 
expression [246].  
There is no essential difference in the binding with RAGE between the macromolecular and 
monomeric AGE. Monomeric AGEs, which generally consist of an N-heterocyclic moiety and an 
amino acid moiety as a part of the AGE−protein linkage are thus attractive as a template for the 
design of novel small-molecule RAGE inhibitors. In particular, argpyrimidine 1, a monomeric 
AGE, was selected for design of the incipient RAGE inhibitors, because the key structure of 
argpyrimidine seems to provide more synthetic accessibility and more drug-like features compared 
with that of other monomeric AGEs. Using the approach of ligand-based drug design, the group of 
Suh discovered a novel series of 4,6-disubstituted 2-aminopyrimidines as RAGE inhibitors. In 
transgenic mouse models of AD, one of the 4,6-bis(4-chlorophenyl)pyrimidine analogs, 
significantly lowered the concentration of toxic soluble Aβ in the brain and improved cognitive 
function. Pyrimidine analogos binds directly to RAGE and thus inhibits the RAGE-Aβ interaction. 
A docking study predicted also the binding mode of the 4,6-bis(4-chlorophenyl)pyrimidine analogs 
to the RAGE V-domain [247].  
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2.4.c.3.  Peptides and polysaccharides. 
 
To date, Heparin and its derivatives are considered the most promising molecules acting as RAGE 
anatgonists. It was recently demonstrated that 2-O ,3-O -desulfated heparin (ODSH) is able to block 
the ligation of RAGE with a number of its important ligands, including CML-BSH, HMGB-1 and 
S100 protein family.  
Heparin and derivatives compete with RAGE ligands due to the presence of electrostatic charges. 
Low-molecular-weight heparin (LMWH) can also bind to RAGE and act as RAGE antagonists. 
LMWH treatment of mice showed preventive and therapeutic effects on albuminuria and increased 
glomerular cell number, mesangial expansion, and advanced glomerulosclerosis ina dose-dependent 
manner[248]. 
 
 
2.4.c.4.  Downregulating RAGE expression. 
 
Another  important molecular strategy is based on downregulating RAGE expression. Drugs and 
natural substances have been found effective to downregulate RAGE expression as found for  
resveratrol[249].and for various plant extracts, of complex composition. Curcumin downregulated 
RAGE expression in rats with experimental diabetes[250].  Not only compounds derived from 
plants can downregulare RAGE expression, for instance alsoselenium supplementation in diet was 
found able to downregulated the expressions of both NFkB and RAGE is rats[251].  
 
 
2.4.c.5.  Antibodies. 
 
The most common approach to prevent the deleterious outcomes of RAGE activation in in vitro 
system and animal models is the application of inactivating monoclonal or polyclonal antibodies 
against RAGE.One of the antibodies against RAGE, designated XT-M4, a rat-derived anti-mouse 
RAGE monoclonal antibody, binds the extracellular region of RAGE and inhibits the interaction of 
RAGE with multiple ligands. This antibody was found  protective inthe mouse cecal ligation and 
puncture-induced (CLP) model of sepsis. As well the mouse derivative antibody, also the 
humanized XT-M4 antibody maintains all the inhibitory and binding properties[252].  
The latest humanized anti-RAGE monoclonal antibody was found able to decrease mortality in 
mice and modulated expression of genes, especially those involved in the inflammatory 
response[253]. 
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3.  Set-up of novel analytical methods for testing. 
RCS trapping agents 
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3.1.  A novel high resolution MS approach for the screening of 4-hydroxy-trans-2-
nonenal sequestering agents. 
 
 
 
3.1.a.  Abstract. 
An in vitro high resolution MS method was set-up to test the ability of compounds, mixtures and 
extracts to inhibit protein carbonylation induced by reactive carbonyl species (RCS). The method 
consists of incubating the protein target (ubiquitin) with 4-hydroxy-trans-2-nonenal (HNE) in the 
presence and absence of the tested compound. After 24 hours of incubation, the reaction is stopped 
and the protein is analyzed by high-resolution mass spectrometry (MS). The extent of protein 
carbonylation is determined by measuring the area of the +11 multicharged peak of the HNE adduct 
in respect to the native form. The method was validated by measuring the effect of well-known RCS 
sequestering agents, namely aminoguanidine, pyridoxamine, hydralazine and carnosine, yielding a 
good reproducibility and the possibility to be automatable. All the compounds were found to dose-
dependently inhibit the protein carbonylation with the following order of potency carnosine  
hydralazine >> aminoguanidine > pyridoxamine, as determined by calculating the UC50 values, that 
is the concentration required to inhibit ubiquitin carbonylationby 50%.  A good correlation was 
found with the results obtained by measuring HNE consumption using an HPLC method optimized  
by a mobile phase set at pH 7.4, in order to stabilize the eluted adducts. The MS approach was then 
applied to test the effect of two selected natural extracts on protein carbonylation, i.e. green coffee 
bean extract and procyanidins from Vitisvinifera. In summary, this paper reports a validated and 
highly reproducible MS method to test the ability of pure compounds as well as natural extracts to 
act as protein carbonylation inhibitors. 
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3.1.b.  Introduction. 
 
Reactive carbonyl species (RCS), generated by the non-enzymatic oxidation of lipids and sugars, 
are involved in several biological effects, most of them leading to a cell damage response[1]. From 
a chemical point of view, RCS can be grouped into three main classes: 1) α,β-unsaturated aldehydes 
such as 4-hydroxy-trans-2-nonenal (HNE) and acrolein; 2) cheto-aldehydes, such as methylglyoxal; 
3) di-aldehdyes such as glyoxal and malondialdehdye[2]. 
The biological response of RCS is mainly due to their ability to covalently modify proteins, leading 
to adducts that are named AGEs, when the RCS are formed by sugars, and ALEs when formed from 
lipids. The damaging effect induced by covalent protein modification can be ascribed to different 
mechanisms, such as protein dysfunction, protein oligomerization, immunoresponce and RAGE 
(receptor for AGEs)activation [1;3]. AGEs and ALEs have been used for several years as 
biomarkers of oxidative stress and several analytical methods and immunological assays have been 
developed for their measurements in both ex vivo and in vitro samples[4; 5; 6]. More recently, due 
to their unequivocal involvement in the pathogenetic mechanisms of several oxidative based 
diseases, AGEs/ALEs are also considered as promising drug targets, and a substantial effort is now 
dedicated to delve into the molecular strategies aimed at preventing, reducing or removing these 
protein oxidation products[7; 8; 9]. Several approaches have so far been considered for AGEs and 
ALEs inhibition and they can be grouped by considering at which level of the damaging 
AGEs/ALEs cascade they are effective and in particular if they act by inhibiting AGEs/ALEs 
formation, accelerating their catabolism or blocking their biological effects. The first level of action, 
the inhibition of AGEs/ALEs formation, also consists of different approaches, and the most 
promising is that based on compounds able to detoxify the reactive carbonyl species (RCS) 
involved in AGEs/ALEs formation[7]. RCS sequestering agents have been demonstrated to be 
effective in several oxidative based animal models and some of them have also shown positive 
effects in clinical trials, thus prompting the interest towards this molecular approach. Pyridoxamine, 
aminoguanidine, hydralazine and carnosine are the main RCS sequestering agents so far reported in 
the literature[7; 10; 11]. Though on one hand their pharmacological activity is very promising, on 
the other hand the clinical applications of these compounds is limited for safety concerns and/or 
lack of selectivity and bioavailability, thus prompting the search of novel compounds effective as 
RCS quenchers. The search for novel effective sequestering compounds primarily requires a reliable 
and accurate in vitro method that can be adapted to a medium/high throughput screening in order to 
test large libraries, which is also able to screen complex mixtures such as natural extracts. 
The analytical methods so far reported do not fulfill these requirements. Most of the assays measure 
the disappearance of the target aldehyde in the presence of the tested compound. The content of the 
aldehyde is determined by a direct spectrophotometric method when the RCS contains a 
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chromophore, such as in the case of α,β-unsaturated aldehydes, or upon a derivatization reaction, 
when the carbonyl moiety is not conjugated, as in the case of MDA, glyoxal or methylglyoxal[12]. 
Often, the direct UV analysis is integrated by an HPLC analysis in order to separate the RCS from 
possible interfering compounds that can be the tested compounds themselves[13;14]. However, 
such an assay is limited by several factors and in particular it cannot be applied to mixtures of 
compounds or extracts, it is not suitable for a high throughput screening and in most cases the 
experimental conditions required for the derivatization reaction or for the HPLC analysis can 
promote the dissociation of the adduct or catalyze its formation, thus under- or over-estimating the 
quenching effect. Another widely used assay is based on measuring the rate of AGEs/ALEs 
formation by incubating the RCS with a protein target, in the presence or absence of the tested 
compound. Such a method is more complete than the previous one, since it includes the protein 
which is the RCS target. AGEs and ALEs formation can then be determined due to an increased 
MW or by Western blot analysis[15;16]. Such a method suffers of several limitations and in 
particular it is quite time-consuming, expensive and is not adapted for the screening of several 
compounds or for accurate quantitative/semi-quantitative analyses. 
Based on these limitations, the aim of the present paper is to set-up and validate a rapid and accurate 
method, based on high resolution MS, able to test the ability of compounds or extracts to inhibit 
protein carbonylation induced by RCS.  To set-up the method, HNE, which is one of the most 
abundant and reactive lipid-derived RCS generated through the β-cleavage of hydroperoxides from 
PUFAs, was used as RCS and ubiquitin as a model of protein substrate. After the set-up process, the 
method was then applied to evaluate the ability of known RCS sequestering agents as well as of 
selected natural extracts to inhibit HNE induced protein carbonylation. 
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3.1.c.  Experimental. 
 
 
3.1.d.  Reagents and materials. 
 
Ammonium bicarbonate (NH4HCO3), formic acid (HCOOH), sodium dihydrogen phosphate 
(NaH2PO4·H2O), sodium hydrogen phosphate (Na2HPO4·2H2O), lyophilized ubiquitin from bovine 
erythrocytes (BioUltra, ≥98%)and LC-MS grade solvents were purchased from Sigma-Aldrich 
(Milan, Italy). Sodium tetrahydridoborate (NaBH4) was purchased from Fluka Analytical. LC-grade 
H2O (18 MΩ∙cm) was prepared with a Milli-Q H2O purification system (Millipore, Bedford, MA, 
USA). All other reagents were of analytical grade. Sequence grade trypsin and Glu-C (protease V8) 
were obtained from Roche Diagnostics S.p.A. (Monza, Italy). 
4-hydroxy-2-nonenal diethylacetal (HNE-DEA) was synthesized according to the literature [17] and 
stored at -20⁰C. For each experiment, fresh 4-hydroxy-2-nonenal (HNE) was prepared starting from 
stored HNE-DEA, which was evaporated under nitrogen stream and hydrolyzed with 1 mM HCl, 
pH 3 for 1 h at room temperature to obtain HNE. The concentration of HNE was estimated by 
measuring the absorbance at λ = 224 nm (molar extinction coefficient = 13750 M-1 x cm-1).  
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3.1.d.1.  Sample preparation. 
  
 
3.1.d.1.1.  In vitro carbonylation of ubiquitin with HNE. 
 
Ubiquitin (10 µM final concentration) was incubated with increasing amounts of HNE (100 µM, 
200 µM, 500 µM and 1 mM, corresponding to molar ratios between the protein and HNE equal to 
1:10, 1:20, 1:50 and 1:100 at 37°C in 10 mM phosphate buffer (Na2HPO4·2H2O, pH adjusted to 7.4 
with NaH2PO4·H2O). Ubiquitin (10 µM) was incubated under the same conditions, but without 
HNE, as control sample. 
The reactions were stopped after 3, 6, 24 or 48 h by centrifugation using Amicon YM3 filters 
(Millipore, Milan, Italy).To do so, 70 µl of solution was diluted with water, loaded on Amicon YM3 
filters (Millipore, Milan, Italy) and centrifuged at 14000 g for 15 min. The eluates were discarded, 
while the ubiquitin solution remained on top of the filter (about 50 µl) was rinsed three times with 
450 µl of H2O to stop the reaction by diluting the excess reagents (HNE and inhibitors). The eluates 
were discarded and the washing procedure was repeated twice. After the last centrifugation step, the 
eluates were discarded and the filters were flipped to recover the ubiquitin solution (about 70 µl). If 
necessary, the sample was diluted to the initial volume (70 µl) with water. Ubiquitin was either 
enzymatically digested or directly injected into the mass spectrometer for intact protein analysis 
(see below). 
 
 
3.1.d.1.2.  In vitro inhibition of ubiquitin carbonylationusing small molecules. 
 
Ubiquitin (10 µM final concentration) was incubated at 37° C in 10 mM phosphate buffer in 
presence of 500µM HNE, together with the known inhibitors of carbonylation hydralazine, 
aminoguanidine, pyridoxamine or carnosine at final concentration equal to 500 µM, 1 mM, 2.5 mM 
and 5 mM - corresponding to molar ratios between HNE and inhibitors equal to 1:1, 1:2, 1:5 and 
1:10. Ubiquitin (10 µM) was incubated with HNE under the same conditions, but without inhibitors, 
as control sample. The reactions were stopped after 24 hours by centrifugation using Amicon YM3 
filters, as described in paragraph 3.1.d.1. 
 
 
 
 
108 
 
3.1.d.1.3.  In vitro inhibition of ubiquitin carbonylation using plant extracts. 
 
Ubiquitin (10 µM final concentration) was incubated for 24 h at 37° C in 10 mM phosphate buffer 
in presence of 500µM HNE, together with commercial lplant extracts obtained from grape seed 
(Leucoselect, IndenaS.p.a., Milan, Italy) or green coffee (EPO S.r.l., Milan, Italy, catalogue number 
3134845).The dried extracts were dissolved in phosphate buffer at final concentrations equal to 31 
mg/ml. After vortexing, the solutions were centrifuged at 14000 g for 15 min; the supernatants were 
collected and loaded on Amicon YM3 filters. After 1 hour centrifugation at 14000 g, the filtered 
solutions - containing molecules smaller than 3 kDa - were incubated with ubiquitin and HNE at 
final concentrations equal to 1, 10 and 25 mg/ml. Ubiquitin (10 µM) was incubated with 500 µM 
HNE without extracts, as control sample. Additional control samples contained 10 µM ubiquitin 
together with grape seed or green coffee extract. For all samples, the reactions were stopped after 24 
hours by centrifugation using Amicon YM3 filters, as described in paragraph 3.1.d.1. 
 
 
3.1.d.1.4.  Intact protein analysis: microflow automated loop injection ESI-MS. 
 
40 µL aliquots of ubiquitin solution recovered from Amicon YM3 filters were mixed with 40 µl of 
denaturing solution (H2O/CH3CN/HCOOH; 40/60/0.2; v/v/v) to reach a final protein concentration 
of 5 µM. Aliquots of 5 µl of the diluted samples were then injected into a LTQ-Obitrap XL mass 
spectrometer using an ESI source (Thermo Scientific, Milan, Italy) equipped with a dynamic 
nanospray probe(Thermo Scientific, Milan, Italy).A fully automated method was used to load the 
sample using an Ultimate 3000 RSLCnano system set to pump an isocratic mobile phase 
(H2O/CH3CN/HCOOH; 70/30/0.1; v/v/v) at a constant flow-rate of 10 l/min. Sample injection and 
spectra acquisition were fully automated and controlled by the software Xcalibur (version 2.0.7, 
Thermo Scientific) and Chromeleon Xpress (Dionex, version 6.80). Source parameters were set as 
follows: positive ion mode, spray voltage 1.5 kV, capillary temperature 200°C, capillary voltage 48 
V, tube lens offset 100 V. Mass spectra were acquired at high resolution (FT analyzer)in profile 
mode using the following settings: scan range 110-2000 m/z, AGC target 5x10
5
, maximum inject 
time 500 ms, resolving power 100000 (FWHM at 400 m/z). A list of 20 identified background 
ions[18]was included in the lock mass feature for real time mass calibration. Spectra were acquired 
using a dedicate processing method for the detection and quantification of the multicharged peaks 
with a charge state of +11 localized in the m/z range 779.00-783.59 or 793.00-797.59, respectively 
for unmodified and HNE-modified ubiquitin. Peak areas were automatically detected and quantified 
post-acquisition using Xcalibur Quan browser. 
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3.1.d.1.5.  Protein digestion. 
 
12.5 µl of ubiquitin solution recovered from Amicon filters (see above) were incubated with 500 
mM NaBH4 (37°C, 1h) to stabilize carbonyl adducts. After 1 hour, the solution containing stabilized 
ubiquitin was mixed with LDS sample buffer (Bio-Rad) and load on a Mini-PROTEAN gel (TGX, 
any Kd, Bio-Rad) for SDS-PAGE. After 20 min run, the gel was stained for 1 hour using 
Coomassie (Bio-Safe G-250 Stain, Bio-Rad) and destained overnight with water. Gel band 
corresponding to ubiquitin (around 8 kDa) were cut, washed with ammonium bicarbonate 50 mM 
and digested with sequencing grade trypsin or Glu-C (both Roche Diagnostics, Monza, Italy). The 
enzymes were resuspended in 50 mM ammonium bicarbonate at 37°C overnight, using 0.4 µg of 
enzymes. The reaction was stopped using 2 µl of 50% trifluoroacetic acid (TFA). Peptides were 
collected by subsequent incubations with extraction solution (30% acetonitrile, 3% TFA, in water) 
and finally by incubation with 100% acetonitrile. For each sample, collected peptides were pooled 
and dried using a vacuum system (Christ, Germany). Peptides were resuspended in 20 µl of 0.1% 
formic acid. 
 
 
3.1.d.1.6.  NanoLC–ESI-MS/MS peptide analysis. 
 
Chromatographic separation was performed by injecting 5 µL of digested peptides resuspended in 
0.1% formic acid on a C18 HALO PicoFrit column (75 µm x 10 cm, 2.7 µm particle size, 100 Å, 
New Objective, USA). The sample was injected by an Ultimate 3000 RSLCnano system and 
electrosprayed using a nanoESI source (Thermo). Peptide separation was performed by a reverse 
phase linear gradient gradientfrom 1% acetonitrile, 0.1% formic acid to 40% acetonitrile, 0.1% 
formic acid over 60 minutes, at flow rate of 300 nl/min. The instrument operated in data-dependent 
mode to acquire both full MS and MS/MS spectra. Full MS spectra were acquired in profile mode 
by the FT analyzer in a scan range equal to 300-1500 m/z, using capillary temperature 220°C, AGC 
scan 5x10
5
 and resolution 60000 FWHM at m/z 400. Tandem mass spectra were acquired by the 
linear ion trap (LTQ) for the 2 most intense ions exceeding 1×10
4 
counts. MS/Ms spectra 
acquisition was set as follows: centroid mode, resolution 15000, precursor ions isolation width of 2 
m/z, AGC target 1×10
4
 and normalized collision energy 30 eV. Dynamic exclusion was enabled to 
reduce redundant spectra acquisition as follows: 3 repeat counts, 30 s repeat duration, 45 s of 
exclusion duration. Monoisotopic precursor selection was enabled, and singly and unassigned 
charged ions were not fragmented. Instrument control and spectra analysis were provided by the 
software Xcalibur 2.0.7 and Chromeleon Xpress 6.80. 
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3.1.d.1.7.  Mass spectral data elaboration and database searching. 
 
The software Proteome Discoverer (Thermo) was used to extract peaks from spectra and to match 
them to the primary sequence of bovine ubiquitin (Uniprot entry sp|P0CG53|1-76). Accordingly to 
the enzyme used for the digestion, trypsin or Glu-C were selected as proteases, allowing a 
maximum of 2 missed cleavages. Peptide and fragment ions tolerance were set to 10 ppm and 0.5 
Da, respectively. Allowed variable modifications were methionine oxidation and HNE-
carbonylation on Lys, Arg and His to form the Michael or base Schiff adducts (respectively 
characterized by an isotopic delta mass equal to 158.13067 and 140.12011 in their reduced forms), 
as reported in the literature[3,4]. Low-confidence peptide matches were filtered out by selecting 
peptide confidence = high. The MS/MS spectra of modified peptides were requested to match the 
expected ions(b and/or y) neighboring the modified amino acid both at the N- and C-termini, to 
obtain a confident mapping of the modification site. 
Semi-quantitative analysis was carried out by calculating the AUC (area under the curve) of the 
extracted ion chromatograms (XIC) for the adducted and native peptides, using m/z values 
corresponding to the either [M+2H]
2+
 or [M+3H]
3+
, accordingly to the charge state reported by 
Proteome Discoverer. The extent of peptide modification was expressed as percentage using the 
following formula: 
%modified peptide= AUCmodified peptide/(AUCmodifiedpeptide+AUCnative peptide) x100 
whereAUCmodified peptide and AUCnative peptide correspond to the area of the modified and native peptide. 
When multiple peaks were present in the XIC, the AUC was calculated on the peak encompassing 
the retention time reported by Proteome Discoverer for the identified peptide. 
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3.1.d.1.8.  HPLC analysis. 
 
The reactivity of each tested compound toward HNE (quenching activity) was evaluated by 
measuring the HNE consumption by HPLC using a quaternary pump HPLC system and a PDA 
detector (Surveyor LC system, ThermoQuest, Milan, Italy) set at 224 nm. Separations were done by 
reversed-phase elution with a Phenomenex Synergy Fusion column (150 mm × 2 mm i.d., 4 μm) 
protected by a Synergy Fusion R–P guard column (CPSAnalitica, Milan Italy), thermostated at 37 
°C, and using Na2HPO4 10 mM pH 7.4/CH3CN, 40/60 (v/v) as mobile phase at a flow rate of 0.25 
ml/min. 
 
 
3.1.d.1.9.  Quantification of inhibitors’ efficacy. 
 
In our analysis, the concentration of quencher able to inhibit adduct formation on ubiquitin by 50% 
was termed UC50; this value refer to the quencher:HNE molar ratio and was computed as following. 
The percentage of modified ubiquitin obtained upon co-incubation with HNE and HNE-
sequestering agents, based on quantification of the z11 peaks (see Paragraph 2.3), was normalized 
against the percentage of modified ubiquitin obtained in control samples, which were incubated 
with HNE without any quencher. Curves plotting the normalized percentages of modified ubiquitin 
versus the Log concentration of quencher (expressed as quencher:HNE molar ratio) were evaluated 
using the non-linear regression analysis tool in GraphPad Prism (version 6.02) to obtain IC50values 
relative to the concentration-response curve. 
A similar procedure was used to obtain Q50 values, referring to the concentration of HNE-
sequestering agent necessary to quench by 50% the HNE signal in HPLC analyses. Data were 
normalized against the intensity of non-quenched HNE and analysed to obtain IC50 values by using 
the non-linear regression by GraphPad Prism, as described above.  
 
 
 
 
 
 
 
 
 
112 
 
3.1.d.1.10.  Molecular modelling. 
 
The resolved structure of human ubiquitin, retrieved from PDB (Id: 1UBQ), was completed by 
adding hydrogen atoms and to remain compatible with physiological pH, Asp, Glu, Lys and Arg 
residues were considered in their ionized form, while His and Cys were maintained neutral by 
default. The completed structure was then minimized until RMS = 0.01 kcal mol-1Å-1 keeping 
fixed the backbone atoms to preserve their experimental folding. The so optimized ubiquitin 
structure was then utilized to predict pose of HNE close to Lys 6 and His 68 by docking simulations 
using PLANTS [19] and focusing the search on a 10 Å radius sphere around the above mentioned 
residues. The simulation was performed by scoring the poses with the ChemPlp scoring functions 
using speed 1 and 20 poses were generated. The so generated best pose was then used to manually 
build the imino adduct on Lys6 and the obtained system was solvated by a 50 Å side cubic box of 
water molecules. After a preliminary minimization to optimize the relative position of solvent 
molecules the system underwent a 10 ns of equilibrating MD simulation with the following 
characteristics (a) Newton's equation was integrated every fs according to Verlet's algorithm; (b) the 
temperature was maintained at 300 ± 10 K by means of the Langevin‟s algorithm; (c) periodic 
boundary conditions were applied to stabilize the solvent clusters; (d) the electrostatic potential was 
treated by PME method. The simulation was carried out in two phases: an initial period of heating 
from 0 K to 300 K over 30000 iterations (30 ps, i.e. 10 K/ps), and the monitored phase of 10 ns. The 
MD run was carried out using Namd2.9 [20]with the force-field CHARMm v22 and Gasteiger‟s 
atomic charges. 
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3.1.e.  Results. 
 
 
 
3.1.e.1.  Intact protein analysis: microflow automated loop injection ESI-MS. 
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Fig 1.  Ubiquitin detection by mass spectrometry analysis in denaturing, acidic conditions. A) 
Multi-charged spectrum of 5 µM ubiquitin. B) Deconvoluted ubiquitin spectrum.C) Zoom on the 
m/z region of the multi-charged spectrum, corresponding to the ubiquitin peak [M+11H]
11+
. 
 
Fig 1A shows the MS spectra of 5µM ubiquitin dissolved in denaturating conditions and 
characterized by the typical multi-charged ions pattern, where charge states span from +7 to +13, 
with the +11 peak representing the most abundant species. Fig. 1B shows the deconvoluted 
spectrum reporting the molecular weight of ubiquitin at 8564.64 Da, while Fig. 1C is a 
magnification of the m/z range 760-820, containing the +11 peak at m/z 779.52067. We set-up an 
automated method to estimate the area under the curve (AUC) of the multicharged peak +11; the 
method was tested by injecting different concentration of ubiquitin spanning the 0.1-10 µM range.  
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Fig 2.  Quantification of the area under the curve (AUC) of the [M+11H]
11+ 
peak for three 
independent analyses at increasing ubiquitin concentration. The regression curve was calculated 
by the linear regression analysis. Squared correlation coefficient: 0.996. 
 
The correlation between the AUC of the +11 multi-charge peak and ubiquitin concentration is 
reportedin Fig. 2, for three replicate experiments. The AUC estimated by the method well 
correlates with the concentration of ubiquitin; the response is linear in the range between 0.1 and 
10 μM with a coefficient of determination (R2) equal to 0.996, and average coefficient of variation 
(CV%) equal to 0.18.  
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3.1.e.2.  Adduct formation on ubiquitin upon in vitro treatment with HNE. 
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Fig 3.  HNE-induced modification on ubiquitin: intact protein analysis. A) Multi-charged spectrum 
for HNE-modified ubiquitin, upon 24 h incubation with HNE (1:50 ubiquitin: HNE molar ratio). 
B)Zoom on the m/z region of the [M+11H]
11+
 peaks corresponding to non-modified and HNE-
modified ubiquitin. C)Quantification of the percentage of modified ubiquitin upon incubation with 
increasing concentration of HNE (equal to 0.1, 0.2, 0.5 and 1 mM, corresponding to 10, 20, 50, 
100-fold excess over ubiquitin concentration, equal to 10 µM). D) Quantification of the percentage 
of modified ubiquitin upon incubation with HNE for 3, 6, 24 and 48 hours (1:50 ubiquitin:HNE 
molar ratio). 
 
Upon ubiquitin incubation with HNE at 1:50 molar ratio, MS spectra present additional multi-
charged ions (Fig. 3A), which are attributed to the formation of a covalent adduct, shifted by 156 
Da in respect to the native protein and referred to the HNE Michal adduct. Fig. 3B shows the native 
+11 peak at m/z 779.51905 and the additional +11 peak observed at m/z 793.80129, attributed to 
the HNE adduct, characterized by a +156 Da increase in respect to the native protein, which 
corresponds to am/z increase of 14 on the basis of the +11 charge state. At increasing 
concentrations of HNE (1:10, 1:20, 1:50 and 1:100 molar ratio as compared to ubiquitin 
concentration), the area of the modified +11 peak increased linearly, in respect to the area of the 
native +11 peak, as shown in Fig. 3C. We then monitored the kinetic of adduct formation at 
different incubation times (3, 6, 24 and 48hours) setting the protein: HNEmolar ratio equal to 1:50. 
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As shown in Fig. 3D, the increase of adduct formation is almost linear up to 24 hours and reaches a 
plateau thereafter.  
The formation of the HNE-protein adducts as well as their detection was found to be highly 
reproducible with a CV%≤ 20%for all the measurements (average CV% equal to 11%). 
Based on the data reported above, we decided to test the effect of carbonylation inhibitors using 
ubiquitin: HNE molar ratio equal to 1:50 -which is in the concentration-response linear range -and 
24 hours as incubation time, since at this time the yield of ubiquitin modification is almost at the 
plateau level (about 50% modified protein). 
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3.1.e.3.  Bottom-up approach: nanoLC–ESI-MS/MS. 
 
To identify the sites of modification, ubiquitin was analyzed by mass spectrometry using a bottom-
up approach. The HNE-modified protein was reduced to stabilize the adducts and digested using 
two different proteases, i.e. trypsin and Glu-C, in order to increase sequence coverage.  
 
peptide sequence modification AA charge MH
+
 enzyme 
            
MQIFVK*TLTGK K6(MA) 1-11 2 1423.860277 Trypsin 
MQIFVK*TLTGKTITLE K6(MA) 1-16 2 1981.169847 Glu-C 
M*QIFVK*TLTGK M1(Ox); K6(SB) 1-11 2 1421.843431 Trypsin 
M*QIFVK*TLTGKTITLE M1(Ox); K6(SB) 1-16 3 1979.152012 Glu-C 
M*QIFVK*TLTGK M1(Ox); K6(MA) 1-11 2 1439.855516 Trypsin 
M*QIFVK*TLTGKTITLE M1(Ox); K6(MA) 1-16 2 1997.161791 Glu-C 
TLTGK*TITLEVEPSDTIENVK K11(MA) 7-27 2 2446.357958 Trypsin 
IQDK*EGIPPDQQR K33(MA) 30-42 2 1681.913378 Trypsin 
NVKAKIQDKEGIPPDQQRLIFAGK*QLE K48(MA) 25-51 3 3221.829685 Glu-C 
GIPPDQQRLIFAGK*QLE K48(MA) 35-51 2 2068.18535 Glu-C 
LIFAGK*QLEDGR K48(MA) 43-54 2 1504.875536 Trypsin 
DGRTLSDYNIQK*E K63(MA) 52-64 2 1696.878099 Glu-C 
TLSDYNIQK*ESTLH*LVLR K63(MA); H68(MA) 55-72 2 2446.422411 Trypsin 
ESTLH*LVLR H68(MA) 64-72 2 1225.753221 Trypsin 
STLH*LVLRLRGG H68(MA) 65-76 3 1479.937015 Glu-C 
 
Tab 1.  HNE-modified peptides identified by bottom-up analysis of ubiquitin upon 24 hours 
incubation with 50-fold excess HNE. The reduced forms of Michael-adducts and Schiff base 
modified amino acids are respectively indicated as MA and SB, together with their localization in 
the ubiquitin sequence.  
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The peptides obtained from the digestion were analyzed by LC-MS/MS using a data-dependent 
method to fragment the most intense ions. Fragmentation spectra were searched against the 
ubiquitin sequence, setting the mass shift equal to +140 and +158 Da as variable modification, 
respectively corresponding to the reduced form of the HNE-deriving Schiff base and Michael 
adduct. Quality filter criteria were applied to obtain genuine peptide identification and to 
unambiguously map the modified residues. Overall, 15 peptides were found to be covalently 
modified by HNE; for each of them, it was possible to localize the site of modification by MS/MS 
spectra. Tab 1 shows the modified peptides and the sites of HNE modification. Different lysine 
residues were modified by HNE Michael adduct (K6, K11, K33, K48, K63), as well as histidine 
H68. Lysine 6 was also modified by HNE as Schiff base. 
 
Fig 4. Mapping of HNE-induced modification on ubiquitin sequence and relative quantification. A) 
MS/MS spectrum of the precursor ion isolated at m/z493.98 and attributed to the [M+3H]
3+
 ion of 
the STLH*LVLRLRGG peptide. b and y fragment ions localize HNE-deriving Michael adduct on 
H68 residue. B-D) Extracted Ion Chromatograms (XICs) for relative quantification of HNE-
modified vs. unmodified peptide. For the modified peptide, them/z493.98422 (± 10 ppm) relative to 
the HNE-modified STLH*LVLRLRGG peptide was extracted in the ubiquitin sample incubated with 
50-fold excess HNE(B)and in control sample, where ubiquitin was not incubated with HNE (D).For 
the unmodified peptide, the m/z 441.27400 (± 10 ppm) relative to the HNE-modified 
STLH*LVLRLRGG peptide was extracted in the ubiquitin sample incubated with 50-fold excess 
HNE (C) and in control sample, where ubiquitin was not incubated with HNE (E). 
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As an example, Fig. 4A shows the MS/MS spectrum relative to the C-terminal peptide 
STLH*LVLRLRGG (amino acids 65-76) modified on the histidine residue (H68). Its mass is 
shifted by 158 Da with respect to the native peptide form ([M+H]
1+
 equal to 1479 Da instead of 
1321 Da) due to the presence of a reduced HNE adducted formed by Michael addition. The 
MS/MS spectrum shows that b2 and y6, y7 and y8 are unmodified, while b4, b5, b6, b7, y9, y10 and 
y11are shifted by 158 Da, thus indicating H68 as the modification site (Fig. 4A). 
The relative abundance of the modified peptides in respect to the native ones was computed by 
measuring the AUC in the extracted ion chromatograms (XIC) obtained for the native and modified 
forms of the peptides. The m/z values corresponding to the double charged [M+2H]
2+
 or triple 
charged [M+3H]
3+
 peptides were used, accordingly to the charge status reported for the identified 
peptides. As an example, the ion chromatograms extracted for the m/z value 493.98422 (±10 ppm), 
which corresponds to the [M+3H]
3+
 ion of the HNE-modified peptide STLH*LVLRLRGG, is 
shown in Fig. 4B and Fig. 4D for the incubated and control sample, respectively. A well detectable 
peak with retention time of 37.12 min was present in the XIC of the ubiquitin sample incubated 
with 500 µM HNE (Fig. 4B), while the peak was absent in the control (Fig. 4D). Fig. 4C and Fig. 
4E show the ion chromatograms extracted for the m/z value 441.27400 (±10 ppm), which 
corresponds to the [M+3H]
3+
 ion of the native, non-modified peptide STLHLVLRLRGG, 
respectively for the incubated and control sample. Easily detectable peaks were present at 33.24 
min in the XIC of both samples.  
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Peptide sequence modification Aa charge MH+ Enzyme 
% modified 
peptide 
              
MQIFVK*TLTGKTITLE K6(MA) 1-16 2 1981.169847 Glu-C 3.7% 
M*QIFVK*TLTGKTITLE M1(Ox); K6(SB) 1-16 3 1979.152012 Glu-C 21.5% 
M*QIFVK*TLTGKTITLE M1(Ox); K6(MA) 1-16 2 1997.161791 Glu-C 4.7% 
IQDK*EGIPPDQQR K33(MA) 30-42 2 1681.913378 Trypsin 45.1% 
GIPPDQQRLIFAGK*QLE K48(MA) 35-51 2 2068.18535 Glu-C 5.1% 
DGRTLSDYNIQK*E K63(MA) 52-64 2 1696.878099 Glu-C 5.0% 
STLH*LVLRLRGG H68(MA) 65-76 3 1479.937015 Glu-C 69.1% 
 
Tab 2.  Relative quantification of HNE-modified peptides vs. their unmodified, native forms. 
Peptide intensity was estimated by using the area under the curve (AUC) in the extracted ion 
chromatograms obtained for the m/z values corresponding to the double or triple-charged forms of 
the peptide, as indicated in the table. 
 
The XIC-based quantification returned the relative amount of modified peptide over the 
corresponding native peptide, reflecting the relative content of each modified residue, as 
summarized in Tab 2. Such quantification was preferentially performed on the peptides obtained by 
Glu-C digestion, since most native forms of HNE-modified peptides were not identified in the 
sample digested with trypsin (see Discussion paragraph). 
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3.1.e.4.  Modelling study. 
 
While detection of the ubiquitin adducts is not the primary objective of the study, a modeling 
analysis was undertaken with a view to rationalizing the remarkable reactivity of His68. Thus, the 
reactivity of the adducted lysine residues is clearly linked to their role in the polyubiquitylation 
mechanism and is in line with previous studies, where it was found to be related to the strength of 
polar interactions that lysines elicit with surrounding residues, the weaker the interaction the higher 
the lysine reactivity[21]. Hence, the modeling study was focused on the analysis of the molecular 
mechanism by which the reactivity of His68 is so significantly enhanced. As recently 
reviewed[22], the imidazole ring is indeed not nucleophilic enough to react as Michael donor group 
therefore, the histidine reactivity must be suitably improved by the surrounding residues acting as 
catalysts of the Michael addition. Such a mechanism might be based on the closeness ( 6 Å) 
between His68 and Lys6 whose capacity to yield Schiff bases was here experimentally confirmed.  
a)
b)
 
Fig 5.  Putative multi-step mechanism explaining the marked reactivity of His68 with HNE, based 
on the closeness between Lys6 and His68 (5A). Such a mechanism involves an imino intermediate 
on Lys6 able to approach the α-carbon atom to His68 in a pose stably conducive to the Michael 
addition (5B). 
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As schematized in Fig 5A, it is possible to hypothesize that the Michael addition on His68 is 
preceded by the Schiff base intermediate on Lys6, which slightly enhances the electrophilicity of 
the β carbon atom and constrains it in a pose stably conducive to the addition. Once Michael adduct 
is formed, the Schiff base can hydrolyze thus restoring the Lys6 amino group. Interestingly, such a 
cross-talk mechanism between Lys6 and His68 has already been proposed to rationalize the 
abundance of acetylated adducts generated when treating ubiquitin with acetyl salicylate[23]. To 
further corroborate the hypothesized mechanism, the supposed imino intermediate was constructed 
by a procedure which combines a docking simulation of HNE focused on the region around Lys 6 
and His68 with a short equilibrating MD run of the corresponding covalent imino adduct.  Fig 5B 
shows the so obtained adduct and evidences how the region surrounding His68 can create a rather 
hydrophobic pocket where the HNE carbon skeleton is suitably accommodated. In this way, the 
imino adduct can assume a pose conducive to the Michael addition since the His68 imidazole ring 
conveniently approaches the reactive HNE α-carbon atom at a distance of about 3Å. Moreover, the 
adduct is also stabilized by a H-bond between the HNE hydroxyl group and Gln40 which further 
constrains HNE in a productive pose. 
By considering that the adducted lysines are normally involved in polyubiquitination mechanisms 
as well as that the metal binding to His68 can alter the ubiquitin folding [24], one may suppose that 
also ubiquitin carbonylation might affect the biological activity of ubiquitin thus suggesting a 
pathogenic mechanism by which HNE can affect protein degradative pathways. 
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3.1.e.5.  Validating the method by known RCS inhibitors. 
 
The MS approach was applied to measure the HNE quenching ability of a set of known RCS 
inhibitors, namely pyridoxamine, hydralazine, aminoguanidine and carnosine. Ten µM ubiquitin 
was co-incubated for 24 hours with 500 µM HNE and increasing concentration HNE sequestering 
agents at the final concentration of 0.5, 1, 2.5 and 5 mM, corresponding to 1:1, 1:2, 1:5 and 1:10 
molar ratios over HNE concentration. The samples were analyzed by mass spectrometry to quantify 
the percentage of HNE-modified ubiquitin, which was calculated by measuring the AUC of the +11 
peaks corresponding to the native and modified forms of the protein. Data were normalized to the 
percentage of modified ubiquitin obtained upon protein incubation with 500 µM HNE without any 
inhibitor, which corresponded to 48% with a CV% equal to 15%. 
A B
C D
 
Fig 6.  Inhibition of HNE-induced carbonylation by known RCS scavengers. The graphs report the 
percentage of HNE-modified ubiquitin upon co-incubation with 50-fold excess HNE and increasing 
concentration of: A)pyridoxamine, B) hydralazine, C) aminoguanidine and D)carnosine. Scavenger 
concentrations were equal to 0.5, 1, 2.5 and 5 mM, corresponding to HNE:scavenger molar ratio 
of 1, 2 5 and 10. The percentage of HNE-modified ubiquitin is expressed relative to the percentage 
of modified protein obtained by treatment with 50-fold excess HNE, without any scavenger.  
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Fig. 6 shows the normalized percentage of HNE-modified ubiquitin at increasing concentration of 
pyridoxamine (Fig. 6A), hydralazine (Fig. 6B), aminoguanidine (Fig. 6C) and carnosine (Fig. 6D) 
as HNE sequestering agents. All the inhibitors show dose-dependent effects over the HNE: 
quencher molar ratios ranging from 1:1 to 1:10. Hydralazine and carnosine were the most effective 
HNE quenchers, inhibiting at least by 80% the formation of HNE adducts at the inhibitor:HNE 
molar ratio 5:1 and showing a significant protective effect already at the molar ratio 1:1. 
Aminoguanidine was the next effective compound, followed by pyridoxamine.  
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3.1.e.6.  Testing the HNE sequestering effect by an HPLC method. 
 
The RCS quenching effect of the selected compounds was then determined by a more conventional 
method based on measuring the HNE disappearance. Most of the HPLC methods reported in the 
literature for measuring HNE are based on an acid mobile phase which though on one hand is 
suitable for the HNE separation, on the other hand can induce some artifactual reactions during the 
HPLC run, such as catalyzing the adduct‟s hydrolysis or its formation by changing the charge state 
of the quencher. For this reason, the method was optimized in order to maintain the mobile-phase at 
pH 7.4. For each sequestering agent a dose-dependent effect on the HNE content was determined 
and the results reported as Q50, which is the concentration able to induce 50% HNE quenching.  
Fig. 7 reports the Q50 values as calculated by using the HPLC method which are compared with the 
UC50 as determined by the MS method.  
 
Fig 7.  Comparison of Q50 and UC50 values obtained for the four tested HNE-sequestering agents 
by HPLC and mass spectrometry-based analyses, respectively. Q50 and UC50 values are generally 
indicated as inhibitor activity; theQ50 values refer to the concentration of the inhibitor necessary to 
quench by 50% the HNE chromatographic signal, while the UC50values refer to the concentration 
of the inhibitor necessary to inhibit by 50% the formation of HNE-adduct on ubiquitin. 
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3.1.e.7.  Testing the ability of natural extract on HNE induced protein carbonylation. 
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Fig 8.   Inhibition of HNE-induced carbonylation by natural extracts. A) Multi-charged spectrum 
obtained by MS analysis of ubiquitin upon incubation with grape seed extract (LE) or green coffee 
been extract (GCB);multi-charged spectrum non-incubated ubiquitin (U) is reported as reference. 
B-C) The graph report the percentage of HNE-modified ubiquitin upon co-incubation with 50-fold 
excess HNE and increasing concentration of LE(B) or GCB (C). The concentration of the extracts 
in the ubiquitin sample was equal to 1, 10 or 25 mg/ml. The percentage of HNE-modified ubiquitin 
is expressed relative to the percentage of modified ubiquitin obtained by treatment with 50-fold 
excess HNE.  
 
As a next step, we evaluated the HNE quenching ability of two natural extracts, namely 
procyanidins from Vitisvinifera (LE) and green coffee bean extract (GCB). It was not possible to 
test their quenching ability on HNE by using the HPLC method, since multiple peaks 
corresponding to different components of the extract co-eluted with the HNE peak (data not 
shown). For mass spectrometry analysis, 10 µM ubiquitin and 500 µM HNE were incubated with 
the natural extracts using a final concentrations equal to 1, 10 and 25 mg/ml. After the removal of 
excess reagent, the samples were analyzed to quantify the percentage of modified ubiquitin. As a 
first step, we evaluated whether incubating the target protein with the natural extracts for 24 hours 
had an effect on the MS spectrum of the protein, possibly deriving from formation of non-covalent 
adducts, protein degradation or oxidation. The results reported in Fig. 8A show that the MS spectra 
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of ubiquitin incubated in the absence or presence of LE and GCB are superimposable with control 
ubiquitin. The two extracts effectively inhibited dose-dependently the HNE induced ubiquitin 
carbonylation and GCB (Fig. 8C) was slightly more effective than LE (Fig. 8B). The precision of 
the method tested on the natural extracts was high, since the averaged coefficient of variation 
measured for the three replicate analyses was 11%. 
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3.1.f.  Discussion. 
 
 
Reactive carbonyl species are bioactive compounds generated by lipid and sugar oxidation, and 
since they are involved in the onset and propagation of several pathogenetic mechanisms, they 
represent a promising and quite novel drug target[2]. The RCS sequestering agents represent a class 
of quite heterogeneous compounds that are able to covalently react with the RCS, inactivating their 
biological response and producing un reactive products. Hydralazine, pyridoxamine, 
aminoguandine and carnosine represent the most studied RCS sequestering agents, whose trapping 
efficacy as well as protective effects have been demonstrated in in vitro and in vivo models[7;11]. 
However the clinical applications of the above mentioned compounds is limited by safety concerns 
and/or limited bioavailability. In detail, hydralazine and aminoguanidine have a promiscuous 
activity and an unsuitable selectivity[11]; carnosine is well absorbed by intestinal peptide 
transporters (hPepT1), but is immediately hydrolyzed in human plasma to its constituent amino 
acids by specific dipeptidases (e.g., serum carnosinase, CN1)[25]. Pyridoxamine has now reached 
clinical phase III due to its significant quenching activity combined with a satisfactory selectivity 
profile [26]but the potential concern with this agent is that it is related to the B vitamin family, 
which has demonstrated some serious adverse drug events such as stroke and myocardial infarction 
in diabetic kidney disease patients[27]. 
Although there is a great interest in the discovery of novel selective and efficient RCS scavengers, 
the number of truly effective carbonyl quenchers hitherto reported is rather limited and this is 
probably due to the lack of suitable screening approaches. The search of novel RCS-sequestering 
agents requires indeed an accurate, highly reproducible and automatable analytical method that can 
test not only pure compounds, but also mixtures and natural extracts. The methods so far reported 
in the literature do not fulfill these basic requirements, as pointed out in the introduction. 
The present paper reports a novel method based on high resolution MS for evaluating the ability of 
compounds, mixtures or natural extracts to inhibit protein carbonylation. HNE was used as RCS 
since it is one of the most abundant and bioactive lipid-derived RCS, but it should be noted that the 
method can also be extended to other RCS able to covalently react with proteins, such as acrolein, 
methylglyoxal or glyoxal, thus permitting discriminationof the efficacy of a test compound towards 
the different RCS involved in protein carbonylation. Ubiquitin was selected as protein target since 
it is commercially available at high purity at a reasonable cost and because its molecular weight is 
suitable for intact protein analysis using a high resolution mass spectrometer such as the Orbitrap. 
Despite lacking cysteine residues, ubiquitin exposes a set of reactive lysines and a highly reactive 
histidine, which make this protein a suitable benchmark to test protein carbonylation and its 
inhibition. The method had a good reproducibility since the average CV% of three independent 
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experiments never exceeded20%, also when the extracts were used as inhibitors. Ubiquitin 
carbonylation by HNE was then fully characterized by MS in terms of stoichiometry and the sites 
of modification fully elucidated by a bottom-up approach and molecular modelling. The method 
was fully automated from the automatic injection of the sample to the quantitative analysis, with 
the final goal to apply the method for a medium throughput screening. Data analysis, consisting of 
calculating the AUC of the +11 multicharged peak relative to the native and HNE-adducted protein 
was automatically performed and the data were exported to an excel data-sheet to calculate the 
percentage of ubiquitin carbonylation. In one day triplicate analysis of a hundred samples can be 
easily processed by one operator. 
Up to now, the RCS sequestering activity of compounds is conventionally evaluated by measuring 
the disappearance of the aldehyde by HPLC and in most cases they require acid conditions to 
derivatize the RCS or to obtain suitable chromatographic conditions. It is well known that acid 
conditions can greatly impact the stability of the RCS adducts, and in particular Schiff bases. 
Moreover, acid conditions can modify the ionization of the test compound - in particular of the 
amino group - thus changing its natural reactivity towards the RCS. The method here described 
overcomes these limits since the pH is maintained to physiological conditions (pH 7.4), until the 
reaction is stopped by removal of excess reagents. The sample is then acidified before mass 
spectrometry analysis, to denaturate and charge the protein, but at this stage the covalent adducts 
are already formed and are stable at this pH condition. 
Another advantage of the method in respect of measuring the disappearance of the RCS by HPLC 
is the observation of the modified protein targeted by the RCS, thus making the analysis more 
reliable.  
We mapped HNE-adducts in the protein sequence by bottom-up analyses. Different residues were 
modified at various degree of efficiency. Two enzymes (trypsin and Glu-C) were used to increase 
the sequence coverage, but also to allow the relative quantification of the modified peptides versus 
the non-modified ones. Such relative quantification was preferentially performed on peptides 
digested with Glu-C, instead of trypsin, since the latter enzyme specifically cleaves the peptide 
bond at the C-terminus of lysine and arginine amino acids, which are nucleophilic residues known 
to be targeted by HNE. Possibly due to the steric hindrance of the HNE Michael adducts, HNE-
modified lysine residues caused trypsin missed cleavages, preventing the detection of the modified 
and unmodified forms of the same peptide. Therefore, relative quantification was performed on 
peptides digested with Glu-C, which preferentially cleave the peptide bond at the C-terminus of 
glutamic acid. The only exception is represented by the peptide IQDK*EGIPPDQQR that was 
detected only in the sample digested with trypsin. Since this peptide presents at the C-terminus an 
arginine residue (not modified by HNE), it was possible to detect both its modified and unmodified 
forms and to perform the relative quantification. 
130 
 
Once implemented, the method was applied to measure and compare the activity of well-known 
RCS scavengers towards protein carbonylation. The results are in good agreement with those 
obtained by measuring the HNE disappearance using an optimized HPLC method based on a 
neutral mobile phase, in order to maintain the stability of RCS adducts and to avoid artifactual 
modification of the natural reactivity of the RCS scavengers. In particular, by calculating the 
disappearance of HNE, the order of potency was as follows: 
hydralazine>carnosine>>aminoguandine>pyridoxamine. The order of potency determined by using 
the MS methods and based on the measurement of the protein carbonylation was 
carnosinehydralazine>>aminoguanidine>pyridoxamine. Overall, the results are quite 
superimposable except for the higher activity of hydralazine in respect to carnosine when the two 
compounds were tested by the HPLC method in respect to the MS assay. Such a difference can be 
easily explained by considering that the substrate protein was present only in the samples analyzed 
by the MS-based method. In detail, hydralazine forms reversible Schiff base with HNE, which 
cannot compete with the formation of Michael adducts on ubiquitin. By contrast, the carnosine-
HNE adduct, that is an irreversible Michael adduct, is not shifted in the presence of ubiquitin; thus 
hydralazine was less efficient when tested in the MS method.  
Currently, increasing interest resides in the detection of RCS sequestering agents present innatural 
extract of vegetable or animal origins. This is due to the fact that several natural components, such 
as polyphenols or peptides, have been reported to possess a quite interesting RCS trapping 
efficiency towards α,β-unsaturated aldehydes, cheto-aldehydes and di-aldehydes[28;29]. Hence, an 
analytical strategy for searching novel RCS sequestering agents is based on screening crude 
mixtures such as protein hydrolyzed, plant extracts and animal derivatives. HPLC based methods 
or methods based on RCS derivatization cannot be applied to such complex matrices, due to the 
presence of the different components that can co-elute with the HNE peak or interfere with the 
derivatizing agent. In the present paper, two selected natural extracts were evaluated as inhibitors 
of protein carbonylation. The measurement of HNE consumption by HPLC was confirmed that this 
strategy cannot be applied due to the simultaneous elution of the HNE peak with different 
components of the extract. The MS method was then tested and found suitable since the amount of 
native and carbonylated ubiquitin was easily determined, also in the presence of the extracts and no 
interfering peaks were observed. The two extracts reduced in a dose-dependent manner the 
percentage of protein carbonylation, the green coffee beans extract being slightly more effective.  
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4.1. Exploring the RCS scavenging activities of the naturally occurring histidine 
containing dipeptides: a comprehensive comparative study. 
 
 
 
4.1.a.  Introduction. 
 
Among the oxidative processes affecting protein structures, carbonylation is a well-characterized 
post-translational modification, involving condensation reactions between electrophilic reactive 
carbonyl species (RCS) and protein nucleophilic residues. The generated covalent adducts can be 
essentially grouped into advanced glycation (AGEs) or lipid-oxidation end products (ALEs), 
depending on the biochemical source of the electrophilic species[1].  
AGEs and ALEs structures can markedly vary depending on: 
A) the chemical nature of the reactive carbonyls [namely, di-carbonyl derivatives, such as 
glyoxal (GO), methylglyoxal (MGO) and malondialdehyde (MDA) or α,β-unsaturated 
carbonyls, such as 4-hydroxy-2-nonenal (HNE), 4-oxo-2-nonenal (ONE), acrolein (ACR)], 
B) thenucleophilicaminoacids undergoing the chemical modification [mostly, Cys, Lys, His 
and Arg side chains]  
C) the involved mechanisms of condensation,  
 
Besides usually inducing protein dysfunction, AGEs and ALEs can also activate signaling 
pathways involved in cellular homeostasis as exemplified by their interaction with the receptor for 
AGEs (RAGE) which is a type I transmembrane glycoprotein belonging to the immunoglobulin 
superfamily of cell surface receptors[2].  
Although the cell possesses a variety of phase I and phase II enzymes able to detoxify the reactive 
carbonyl species and/or their corresponding adducts, several conditions of oxidative stress can 
compromise such antioxidant defenses thus resulting in an accumulation of protein carbonyls.  
Besides being widely accepted biomarkers to monitor the course of oxidative based diseases, a 
substantial amount of literature is now available reporting the molecular and cellular pathogenic 
mechanisms by which AGEs/ALEs accumulation acts as a causative in the onset and progression of 
different diseases including neurodegeneration, atherosclerosis, muscle wasting, insulin resistance, 
diabetic nephropathies and aging. Therefore, AGEs and ALEs can be seen as promising targets for 
therapeutic intervention as confirmed by several studies showing that compounds effective as 
inhibitors of AGEs/ALEs or able to block their biological effects can significantly ameliorate 
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different oxidative based diseases. Among the possible molecular strategies, direct carbonyl 
quenching appears to be truly effective since it allows RCS to be covalently trapped and converted 
into nontoxic and easily excreted derivatives so inhibiting protein carbonylation and all 
downstream pathways[3].  
 
Some known carbonyl quenchers have reached clinical studies: for example, aminoguanidine was 
found to be very effective in scavenging RCS but the clinical trials were discontinued because of its 
promiscuous activity (it is a NO-synthase inhibitor) and unselective quenching profile since it traps 
and depletes also physiological carbonyls. Whereas, pyridoxamine has now reached clinical phase 
III due to its significant quenching activity combined with a satisfactory selectivity profile. Among 
the marketed drugs, hydralazine, the well-known antihypertensive agent, showed a promising 
carbonyl quenching activity but its use is hampered by its promiscuous activity and an unsuitable 
selectivity. Lastly, metformin (and its biguanide analogues), the first-line antidiabetic drug, was 
found to directly quench RCS in several in vitro and in vivo models thus suggesting that, besides its 
known antihyperglycemic effect, it may also decrease  
carbonyl stress with beneficial effects for the prevention of diabetic complications[4]. Among the 
naturally occurring carbonyl quenchers, carnosine (Ala-His) and other related histidine containing 
dipeptides (e.g., anserine, homocarnosine, Gly-His, carnosinamide, carcinine, see Fig 1) have 
attracted considerable interest for their protective effects against ALEs formation as evidenced by 
several in vivo models for oxidative based disorders[5].  
Although such a protective activity can involve different molecular mechanisms, there is enough 
evidence to indicate that carnosine acts by a direct quenching mechanism, at least for α,β-
unsaturated carbonyls. Nevertheless, the beneficial activity of carnosine is limited in humans by its 
unfavorable pharmacokinetic profile, since it is actively absorbed by intestinal peptide transporters 
(hPepT1) but immediately hydrolyzed in human plasma to its constituent amino acids by specific 
dipeptidases (e.g., serum carnosinase, CN1). Considering its potential therapeutic applications as 
recently reviewed, it is not surprising that many synthetic carnosine analogues have been reported 
in the last few years[6]. 
 
While considering the remarkable interest for carnosine (and its natural derivatives) as well as the 
promising results obtained in several animal models, the specific quenching profiles of these 
molecules against RCS have been sporadically examined and most reported studies had the 
objective of investigating the quenching molecular mechanism of only a few molecules without a 
broad comparative character. Moreover, the quenching activities were often determined by utilizing 
different approaches and/or different protocols without allowing an easy comparison of the 
obtained data. In this way, there is not an accepted wealth of fully comparable quenching activities 
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although such data might deepen our understanding of the quenching mechanisms thus supporting 
the rational design of improved derivatives. As an aside, the same limitation also affects the 
quenching activities for the mentioned marketed drugs and so it is impossible to compare them 
with other carbonyl quenchers such as the histidine containing dipeptides. 
On these grounds, the present study was undertaken with the aim of acquiring truly comparable 
quenching activities for carnosine and its naturally occurring derivatives as well as for the 
mentioned known scavengers that can be seen as reference compounds. In detail, this comparative 
analysis was focused on 4-hydroxy-2-nonenal (HNE) as it is the most important example of α,β-
unsaturated carbonyls. Since an unselective quenching profile has been one of the most impeding 
limitation in the development of new carbonyl quenchers, the selectivity of the examined molecules 
was also assessed by monitoring their quenching activity against pyridoxal, which was chosen as a 
well-known example of physiological carbonyl compound. These quenching analyses involved 
firstly a quantitative study based on well standardized chromatographic techniques and then the so 
obtained quenching activities were compared with the ability of these quenchers to competitively 
inhibit the protein carbonylation using a recently approach proposed by us. Moreover, the adducts 
formed by the active compounds were determined by mass spectrometry thus also allowing a 
fruitful comparison of the involved quenching mechanisms.  
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4.1.b.  Materials and methods. 
 
 
4.1.b.1.  Reagents and materials.  
 
All chemicals and reagents were of analytical grade and purchased from Sigma–Aldrich Chemical 
(Milan, Italy). LC-MS grade solvents were purchased from Sigma-Aldrich from Sigma–Aldrich 
Chemical (Milan, Italy). LC-grade H2O (18 mW) was prepared with a Milli-Q H2O purification 
system (Millipore, Bedford, MA, USA). 4-hydroxy-2-nonenal diethylacetal (HNE-DEA) was 
synthesized according to the literature[7] and stored at -20⁰C. For each experiment, fresh 4-
hydroxy-2-nonenal (HNE) was prepared starting from stored HNE-DEA, which was evaporated 
under nitrogen stream and hydrolyzed with 1 mM HCl, pH 3 for 1 h at room temperature to obtain 
HNE. L-Carnosine, D-carnosine (β-alanyl-L-histidine), N-acetyl-carnosine and carnosinol and 
methylglyoxal, HNE were gifts from Flamma S.p.A. (Chignolo d‟Isola, Bergamo, Italy).  
L-Histidine, β-alanine, homocarnosine, anserine, carnosinamide, glycine-histidine, carcinine, 
pyridoxamine, hydralazine, amminoguanidine, and metformin and pyridoxal were from Sigma-
Aldrich Chemical (Milan, Italy). 
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4.1.b.2.  HNE incubation and HPLC analysis. 
 
The reactivity of each tested compound toward HNE and pyridoxal (quenching activity) was 
directly evaluated by measuring the HNE consumption byHPLC system(Surveyor, 
ThermoFinnigan Italia, Milan, Italy), equipped with a quaternary pump, a Surveyor UV-vis diode 
array programmable detector 6000 LP set at 224 nm, a vacuum degasser, a thermostated column 
compartment, and a Surveyor autosampler (200 vials capacity),was used for solvent and sample 
delivery. Separations were done by reversed-phase elution with a Phenomenex Synergy Fusion 
column (150 mm × 2 mm i.d., 4 μm) protected by a Synergy Fusion R–P guard column 
(CPSAnalitica, Milan Italy), thermostated at 37 °C, and using Na2HPO4 10 mM pH 7.4/CH3CN, 
40/60 (v/v) as mobile phase at a flow rate of 0.25 mL/min. 
HNE and pyridoxal (100µM in phosphate buffer, pH 7.4, 10mM) were incubated with each 
compound considering several quencher/RCS ratios ranging from 1/10 to 10/1 in 10mM phosphate 
buffer (pH 7.4) for 3 and 24 h at 37 C°.  
The reactivity of each tested compound toward MGO (quenching activity) was than directly 
evaluated by measuring the MGO consumption by the sameHPLC system(Surveyor, 
ThermoFinnigan Italia, Milan, Italy) in which the Surveyor UV-vis diode array programmable 
detector 6000 LP was set at 285 nm. Separations were done by reversed-phase elution with a 
Thermo scientific Hypercarb column (100 mm × 2.1 mm i.d., 3μm) ) protected by a MAX-RP 
guard column(4 _ 2 mm; 4 µm) thermostated at 37 °C in the following conditions: gradient elution 
was performed, afterwards 6 min of conditioning phase [95% A (H2O) , 5% B (MeOH)] after 5 min 
from95% solvent A, 5% solvent B to50% solvent A, 50% solvent B, and the composition of the 
eluent was then restored to 100% A within 5 min, and the system was re-equilibrated for 6 min.; 
flow rate 0.3 mL/min. 
MGO (1mM in phosphate buffer, pH 7.4, 10mM) was incubated with each compound considering 
several quencher/RCS ratios ranging from 1/10 to 10/1 in 10mM phosphate buffer (pH 7.4) for 3 
and 24 h at 37 C°.  
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4.1.b.3.  Quantification of aldehydes efficacy and selectivity. 
 
In our analysis, the quenching activities towards HNE, MGO and pyridoxal as derived by both 
HPLC and competitive studies (the latter only for HNE and MGO). They were obtained by 
monitoring the consumption percentages (Q%  SD) of the carbonyl species after 3 and 24 h (the 
first only for HNE) and considering several quencher/RCS ratios ranging from 1/10 to 10/1.  
Besides, have been evaluated the consumption percentage averages as monitored by using an 
indicative 1/1 ratio (Q1/1),  the extrapolated ratio (R50) with which the quencher consumes the 50% 
of the tested carbonyl compound and taking a cue from the Stern-Volmer constant (KSV), 
commonly used to parameterize fluorescence quenching, a quenching constant (KQ) is here 
proposed corresponding to the slope of the plot of Q%0/Q% versus the quencher/RCS ratio. The 
plots used to calculate the KQ values were evaluated using analysis tool in GraphPad Prism (version 
6.02). 
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4.1.b.4.  ESI-MS instrument analysis for reaction products identification and 
characterization. 
 
HNE and pyridoxal (800 µM in phosphate buffer, pH 7.4, 1-10mM) were incubated both alone and 
with each compound considering several quencher/RCS ratios ranging from 1/10-1/1-10/1 from 
1mM to 10mM phosphate buffer (pH 7.4)in order to maintain compounds in the undissociated form 
for 24 h at 37 C°.  
MGO (8mM in phosphate buffer, pH 7.4, 10mM) was incubated both alone and with each 
compound considering several quencher/RCS ratios ranging from 1/10-1/1-10/1 from 10mM to 
100mM phosphate buffer (pH 7.4) in order to maintain compounds in the undissociated form for 24 
h at 37 C°.  
The reaction mixtures, containing each compound above listed, were diluted at a final 
concentration of 50µM (HNE, MGO and PL are not detectable by mass spectrometry) in 100% 
Milli-Q H2O and then infused into the mass spectrometer using an Hamilton syringe at a flow rate 
of 10 µL/min. 
ESI/MS and ESI-MS/MS analyses were done on a Thermo FinniganLCQ Advantage 
(Thermoquest, Milan, Italy) ion trap mass spectrometer was equipped with an electrospray 
interface (ESI), which was operated in the positive-ion mode, and controlled by Xcalibur software 
(version 1.4). Spectra were acquired in positive-ion modes, with a scan range m=z100–1000 (scan 
rate 0.5 scans/s). ESI interface parameters (positive-ion mode) were set as follows: middle position; 
capillary temperature 270 °C; spray voltage 4.0 kV. Nitrogen was used as the nebulizing gas at the 
following pressure: sheath gas 30 psi; auxiliary gas 5 a.u. The samples rack was maintained at 37 
°C. MS conditions and tuning were optimized for each compound. The intensity of the [M+H]
+
 
ions of the test compounds were monitored and adjusted to the maximum by using the Quantum 
Tune Master® software.   
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4.1.b.5.  Competitive studies. 
 
Competitive studies were reported as described in the chapter 3.1. Briefly, ubiquitin (10 µM final 
concentration) was incubated at 37° C in 10 mM phosphate buffer in presence of 500 µM HNE or 
MGO, together with the inhibitors at final concentration equal to 500 µM, 1 mM, 2.5 mM and 5 
mM - corresponding to molar ratios between HNE and inhibitors equal to 1:1, 1:2, 1:5 and 1:10. 
Ubiquitin (10 µM) was incubated with HNE or MGO under the same conditions, but without 
inhibitors, as control sample. The reactions were stopped after 24 hours by centrifugation using 
Amicon YM3 filters. 
40 µL aliquots of ubiquitin solution recovered from Amicon YM3 filters were mixed with 40 µl of 
denaturing solution (H2O/CH3CN/HCOOH; 40/60/0.2; v/v/v) to reach a final protein concentration 
of 5 µM. Aliquots of 5 µl of the diluted samples were then injected into a LTQ-Obitrap XL mass 
spectrometer using an ESI source (Thermo Scientific, Milan, Italy) equipped with a dynamic 
nanospray probe (Thermo Scientific, Milan, Italy). A fully automated method was used to load the 
sample using an Ultimate 3000 RSLCnano system set to pump an isocratic mobile phase 
(H2O/CH3CN/HCOOH; 70/30/0.1; v/v/v) at a constant flow-rate of 10 µl/min. Sample injection and 
spectra acquisition were fully automated and controlled by the software Xcalibur (version 2.0.7, 
Thermo Scientific) and Chromeleon Xpress (Dionex, version 6.80). Source parameters were set as 
follows: positive ion mode, spray voltage 1.5 kV, capillary temperature 200°C, capillary voltage 48 
V, tube lens offset 100 V. Mass spectra were acquired at high resolution (FT analyzer) in profile 
mode using the following settings: scan range 110-2000 m/z, AGC target 5x105, maximum inject 
time 500 ms, resolving power 100000 (FWHM at 400 m/z). A list of 20 identified background ions  
was included in the lock mass feature for real time mass calibration. Spectra were acquired using a 
dedicate processing method for the detection and quantification of the multicharged peaks with a 
charge state of +11 localized in the m/z range 779.00-783.59 or 793.00-797.59, respectively for 
unmodified and HNE-modified ubiquitin. Peak areas were automatically detected and quantified 
post-acquisition using XcaliburQuan browser.  
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4.1.c.  Results.  
 
 
4.1.c.1.  Overview. 
Fig 1 collects the analyzed quenchers and shows that, as mentioned in the introduction, they can be 
subdivided into two groups: the first includes natural carnosine derivatives, while the second 
comprises well-known quenchers although quite promiscuous. 
 
Fig 1.  Structures of the RCS scavenger compounds tested in this dissertation. Column A) Natural 
RCS scavenger compounds. Column B) Synthetic RCS scavenger compounds. 
 
Taken together, the examined carnosine analogues allow the investigation of how the quenching 
activity is influenced by (1) the length of the N-terminus residue (by comparing homocarnosine, 
carnosine and Gly-His); (2) the modification of the carboxyl group (by comparing carnosine, 
carnosinamide, carcinine and carnosinol); (3) the modification of the histidine imidazole ring (by 
considering anserine). Again, the comparison of carnosine, histidine, β-alanine and their physical 
mixture reveals the specific role of carnosine constituents as well as the synergic effect exerted 
when they are fused in a dipeptide. Lastly, N-acetyl carnosine can be seen as a negative control to 
verify the pivotal role of the terminal amino group. 
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All reference compounds are characterized by a nucleophilic nitrogen-containing function which 
should play a key role in quenching activity and is largely in its neutral form at physiological pH. 
As detailed below, they can be grouped depending on their whole ionization state, since 
hydralazine and pyridoxamine mostly exist in their unionized form at physiological pH, while 
aminoguanidine and metformin exist as hydrophilic cationic species due to the strong basicity of 
their guanidine function. 
 
 
 
 
 
 
 
 
 
 
 
 
 
Tab 1.  Ionization constants of the RCS scavenger compounds tested in this dissertation. a) the pK 
values for D-carnosine were not determined since they are identical to those of its isomer. b) pK 
values taken from literature since they are somewhat out of the ranges of the used apparatus. 
 
 
 
 
Compound pK1 pK2 pK3 
L-carnosine 2.76 9.33 6.72 
D-carnosine
a
 n.d n.d n.d 
Carnosinol 3.61 9.78 6.55 
Histidine
b
 1.77 9.18 6.10 
β-Alanineb 3.60 10.19 --- 
Homocarnosine 2.75 9.89 6.79 
Anserine 2.70 9.37 7.08 
N-acetylcarnosine 2.83 --- 6.85 
Carnosinamide 
--- 9.31 6.28 
Gly-His 
2.39 8.05 6.73 
Carcinine 
--- --- --- 
Pyridoxamine 10.24 7.97 3.39 
Hydralazine --- 7.18 1.52 
Aminoguanidine --- 11.08 --- 
Metformin
b
 --- 11.80 2.50 
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To better analyse the behavior of the ionizable groups, Tab 1 collects the ionization constants of the 
considered quenchers. Concerning the carnosine derivatives, one may note that the acidity of the 
carboxyl group (pK1 values) is minimally influenced by the remaining part of the molecule and 
only the single residues (His and β-Ala) show rather different pK1 values.  
The basicity of the imidazole ring (pK3 values) appears to be rather constant, anserine showing the 
most basic imidazole due to its N-methylation. Differently, the basicity of the amino groups (pK2 
values) shows a marked variability spanning about two logarithmic units. It mainly depends on the 
distance from the peptide bond which decreases the amine‟s basicity due to its electron-drawing 
effect.  
With regard to the examined reference compounds, both hydralazine and pyridoxamine possess a 
weakly basic function which is mostly responsible for their reactivity (pK2, see below), while the 
protonation of their hetero aromatic rings cannot occur at physiological pH (pK3 values). Notably, 
pyridoxamine also possesses a weakly acid phenolic group (pK1) which it is suggested plays an 
ancillary role in determining reactivity towards RCS. Finally, the ionization state of 
aminoguanidine and metformin is evenly influenced by the strong basicity of the guanidine 
function the protonated state of which is the most probable at physiological pH. 
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4.1.c.2.  Quenching activity towards HNE and MGO. 
 
Tab 2.  Quenching activities of the RCS scavenger compounds tested towards HNE, MGO and PYR 
expressed as percentages of aldehyde reacted in the presence of the test compounds, after 24 h and 
reporting  1) consumption percentage averages monitored by using an indicative 1/1 ratio (Q1/1), 2 the 
extrapolated ratio (R50), 3 quenching constant (KQ) corresponding to the slope of the plot of Q%0/Q% 
versus the quencher/RCS ratio. 
Compound 
HNE MGO Pyridoxal 
Q%1/1 R50 KQ Q%1/1 R50 KQ Q%10/1 KQ 
L-carnosine 
37.28 
 2.29 
1.52 1.28 
12.82 
 1.62 
3.96 0.028 
0.01  
0.98 
0.0001 
D-carnosine 
36.33 
 1.92 
2.06 0.62 
1.26  
0.88 
7.29 0.0026 
0.22  
0.09 
0.0002 
Carnosinol 
61.52 
 
1.88 
1.48 0.89 
36.39 
1.65 
1.23 1.256 
0.03  
0.09 
0.0003 
Histidine 
18.27 
 0.30 
5.99 0.13 
8.92  
0.38 
n.d. 0.014 
2.90  
0.36 
0.0015 
β-Alanine 2.33   
0.51 
n.d. 0.0091 
0.67  
0.76 
n.d. 0.0074 
1.01  
0.33 
0.0005 
β-Ala + His 
30.01 
 3.19 
2.09 0.39 
1.28  
0.61 
12.12 0.041 
4.48  
0.48 
0.0025 
Homocarnosine 5.47  
1.28 
n.d. 0.015 
0.28  
0.08 
7.36 0.0067 
1.58  
1.11 
0.0003 
Anserine 
16.60 
 0.16 
2.14 0.54 
2.68  
1.11 
n.d. 0.0022 
5.80  
0.23 
0.0038 
N-
acetylcarnosine 
0.33  
0.14 
n.d. 0.0029 
0.13  
1.73 
n.d. 0.004 
5.44  
0.82 
0.0042 
Carnosinamide 
35.75 
 4.70 
1.44 1.77 
48.78 
 2.32 
0.78 1.48 
8.46  
2.37 
0.0078 
Gly-His 
38.70 
 3.44 
1.66 0.97 
19.30 
 3.21 
4.68 0.26 
9.72  
3.23 
0.0099 
Carcinine 2.23  
0.78 
9.53 0.11 
0.69  
0.01 
12.02 0.013 
2.66  
0.27 
0.0021 
Pyridoxamine 2.11  
0.47 
11.78 0.074 
2.47  
1.38 
9.31 0.081 
2.15  
0.08 
0.0017 
Hydralazine 
87.21 
 3.16 
0.33 10.29 
48.65 
 4.19 
0.85 2.58 100.0 9.44 
Aminoguanidine 2.27  
0.69 
8.40 0.16 
34.72 
 2.67 
1.67 0.96 
12.79 
 0.09 
0.011 
Metformin 0.47  
0.52 
n.d. 0.0039 
2.79  
0.94 
13.66 0.058 
3.05  
0.84 
0.0019 
148 
 
 
Tab 3.  Quenching activities of the RCS scavenger compounds tested towards HNE and pyridoxal as 
derived by both HPLC and competitive studies (MS). 
 
 
Compound 
HNE Pyridoxal 
HPLC studies MS competitive studies HPLC studies 
Q%1/1 
R5
0 
KQ Q%1/1 R50 KQ Q%10/1 KQ 
L-carnosine 
37.28  
2.29 
1.
52 
1.28 
25.42  
3.73 
1.34 4.11 
0.01  
0.98 
0.000
1 
D-carnosine 
36.33  
1.92 
2.
06 
0.62 
23.36  
3.06 
1.41 4.44 
0.22  
0.09 
0.000
2 
Carnosinol 
61.52  
1.88 
1.
48 
0.89 
38.12 
4.01 
1.21 3.81 
0.22  
0.09 
0.000
2 
Histidine 
18.27  
0.30 
5.
99 
0.13 
0.08  
3.33 
6.55 0.29 
2.90  
0.36 
0.001
5 
β-Alanine 
2.33   
0.51 
n.
d. 
0.00
91 
0.65  
2.80 
7.89 0.23 
1.01  
0.33 
0.000
5 
β-Ala + His 
30.01  
3.19 
2.
09 
0.39 
4.15  
2.11 
6.72 0.32 
4.48  
0.48 
0.002
5 
Homocarnosine 
5.47  
1.28 
7.
36
. 
0.01
5 
15.61  
3.20 
2.03 2.99 
1.58  
1.11 
0.000
3 
Anserine 
16.60  
0.16 
2.
14 
0.54 
12.00  
2.09 
2.61 0.81 
5.80  
0.23 
0.003
8 
N-
acetylcarnosine 
0.33  
0.14 
n.
d. 
0.00
29 
5.78  
0.43 
7.47 0.15 
5.44  
0.82 
0.004
2 
Carnosinamide 
35.75  
4.70 
1.
44 
1.77 
15.52  
3.80 
1.85 1.09 
8.46  
2.37 
0.007
8 
Gly-His 
38.70  
3.44 
1.
66 
0.97 
4.81  
2.97 
3.52 0.65 
9.72  
3.23 
0.009
9 
Carcinine 
2.23  
0.78 
9.
53 
0.11 
0.91  
0.70 
4.89 0.33 
2.66  
0.27 
0.002
1 
Pyridoxamine 
2.11  
0.47 
11
.7
8 
0.07
4 
0.04  
3.41 
10.1 0.12 
2.15  
0.08 
0.001
7 
Hydralazine 
87.21  
3.16 
0.
33 
10.2
9 
15.22  
3.29 
1.74 2.15 100.0 9.44 
Aminoguanidine 
2.27  
0.69 
8.
40 
0.16 
3.94  
3.19 
8.15 0.15 
12.79  
0.09 
0.011 
Metformin 
0.47  
0.52 
n.
d. 
0.00
39 
2.34  
1.69 
6.95 0.15 
3.05  
0.84 
0.001
9 
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Compound 
MGO Pyridoxal 
HPLC studies MS competitive studies HPLC studies 
Q%1/1 R50 KQ Q%1/1 R50 KQ Q%10/1 KQ 
L-carnosine 
12.82 
 1.62 
3.96 0.028 
4.12  
0.58 
8.42 0.0085 
0.01  
0.98 
0.0001 
D-carnosine 
1.26  
0.88 
7.89 0.0026 
2.21  
0.99 
n.d 0.0120 
0.22  
0.09 
0.0002 
Carnosinol 
36.39
 
1.65 
1.23 1.256 
13.56  
2.12 
3.56 0.0036 
0.22  
0.09 
0.0002 
Histidine 
8.92  
0.38 
n.d. 0.014 
2.14  
1.15 
n.d 0.042 
2.90  
0.36 
0.0015 
β-Alanine 
0.67  
0.76 
n.d. 0.0074 
0.21  
0.30 
n.d 0.057 
1.01  
0.33 
0.0005 
β-Ala + His 
1.28  
0.61 
12.12 0.041 
0.85  
0.33 
9.58 0.036 
4.48  
0.48 
0.0025 
Homocarnosine 
0.28  
0.08 
7.36 0.0067 
0.30  
0.27 
n.d 0.027 
1.58  
1.11 
0.0003 
Anserine 
2.68  
1.11 
n.d. 0.0022 
0.85  
0.09 
n.d 0.081 
5.80  
0.23 
0.0038 
N-acetyl carnosine 
0.13  
1.73 
n.d. 0.0004 
0.11  
0.43 
n.d 0.0084 
5.44  
0.82 
0.0042 
Carnosinamide 
48.78 
 2.32 
0.78 1.48 
15.21  
2.86 
2.15 0.055 
8.46  
2.37 
0.0078 
Gly-His 
19.30 
 3.21 
4.68 0.26 
4.52  
1.09 
6.96 0.072 
9.72  
3.23 
0.0099 
Carcinine 
0.69  
0.01 
12.02 0.013 
0.10  
0.03 
n.d 0.0035 
2.66  
0.27 
0.0021 
Pyridoxamine 
2.47  
1.38 
9.31 0.081 
0.12  
0.12 
10.78 0.063 
2.15  
0.08 
0.0017 
Hydralazine 
48.65 
 4.19 
0.85 2.58 
14.21  
2.04 
3.12 0.028 100.0 9.44 
Aminoguanidine 
34.72 
 2.67 
1.67 0.96 
11.27  
1.99 
4.21 0.063 
12.79  
0.09 
0.011 
Metformin 
2.79  
0.94 
13.66 0.058 
0.57  
0.17 
9.05 0.086 
3.05  
0.84 
0.0019 
 
Tab 4.   Quenching activities of the RCS scavenger compounds tested towards MGO and pyridoxal 
as derived by both HPLC and competitive studies (MS). 
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4.1.c.3.   Quenching activity towards HNE. 
 
Tables 3,4 collect the quenching activities towards HNE and pyridoxal as derived by both HPLC 
and competitive studies (the latter only for HNE). They were obtained by monitoring the 
consumption percentages (Q%  SD) of the carbonyl species after 3 and 24 h and considering 
several quencher/RCS ratios ranging from 1/10 to 10/1. For easy comparison, Table 2 summarizes 
these data focusing on the consumption percentages after 24 h and reporting (1) the consumption 
percentage averages as monitored by using an indicative 1/1 ratio (Q1/1), (2) the extrapolated ratio 
(R50) with which the quencher consumes the 50% of the tested carbonyl compound and (3) taking a 
cue from the Stern-Volmer constant (KSV), commonly used to parameterize fluorescence 
quenching, a quenching constant (KQ) is here proposed corresponding to the slope of the plot of 
Q%0/Q% versus the quencher/RCS ratio.  
 
 
4.1.c.4.    HNE Quenching by HPLC analyses. 
 
As a preamble, it should be remembered that carnosine derivatives react with α,β-unsaturated 
aldehydes through a multi-step mechanism involving an initial reversible unsaturated imino 
intermediate followed by the key intramolecular Michael addition between the histidine imidazole 
ring and the acceptor β-carbon atom (Fig. 2) [8]. 
 
 
 
Fig 2.  Reaction mechanism of the carnosine incubated  with HNE 
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Several hitherto reported quenching activities have been obtained by HPLC analyses using an 
acidified mobile phase which hydrolyses the imino intermediates and so the monitored activities 
were ascribable only to the quencher‟s ability to yield the final Michael adduct[9].  
To remain fully compatible to physiological conditions, the here reported activities (see Tab 2) are 
obtained using a mobile phase buffered at pH = 7.4. Hence, one may expect that the here reported 
activity is somewhat higher especially for those quenchers which easily form imino adducts 
regardless of their ability to transform them in stable Michael adducts. Albeit indirectly, the role of 
Schiff base formation at the equilibrium could be evaluated by considering the quenching of 
pyridoxal (Tab 2) 
A bird‟s eye view of Table 2suggests that the Q1/1 values are rather homogeneous and allow the 
tested quenchers to be roughly grouped into active (Q1/1> 30), intermediate  (Q1/1 around 20) and 
inactive compounds (Q1/1< 10), most derivatives belonging to the two extreme groups. Whereas, 
the R50 values and, even more so, the KQ constants, accounting for more tested ratios, appear to be 
broadly distributed allowing a better differentiation of the examined quenchers. A clear example of 
these different distributions is offered by the physical mixture His + β-Ala, which shows a Q1/1 
value which is comparable to that of L-carnosine, but a KQ constant which is about one fourth of 
that of L-carnosine. In this case, the difference evidenced by the KQ values appears to be more 
reasonable and confirms the synergic effect of the two amino acids when fused in a dipeptide as 
extensively discussed in previous studies. 
Regarding the length of the N-terminal residue, the reported data suggest that its extension (as seen 
in homocarnosine) is particularly detrimental, a result which can be explained by considering the 
stronger basicity (see Tab 1) of its amino group which prevents the imine formation. Conversely, 
shortening the N-terminal residue does not influence the quenching activity since Gly-His reports a 
reactivity comparable with that of L-carnosine. This result might be affected by the lower basicity 
of Gly-His, which promotes the imino formation regardless of the following Michael addition. 
Such a hypothesis is confirmed by the remarkable activity of gly-his towards pyridoxal (see Tab 3) 
as well as by the recently reported modest HNE quenching (about one half of L-carnosine) as 
obtained by gly-his in acidic condition.  
A similar behaviour is shown by carnosinamide, the remarkable activity of which might be due to 
the sum of both the Michael adduct and the imine formation, the latter playing a predominant role 
as suggested by its significant activity towards pyridoxal (see Tab 3) and confirmed by the reported 
poor HNE quenching activity as monitored in acidic conditions. The formation of both the imine 
and Michael adduct between carnosinammide and HNE was then confirmed by the MS analysis of 
the reaction mixture after 24 hours of incubation. As shown in Fig. 2 the imine and Michael 
adducts were easily identified at m/z 365 and m/z 383, respectively, and the structures fully 
characterized by MS/MS analysis. 
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Fig 3.  Mass spectra of the reaction mixture of  carnosinamide-HNE after 24h of incubation at 
37°C. A)  mass spectrum of the reaction Mixture of  carnosinamide-HNE characterized by the 
peaks  m/z 226 attributed to the carnosinamide, m/z  365 attributed to the Schiff Base and m/z 393 
attributed to the Michael Adduct.  B)  MS/MS spectrum of the Michael Adduct with am/z 393 
(collision energy 30V)  C)  MS/MS spectrum of the Schiff Base with am/z 365 (collision energy 
20V). 
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Taken together, the analyzed compounds confirm that the carboxylic function is not required for 
activity, a result which brings to mind the marked HNE quenching observed for the D-carnosine 
methyl ester. Nevertheless, the scarce activity of carcinine suggests that the carboxylic function 
cannot be completely removed, while it can be conveniently replaced by different H-bonding 
groups. 
Such considerations led to the design of carnosinol, a carnosinase resistant peptidomimetic where 
the hydroxyl group replaces the carboxylic function of carnosine. Carnosinol was found 
significantly more reactive in respect to carnosine and this can be clearly addressed to the ability of 
the hydroxyl group to form an hemiacetal intermediate with HNE which catalyzes the Michael 
adduct formation. 
Hence, regarding the HNE quenching mechanism of carnosinol we can propose one reaction 
mechanism similar to that already clarified for carnosine and based on the formation of an imine 
derivative that catalyse the Michael adduct as reported in the fig 4. 
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Fig 4.  Reaction mechanism 1 of the carnosinol incubated  with HNE through imino formation. 
 
The higher quenching activity of carnosinol in respect to carnosine is explained by considering the 
ability of the hydroxyl group to form an unsaturated hemiacetal that catalyzes the Michael adduction 
through a mechanism proposed in fig. 4. In particular the hemiacetal intermediate dehydrates giving 
an unsaturated enol which is in equilibrium with the corresponding a,β unsaturated keto adduct 
which in turn condenses with the imidazole ring yielding the final Michael Adduct. 
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Fig .5 Reaction mechanisms 2 of the carnosinol incubated  with HNE through hemiacetal  formation. 
 
Fig 5 shows the MS spectrum of the reaction mixture containing carnosinol and HNE. Besides the 
peak ion at m/z 213 referred to the unreacted carnosinol, two peaks are well detected at m/z 369 and 
351 which can be attributed to the Schiff base and to the Michael adduct, respectively. Moreover, on 
the basis of the additional mechanism involving the hydroxyl group, The two peaks can also be 
attributed to the enol/keto-adduct at m/z 351 and to the unsaturated hemiacetal adduct at m/z 369 
which are isobaric to the Schiff base and to Michael adduct, respectively. The structure of the four 
proposed reaction products were then confirmed on the basis of the MS/MS fragment ions and the 
attributed fragment ions are reported in Fig. 6. 
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Fig 6.  Mass spectra of the reaction mixture of  carnosinol-HNE after 24h of incubation at 37°C. 
A)  mass spectrum of the reaction Mixture of  carnosinol-HNE characterized by the peaks  at 
m/z 213 attributed to the carnosinol, m/z 351 attributed to the Schiff Base and m/z 369 attributed to 
the Michael Adduct.  B)  MS/MS spectrum of the Michael Adduct at m/z 369 (collision energy 35V)  
C)  MS/MS spectrum of the Schiff Base at m/z 351 (collision energy 25V). 
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Fig 7. Mass spectra relative to the reaction mixture containing carnosinol and HNE incubated 
for24h  at 37°C.  A)mass spectrum of the reaction Mixture of carnosinol-HNE characterized by the 
peaks at m/z 213 attributed to the carnosinol, m/z 351 attributed to both the Schiff Base and 
enol/keto-adduct, m/z 369 attributed to both the Michael Adduct and the unsaturated hemiacetal 
adduct. B)MS/MS spectrum of hemiacetal with am/z 369 (collision energy 25V) C)MS/MS spectrum 
of the Michael Adduct derived from the  unsaturated keto/enol with am/z 351 (collision energy 30V).  
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As mentioned above commenting on the activity of the physical mixture, the obtained results 
confirm the synergic effect of carnosine since the two amino acids alone show modest activity. 
Finally, the reported quenching activities confirm that L-carnosine and D-carnosine show a 
similar activity towards HNE, although fig 2 evidences a greater activity of L-carnosine at the 
highest ratios. This unexpected result suggests that the diasteroisomeric intermediates which 
form during the quenching mechanism may differ in their reactivity.   
With regard to the reference compounds, hydralazine shows an impressive reactivity since it 
quenches almost all HNE in the reported 1/1 ratio even though such a reactivity can be due to the 
marked ability of the hydrazine function to give stable imino adducts as suggested by its marked 
quenching towards pyridoxal. Conversely, the other three compounds are substantially inactive 
thus indicating that their nucleophilic groups are able to yield neither stable imines nor Michael 
adducts.  
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4.1.c.5.    HNE Quenching by MS competitive studies. 
 
As we recently proposed, a more realistic picture of the quenching ability of the tested compounds 
can be given by competitive studies by which the activity of a given compound is evaluated by 
monitoring its capacity to inhibit the formation of the HNE induced adducts on a target protein, the 
human ubiquitin, whose carbonylation specifically involves Lys6 and His68, as recently 
investigated (see chapter 3.a.1.). These competitive data should be more realistic for two major 
reasons. First, the so obtained quenching activities account also for kinetic factors since slow 
reacting quenchers cannot compete with HNE thus providing lower quenching activity, regardless 
of their intrinsic reactivity which was already monitored by HPLC studies. Second and despite 
being measured at physiological pH, the reversible adducts (e.g. the Schiff bases) cannot compete 
at the equilibrium with protein carbonylation and thus these competitive activities should account 
only for the formation of stable and irreversible adducts (e.g. the Michael adducts).  
Moreover, it should be noted that these results can be affected by nonspecific non-covalent 
interactions between protein and quencher. Such interactions can overestimate the quenching 
ability when they shield protein regions around the adducted residue(s), or they can underestimate 
activity when they involve unreactive protein regions by which they remain trapped. An illustrative 
example of this biasing protein-quencher interaction is provided by N-acetyl carnosine, which 
shows a modest albeit detectable activity even though its masked amino group should prevent the 
formation of the key imino intermediate. This result may be justified by considering that N-acetyl 
carnosine, due to its anionic state, stably interacts with the cationic residues on the protein surface, 
and thus the reactive Lys6 residue remains masked and less inaccessible to HNE.  
Fig 3 and Tab 2 summarize the obtained data showing a broad distribution of the quenching 
activities thus allowing a clear differentiation of the tested compounds. As expected, the reported 
data are, on average, lower than the corresponding activities as derived by HPLC analyses. 
However, Tab 2 shows a remarkable correlation between the R50 values obtained by the two 
utilized approaches and the fact that these two parameters correlate despite their different nature 
can be seen as a mutual validation of the respective methods used to derive them. 
The first consideration involves the two carnosine enantiomers which show the highest quenching 
activity even considering the reference compounds. This result can be easily explained considering 
that the impressive activity of hydralazine as observed by HPLC studies is largely influenced by its 
ability to yield stable but reversible imino adducts, while quenching of the carnosine enantiomers 
involves preferentially the irreversible Michael adducts.  
With regard to the length of the N-terminal residue, the competitive data appear to be significantly 
different compared to those obtained by HPLC analyses. Indeed, both extension and shortening are 
here found to be detrimental even though the extension appears to possess a less negative effect 
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since homocarnosine retains a quenching activity which is about one half that of carnosine, while 
Gly-His shows a more marked drop in activity. This different result suggests that homocarnosine, 
although its greater basicity hampers the initial imino formation, can conveniently yield the final 
Michael adducts. Whereas, Gly-His, although its lower basicity promotes the initial imino 
formation, cannot easily give the final Michael adducts due to the instability of the constrained 
macrocyclic intermediates, a drawback affecting all carnosine derivatives in which β-Ala is 
replaced by an α-amino acid.  
Similarly, carnosinamide appears to be less reactive in these competitive studies compared to the 
HPLC results. As recently reported, such a decrease in activity can be explained considering that 
the terminal amido group can stabilize π-π stacking contacts with the imidazole ring thus 
hampering its interaction with the acceptor β-carbon atom. The very poor activity of carcinine 
confirms that the carboxyl group can be modified but not completely removed. 
Though showing some modest differences compared to HPLC data, these competitive results 
confirm the substantial inactivity of the single amino acids as well as of their physical mixture and 
reveal a group of carnosine derivatives (namely, anserine, homocarnosine and carnosinamide) 
which, while showing lower activity compared to that of carnosine, conserve a significant 
quenching activity which render them potential alternatives to carnosine itself. Carnosinol was 
confirmed the most reactive and efficient tested compound. 
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4.1.c.6.  Pyridoxal Quenching by HPLC analyses and ligand selectivity. 
 
Fig 4 and Tab 2 collect the obtained data concerning the consumption of pyidoxal at different ratios 
after 24 h. Since this quenching is an undesired feature, Tab 2 reports the consumption percentage 
averages as monitored by using the most challenging 10/1 ratio (Q1/10 instead of Q1/1 data) plus the 
corresponding KQ constants. The corresponding R50 values are not reported since most compounds 
are too poorly reactive towards pyridoxal to extrapolate such a parameter. 
Tab 2 reveals indeed that most of the tested compounds possess a very low quenching activity 
towards pyridoxal and only two quenchers, hydralazine and aminoguanidine, show a Q10/1 value 
greater than 10%. Specifically, hydralazine shows a remarkable quenching activity towards 
pyridoxal, which is comparable to that towards HNE, as seen in their KQ values, and renders the 
quencher unsafely unselective, a well-known problem first observed by Rumsby and Shepherd in 
1979[10]. 
Similarly, the significant pyridoxal quenching exhibited by aminoguanidine can easily explain why 
its clinical trials were discontinued, even though the corresponding pyridoxal-aminoguanidine 
adduct was found to maintain a significant capacity to prevent neuropathy and cataract in diabetic 
rats which is ascribable to the pyridoxal‟s antioxidant activity. Finally, the obtained results confirm 
the satisfactory selectivity of both pyridoxamine and metformin thus explaining why pyridoxamine, 
while considering the cardiovascular adverse drug events typically related to compounds belonging 
to the vitamin B family, is under investigation in a trial involving 300 patients to further test the 
effects of pyridoxamine on the serum creatinine level[11].  
 
All carnosine derivatives show very modest quenching activity towards pyridoxal even though one 
may note two compounds, namely Gly-His and carnosinamide, the Q10/1 values of which approach 
the threshold of 10% thus representing the less selective carnosine derivatives. Interestingly, these 
two analogues show marked differences in HNE quenching between HPLC and competitive data 
further emphasizing their remarkable propensity to yield stable (but reversible) imino adducts. 
Nevertheless, their reactivity suggests different explanations. For Gly-His, it is ascribable to the 
lower basicity of its amino group which increases the relative abundance of its neutral and reactive 
form. Whereas, the reactivity of carnosinamide may be explained by supposing that its amino 
group, not involved in intramolecular ion-pairs, is more accessible regardless of its basicity.  
The correlations between pyridoxal quenching and HPLC data for HNE quenching are documented 
by Tab 2 which shows a fair correlation between the corresponding Q1/1 and Q1/10 percentages (r
2
 = 
0.58) while there is no correlation between the corresponding parameters of pyridoxal quenching 
and MS competitive analyses (r
2
 = 0.02). Overall, these results bring to mind the similarly poor 
correlations obtained by analysing proteinogenich istidine containing dipeptides and emphasize that 
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pyridoxal and HNE quenching occur through two completely distinct mechanisms since the former 
is a single step process not involving the irreversible Michael addition. Nonetheless, the HPLC 
data, when acquired at pH = 7.4, unavoidably account also for the reversible imino formation thus 
justifying the greater correlation as discussed above.  
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4.1.c.7.  MGO Quenching by HPLC and MS competitive studies. 
 
As ascribable in the case of HNE analysis, Tab 2 and 4 summarize the obtained data showing a broad 
distribution of the quenching activities thus allowing a clear differentiation of the tested compounds. 
As expected, the reported data are, on average, lower than the corresponding activities as derived by 
HPLC analyses. However, a remarkable correlation between the R50 values obtained by the two 
utilized approaches and the fact that these two parameters correlate despite their different nature can 
be seen as a mutual validation of the respective methods used to derive them. 
 
 
 
Fig 8.  General scheme of the reaction products formation of glyoxal and gethylglyoxal with Lysine 
residues in protein. 
 
As reported in Tab 4, contrary to what observed for HNE, L-car shows only a slight higher activity in 
respect to the mixture His + Ala, thus suggesting that the quenching activity towards MGO strongly 
depends on the amino group. The higher activity of β-Alain respect to His as MGO scavenger can be 
addressed to the large difference in the amino group basicity. The key effect of the amino group 
basicity on MGO quenching is clear shown by considering the following compounds:  
homocarnosine, L-carnosine, Gly-His where the quenching activity well correlates with the amino 
group basicity. 
The high reactivity of carnosinamide further confirms the key role of the amino group. In particular 
the high reactivity of the carnosinamide can be ascribed to the fact that here the amino group is not 
involved in intramolecular salt bridge and thus is more susceptible to the reaction with MGO. 
Other groups can clearly affect the reactivity of the sequestering agent towards MGO, such as the 
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imidazolic ring as highlighted by anserine.  
The involvement of the amino group in the chemical reaction is well confirmed by the 
characterization of the adducts by MS. Most of the considered sequestering agents form a MOLD 
like reaction products that is generated by the reaction of the amino groups of two sequestering 
agents with two MGO, leading to an imidazolium cross-link.  
As an example here below is the MS spectra of the reaction mixture (24 hrs incubation) of Gly-His 
with MGO which is characterized by the ion referred to the MOLD like adduct at m/z 461.89 and the 
di-imine-GOLD derivative formed by ring opening. 
 
 
 
Fig 9.  Mass spectra of the reaction mixture of  Gly-His with MGO after 24h of incubation at 37°C. 
A)  mass spectrum of the reaction mixture of  Gly-His-MGO characterized by the peaks   
m/z 213 attributed to the Gly-His- m/z,461 attributed to the MOLD (Methylglyoxal-derived Lysine 
Dimer.) B)  MS/MS spectrum of the MOLD adduct with am/z 461 (collision energy 30V). 
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The reaction mechanism is summarized in fig 10. 
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Fig 10.  Reaction mechanism of the Gly-His incubated  with MGO. The first reaction step leads to 
the MOLD like adduct (Methylglyoxal-derived Lysine Dimer) arising from the reaction between  two 
molecules of Gly-His with two molecules of MGO, followed by the ring opening and the concomitant   
diimine-GOLD derivative formation. 
 
The characterized adducts confirm the key role of the amino basicity which influences also the 
addition mechanisms. A similar reaction mechanism was also observed for carnosine although in this 
case the MOLD like adduct at m/z 501 was identified as the unique detectable adduct while the imino 
adducts was undetected to the higher basicity of carnosine that make the immine derivative less 
stable. 
 
 
 
 
 
Fig 11.  Reaction mechanism of carnosine with MGO forming the MOLD like adduct 
(Methylglyoxal-derived Lysine Dimer) adduct which is generated by the reaction between  two 
molecules of carnosine with two molecules of MGO. 
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Fig 12.  Mass spectra of the reaction mixture of  carnosine-MGO after 24h of incubation at 37°C. 
A)  mass spectrum of the reaction mixture of  carnosine-MGO characterized by the peaks   
m/z 227 attributed to the carnosine, m/z  501 attributed to the MOLD (Methylglyoxal-derived Lysine 
Dimer.)B)  MS/MS spectrum of the MOLD adduct with am/z 501 (collision energy 35V) . 
 
Although the quenching mechanism for MGO appears to be strictly related to its condensation with 
the quencher‟s amino group, the marked difference between L-car and D-car suggest a more 
complex adducts which involve diastereoisomeric intermediates which render the quenching 
mechanism enantioselective. 
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Fig 13.  Mass spectra of the reaction mixture of carnosinol-MGO after 24h of incubation at 37°C. 
A)  mass spectrum of the reaction mixture of  carnosinol-MGO characterized by the peaks   
m/z 213 attributed to the carnosinol, m/z  472 attributed to the MOLD (Methylglyoxal-derived Lysine 
Dimer.)B)  MS/MS spectrum of the MOLD adduct with am/z 472 (collision energy 35V).   
 
Similalry to carnosine, also carnosinol reacts with MGO forming a MOLD like adduct at m/z 472.15 
as shown in Fig 13 The higher quenching activity of carnsoinol in respect to carnosine could be 
explained by considering the presence of the hydroxyl function which can contribute to the MGO 
quenching through the formation of an hemiacetal adduct.  
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4.2.  Exploring the space of histidine containing dipeptides in search of 
novel efficient RCS sequestering agents. 
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4.2.a.  Abstract. 
 
The study reports a set of forty proteinogenic histidine-containing dipeptides as potential 
carbonyl quenchers. The peptides were chosen to cover as exhaustively as possible the 
accessible chemical space, and their quenching activities towards 4-hydroxy-2-nonenal 
(HNE) and pyridoxal were evaluated by HPLC analyses. The peptides were capped at the 
C-terminus as methyl esters or amides to favor their resistance to proteolysis and 
diastereoisomeric pairs were considered to reveal the influence of configuration on 
quenching. On average, the examined dipeptides are less active than carnosine (βAla + 
His) thus emphasizing the unfavorable effect of the shortening of the βAla residue as 
confirmed by the control dipeptide Gly-His. Nevertheless, some peptides show promising 
activities towards HNE combined with a remarkable selectivity. The results emphasize the 
beneficial role of aromatic and positively charged residues, while negatively charged and 
H-bonding side chains show a detrimental effect on quenching. As a trend, ester 
derivatives are slightly more active than amides while heterochiral peptides are more active 
than their homochiral diastereoisomer. Overall, the results emphasize that quenching 
activity strongly depends on conformational effects  and vicinal residues (as evidenced by 
the reported QSAR analysis), offering insightful clues for the design of improved carbonyl 
quenchers and to rationalize the specific reactivity of histidine residues.  
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4.2.b.  Introduction. 
 
Reactive carbonyl species (RCSs) are electrophilic molecules which react with nucleophilic groups 
in proteins yielding oxidative-based non-enzymatic protein adducts[1-3]. These covalent adducts 
can be subdivided into two major classes depending on the source of the reactive species. 
Advanced glycation end products (AGEs) are generated by sugars or sugar derivatives including 
di-carbonyl derivatives such as glyoxal (GO), methylglyoxal (MGO), and 3-desoxyglucosone (3-
DG), while lipid-oxidation end products (ALEs) are formed by the oxidative reactions of lipids 
comprisingα,β-unsaturated carbonyls such as 4-hydroxy-2-nonenal (HNE),4-oxo-2-nonenal (ONE) 
and acrolein (ACR)[4, 5]. AGEs and ALEs are involved in oxidative cellular damage through 
different mechanisms[6] including protein dysfunction, protein oligomerization and 
fibrillogenesis[7], altered signal transduction, immune response[8] and activation of the receptor 
for AGEs (RAGE)which is a type I transmembrane glycoprotein of the immunoglobulin 
superfamily of cell surface receptors[9]. AGEs and ALEs have been widely accepted as biomarkers 
for oxidative-based diseases[10]. Moreover, taking into account the most recent studies reporting 
that AGEs and ALEs are involved in the pathogenesis of several diseases, including diabetes and 
arteriosclerosis, they are now also considered as promising targets for therapeutic intervention. This 
is promoting the design of carbonyl scavengers able to trap RCSs converting them into nontoxic 
and easily excretable derivatives so inhibiting protein carbonylation and all downstream pathways 
[11,12]. 
Although clinical investigations are still very limited, several in vitro and in vivo animal studies 
demonstrated that carnosine (βAla-His), an endogenous dipeptide found in millimolar 
concentrations in some tissues such as brain, heart and skeletal muscles[13, 14], is able to detoxify 
RCS, inhibiting AGEs and ALEs formation and restraining oxidative-based diseases. The 
mechanism by which carnosine prevents AGEs and ALEs formation is still under investigation and 
the involvement of multiple molecular mechanisms should be considered, given that the formation 
of AGEs and ALEs can involve different reactions and several catalysts including transition metals 
[15, 16]. Nevertheless, there is enough evidence to indicate that carnosine acts by a direct 
quenching mechanism, at least for α,β-unsaturated aldehydes as clearly demonstrated by two 
independent groups[17, 18].  
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Fig 1.  Quenching mechanisms of carnosine with HNE and pyridoxal. One may note that 
quenching of pyridoxal involves a reversible condensation which yields the corresponding imine 
adduct, whereas HNE quenching occurs through a multi-step mechanism involving firstly the 
reversible imine intermediate, then the key intramolecular Michael addiction and lastly the 
hydrolysis of imine group to give the final hemiacetal adduct. 
 
As shown by Fig 1, carnosine reacts with α,β-unsaturated aldehydes through a multi-step 
mechanism involving the initial formation of a reversible unsaturated imino intermediate followed 
by the key intramolecular Michael addition between the histidine imidazole ring and the acceptor 
β-carbon atom. The imino intermediate acts as an intramolecular catalyst promoting a stable 
approach between the two reacting centers, thus explaining why a mixture of the two separate 
amino acids (βAla + His) does not possess a significant quenching activity. Similarly, the 
reversible nature of the imino intermediate can explain why carnosine selectively quenches reactive 
α,β-unsaturated carbonyls without stably trapping physiological carbonyl compounds[19]. 
Despite these promising results, the beneficial activity of carnosine is limited in humans due to its 
unfavorable pharmacokinetic profile. Indeed, carnosine is actively absorbed by peptide transporters 
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(hPepT1) [20] but immediately hydrolyzed in human plasma to its constituent amino acids by 
specific dipeptidases such as serum carnosinase (CN1) [21]. Considering the therapeutic interest of 
carnosine, it comes as no surprise that many analogues have been reported in the last few years. As 
recently reviewed[22], these derivatives have been designed with a view to A) increasing 
quenching activity, B) maintaining the mentioned selectivity, and C) ensuring a satisfactory oral 
bioavailability by preventing carnosinase-catalyzed hydrolysis while preserving active absorption 
by hPepT1. A critical analysis of all reported carnosine analogues[22], combined with 
computational studies involving serum carnosinase and peptide transporters[23-25], revealed that 
the carboxyl terminus and the β-alanine carbon skeleton can be largely modified to improve 
pharmacokinetic profile without detrimentally affecting quenching activity. Notably, C-terminus 
capping is a well-known strategy to enhance plasma stability by hampering peptide recognition by 
all hydrolases, thus suggesting that such a modification should prevent the hydrolytic effects of 
both specific carnosinases and nonspecific peptidases[26]. Conversely, the primary amino group 
and the imidazole ring are mandatory for quenching activity and cannot be modified without 
markedly altering efficiency and/or selectivity.  However, it is worth observing that all proposed 
derivatives modified at the β-alanine residue were produced by replacing it with other β-amino 
acids, while the possibility of replacing β-alanine with proteinogenic α-amino acids has never been 
examined comprehensively. 
 
On these bases, the present study was undertaken to investigate the quenching activity of 
proteinogenic histidine-containing dipeptides exploring as exhaustively as possible their accessible 
chemical space. Since the carnosine carboxyl group is not required for carbonyl scavenging and its 
modifications can improve the resulting pharmacokinetic profile (see above), the dipeptides were 
prepared with the C-terminus capped by a methyl ester or a primary amido group so as to study 
dipeptides which should be still recognized by peptide transporters and resistant to proteolysis. 
Moreover, the study considered diastereoisomeric pairs of dipeptides produced by alternating the 
absolute configuration of the histidine residue with a view to revealing the effect of configuration 
on quenching activity. Indeed, while the two carnosine enantiomers have the same quenching 
activity[27], a result easily explainable since two enantiomers must possess the same chemical 
reactivity, the introduction of a second chiral center should allow diastereoisomeric differences 
useful for a better understanding of the precise scavenging mechanism.  
The results obtained in this work should provide new clues to design carnosine analogues which, 
while maintaining the same reactive moieties, are structurally quite different compared to the 
parent compound. Finally, the quenching activity of these proteinogenic dipeptides could improve 
our understanding of the factors influencing protein carbonylation, showing in particular whether 
dietary or endogenous proteins can become detoxifying agents after partial digestion. 
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4.2.c.  Experimental. 
 
 
4.2.c.1.  Reagent and materials. 
 
4.2.c.1.1.  Chemicals. 
 
The forty analyzed dipeptides (twenty diastereoisomeric pairs) are listed in Tab 1. The twenty 
methyl esters (Tab 1A, of general formula NH2-L-X-(L or D)-His-OMe) were synthesized as 
described in a previous study [39], while the twenty amides (Tab 1B, of general formula NH2-L-X-
(L or D)-His-NH2) were purchased from EZBiolab (EZBiolab Inc, Carmel, IN, USA)with a purity 
greater than 95%. Lastly, Gly-His was purchased by Sigma-Aldrich (St Louis, MO, USA). HNE 
was prepared from synthesized 4-hydroxy-non-2-enal diethylacetal as previously described [36] 
and quantitated by UV spectroscopy (λ max 224 nm; ε=  13.75 x 104 cm-1 M-1). 
 
 
4.2.c.1.2.  Quenching activity and selectivity by HPLC studies. 
 
The reactivity of each dipeptide toward 4-hydroxy-2-nonenal (HNE, quenching activity) was 
evaluated by measuring the HNE consumption (50 µM in 10 mmol PBS, pH 7.4) in the presence of 
the tested compound (1 mM ) during a fixed incubation time (180 min, T = 37 ° C). HNE 
consumption was determined by HPLC using a quaternary pump HPLC system and a PDA detector 
(Surveyor LC system, ThermoQuest, Milan, Italy) set at 224 nm. Separations were done by 
reversed-phase elution with a Phenomenex Synergy Fusion column (150 mm x 2 mm i.d.,4 μm) 
protected by a Synergy Fusion R-P guard column (CPS Analitica, Milan Italy), thermostated at 
37°C, and using H2O/CH3CN/ HCOOH, 40/60/0.1 (v/v/v) as mobile phase at a flow rate of 0.25 
ml/min. Selectivity was determined after the same incubation time  and using pyridoxal (PYR)  as 
the target aldehyde (as represented in Fig 1). Pyridoxal consumption was determined by HPLC 
using a fluorimetric detector as previously reported[40]. All results are reported as percentages of  
aldehyde  consumption with respect to a blank incubated in the absence of the tested compound. 
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4.2.c.1.3.  Serum stability. 
 
Serum stability was evaluated by incubating the target peptide (50 µm final concentration) in 
human serum from healthy donors (30–40 years). After incubation for 30 min at 37°C, the 
incubation mixture was chilled in ice, spiked with Tyr-His as internal standard (50 µM final 
concentration), deprotonated by perchloric acid (PCA, 700 mM final concentration), and 
centrifuged at 18000 rpm (30000 g) for 10 min. The supernatants were then diluted 1:1 (v/v) with 
mobile phase A (CH3CN/H2O/heptafluorobutyric acid 90:10:0.1 v/v/v), filtered through 0.2 µm 
filters, and then injected into the LC–MS system. Analyses were performed using a 
ThermoFinnigan Surveyor LC system equipped with a quaternary pump, a Surveyor autosampler, a 
vacuum degasser, and connected to a TSQ Quantum Triple Quadrupole Mass Spectrometer 
(ThermoFinnigan Italia, Milan, Italy). Chromatographic separations were done by reverse phase 
elution with a Phenomenex Sinergy polar-RP column (150mm×2mm i.d.; particle size 4μm) 
(Chemtek Analytica, Anzola Emilia, Italy) protected by a polar-RP guard column (4mm×2mm i.d.; 
4μm) kept at 25 °C and by a gradient elution from 100% phase A to 80% phase B (CH3CN) in 12 
min at a flow rate of 0.2 ml min
-1
 (injection volume 10 µl); the composition of the eluent was then 
restored to 100% A within 1 min, and the system was re-equilibrated for 6 min. The mass 
spectrometer was equipped with an electrospray interface (ESI), which was operated in the 
positive-ion mode, and controlled by Xcalibur software (version 1.4).The samples rack was 
maintained at 4 °C. ESI interface parameters (positive-ion mode) were set as follows: middle 
position; capillary temperature 270 °C; spray voltage 4.0 kV. Nitrogen was used as the nebulizing 
gas at the following pressure: sheath gas 30 psi; auxiliary gas 5 a.u. MS conditions and tuning were 
optimized for each peptide by mixing through a T-connection the water-diluted stock solutions of 
analytes (flow rate 10 μl/min), with the mobile phase A maintained at a flow rate of 0.2 ml/min: the 
intensity of the [M+H]
+
 ions of the target peptide were monitored and adjusted to the maximum by 
using the Quantum Tune Master® software.  The serum content of each peptide was determined by 
recording the single ion traces (SICs) relative to the [M+H]
+
 in positive ion mode and using Tyr-
His as internal standard.  The results are reported as percentage remaining of the tested compound 
with respect to a blank incubated in the absence of serum.  
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4.2.c.1.4.   Computational studies.  
 
The amide derivatives were analyzed by the same computational procedures as carried out for the 
methyl esters in the previous study[39]. In detail, they underwent MD simulations in vacuo, in 
water and in chloroform to investigate their dynamic behavior in media of different polarity. The 
MD runs lasted for 10 ns and the computational details can be found elsewhere[39].  
The reported predictive equations were developed by using the property averages and ranges as 
obtained by above mentioned MD simulations as well as a set of well-known 2D/3D descriptors as 
computed by the VEGA suite of programs[47]. Moreover and since all tested peptides underwent 
MD runs, all considered conformer-dependent 3D descriptors were calculated by averaging the 
corresponding values for all frames memorized during MD simulations in vacuo. As evidenced by 
previous analyses[48], such averages should be indeed more informative than a single property 
value albeit computed for the lowest energy conformation.  
 
As indicated above, the equations were iteratively generated by multiple linear regression analysis 
as implemented in the Analyse-it program (Analyse-it Software, Ltd., Leeds, UK). The equations 
included at most four non-interrelated (i.e. variance inflation factor, VIF, greater than 5) 
independent variables automatically selected  from among the 35 molecular descriptors as 
described above. 
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4.2.d.   Results. 
 
 
4.2.d.1.  Overview. 
 
The forty dipeptides were protected either as methyl esters (Tab S1A) or as primary amides (Tab 
S1B). These protecting groups were chosen following a recent study on D-carnosine prodrugs 
which evidenced that D-carnosine methyl ester is completely stable in human plasma and possesses 
a quenching activity almost identical to that of unmodified D-carnosine[28]. Similarly, Bertinaria 
and co-workers reported a set of amide analogues generated by coupling the carnosine carboxyl 
group with bulky primary amines[29]; these compounds were found to be stable but to have a 
quenching activity somewhat weaker than that of carnosine. Collectively, these results confirm that 
C-terminus modification is a suitable strategy to ensure plasma stability (as experimentally 
confirmed for some dipeptides, see below) and suggest that the smaller the protecting group the 
greater the quenching activity thus rationalizing the modifications exploited here. 
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Table S1A. Methyl esters 
Dipeptide HNE PYR 
HNE/PYR 
 quenching Dev. Std quenching Dev. Std 
Carnosine 48.20 --- 5.57 --- 8.65 
Gly-His 9.11 0.75 3.77 0.55 2.42 
L-Asn-L-His-OMe 9.59 3.08 1.00 0.44 9.59 
L-Asn-D-His-OMe 9.50 3.27 1.14 0.64 8.33 
Δ (Asn-His-OMe) +0.09 p > 0.05 -0.14 p > 0.05 +1.26 
L-Cys-L-His-OMe 100.00 --- 25.26 1.56 3.96 
L-Cys-D-His-OMe 100.00 --- 40.78 0.73 2.45 
Δ (Cys-His-OMe) 0.00 ND -15.52 p < 0.05 +1.51 
L-Glu-L-His-OMe 12.21 4.37 0.76 0.78 16.07 
L-Glu-D-His-OMe 13.12 2.15 0.73 1.19 17.97 
Δ (Glu-His-OMe) -0.91 p > 0.05 +0.03 p > 0.05 -1.91 
L-His-L-His-OMe 6.00 1.75 1.82 1.14 3.30 
L-His-D-His-OMe 8.86 2.13 7.70 0.78 1.15 
Δ (His-His-OMe) -2.86 p > 0.05 -5.88 p < 0.05 +2.15 
L-Lys-L-His-OMe 31.27 1.06 1.87 0.54 16.72 
L-Lys-D-His-OMe 10.20 0.98 0.35 0.11 29.14 
Δ (Lys-His-OMe) +21.07 p < 0.05 +1.52 p < 0.05 -12.42 
L-Met-L-His-OMe 0.17 0.80 2.61 0.17 0.07 
L-Met-D-His-OMe 1.81 1.49 3.11 0.29 0.58 
Δ (Met-His-OMe) -1.64 p > 0.05 -0.50 p < 0.05 -0.52 
L-Ser-L-His-OMe 5.18 0.14 0.10 0.65 51.80 
L-Ser-D-His-OMe 5.91 0.37 2.08 1.55 2.84 
Δ (Ser-His-OMe) -0.73 p > 0.05 -1.98 p > 0.05 +48.96 
L-Trp-L-His-OMe 11.71 2.51 4.20 0.23 2.79 
L-Trp-D-His-OMe 18.83 3.75 5.81 0.55 3.24 
Δ (Trp-His-OMe) -7.12 p < 0.05 -1.61 p < 0.05 -0.45 
L-Tyr-L-His-OMe 12.53 0.78 4.02 0.29 3.12 
L-Tyr-D-His-OMe 27.44 1.08 1.29 1.08 21.27 
Δ (Tyr-His-OMe) -14.91 p < 0.05 +2.73 p < 0.05 -18.15 
L-Val-L-His-OMe 4.97 2.46 0.87 0.42 5.71 
L-Val-D-His-OMe 16.92 1.27 3.62 4.27 4.67 
Δ (Val-His-OMe) -11.95 p < 0.05 -2.75 p > 0.05 +1.04 
Means 20.31± 
28.31 
 5.46 ± 9.94  10.24  ± 12.64 
(L, L) Means 19.36 ± 
29.53 
 4.25 ± 7.51  11.31  ± 15.32 
(L, D) Means 21.26 ± 
28.59 
 6.66 ± 12.22  9.17 ± 10.01 
Δ Mean 
-1.90 ± 
9.64 
 -2.41 ± 5.18  +2.15 ± 17.79 
 
 
 
 
 
178 
 
 
Table S1B. Amides 
Dipeptide HNE PYR 
HNE/PYR 
 quenching Dev. Std quenching Dev. Std 
L-Gln-L-His-NH2 9.37 0.56 2.65 0.64 3.54 
L-Gln-D-His-NH2 14.76 0.68 1.57 1.44 9.40 
Δ (Gln-His-NH2) -5.39 p < 0.05 1.08 p > 0.05 -5.87 
L-Cys-L-His-NH2 100 --- 27.7 0.96 3.61 
L-Cys-D-His-NH2 100 --- 37.2  0.84 2.69 
Δ (Cys-His-NH2) 0.00 ND -9.50 p < 0.05 +0.92 
L-Asp-L-His-NH2 5.99 0.92 1.49 0.97 5.16 
L-Asp-D-His-NH2 5.98 0.58 1.16 1.31 4.02 
Δ (Asp-His-NH2) 0.01 p > 0.05 0.33 p > 0.05 +1.14 
L-His-L-His-NH2 9.81 0.21 7.86 0.32 1.35 
L-His-D-His-NH2 9.16 0.6 7.28 0.66 1.26 
Δ (His-His-NH2) 0.65 p > 0.05 0.58 p > 0.05 +0.01 
L-Lys-L-His-NH2 15.72 0.27 0.41 0.56 38.34 
L-Lys-D-His-NH2 4.16 0.45 0.75 0.41 5.55 
Δ (Lys-His-NH2) 11.56 p < 0.05 +0.34 p > 0.05 -32.79 
L-Trp-L-His-NH2 8.62 0.12 1.86 0.74 6.01 
L-Trp-D-His-NH2 11.17 0.72 0.13 0.05 86.20 
Δ (Trp-His-NH2) -2.55 p < 0.05 1.76 p < 0.05 -80.19 
L-Thr-D-His-NH2 12.12 0.81 6.62 0.33 1.83 
L-Thr-L-His-NH2 3.90 0.58 1.42 0.83 2.75 
Δ (Thr-His-NH2) -8.22 p < 0.05 -5.20 p < 0.05 +0.92 
L-Arg-L-His-NH2 7.79 0.72 0.26 0.12 29.96 
L-Arg-D-His-NH2 12.0 0.63 0.43 0.2 27.91 
Δ (Arg-His-NH2) -4.21 p < 0.05 -0.17 p > 0.05 -2.05 
L-Phe-L-His-NH2 9.79 0.47 1.22 0.6 8.02 
L-Phe-D-His-NH2 6.7 0.46 0.7 0.08 9.57 
Δ (Phe-His-NH2) -3.09 p < 0.05 -0.52 p > 0.05 +1.55 
L-Ile-L-His-NH2 7.09 0.79 2.02 0.73 3.51 
L-Ile-D-His-NH2 5.13 0.15 0.59 0.34 8.69 
Δ (Ile-His-NH2) 1.96 p < 0.05 1.43 p < 0.05 -5.19 
Means 17.96 ± 
28.24  
 5.17 ± 9.74  13.25 ± 
20.13 
(L, L) Means 18.63 ± 
28.72 
 5.21 ± 8.30  10.13 ± 
12.95 
(L, D) Means 17.29 ± 
29.28 
 5.12 ± 
11.45 
 15.81 ± 
25.89  
Δ Mean -0.93 ± 
5.37 
 
-0.99 ± 
3.57 
 
-12.15 ± 
26.03  
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Table S1C.  Overall means 
Dipeptide HNE PYR HNE/PYR 
Overall mean 19.14  ± 27.93 5.31 ±  9.72 11.74 ± 16.61 
Overall means of esters 20.31 ± 28.31 5.46 ± 19.89 10.24 ± 12.64 
Overall means of amides 17.96 ± 28.24  5.17 ± 9.74 13.25 ± 20.13 
Overall (L, L) means 18.99 ± 28.36 4.73 ± 7.72 10.72 ± 13.81 
Overall (L, D) means 19.27 ± 28.24 5.89 ± 11.55 12.48 ± 19.40 
Overall Δ mean -2.41 ± 7.34 -1.25 ± 4.55 4.03 ± 23.11 
 
Tab S1.  Quenching activities of the forty analyzed dipeptides expressed as percentages of aldehyde 
reacted in the presence of the tested compound (Tab S1A for esters and Tab S1B for amides), plus 
the corresponding diastereoisomeric differences expressed as (L, L) – (L, D). Data for carnosine 
were taken from [36]. Tab S1C reports overall means (± SDs) combining Tab S1A and S1B. 
 
For each dipeptide, Tab S1 and Fig 2(Tab S1A, Fig 2A ester derivatives as well as Tab S1B and 
Fig 2B for amides) report quenching activities toward 4-hydroxy-2-nonenal (HNE, chosen as 
representative of α,β-unsaturated aldehydes), and pyridoxal (PYR, chosen as representative of 
physiological carbonyl compounds). These quenching activities are expressed as percentages of 
quenched carbonyl compound after a fixed incubation time of 180 min. Tab S1 and Fig 2 report 
also the corresponding standard deviations as well as the dipeptide selectivity calculated as the ratio 
between the quenching activities toward HNE and PYR.  For each diastereoisomeric pair, Tab S1 
and Fig 2C show the resulting differences, their statistical significance (as computed by a t-test) 
plus some overall means (Tab S1C).  
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Fig 2A. 
 
 
 
 
Fig 2B. 
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Fig 2C. 
 
 
Fig 2.  Bar plots for the quenching activities of the forty analyzed dipeptides expressed as 
percentages of aldehyde reacted in the presence of the tested compound (white bars for HNE and 
gray bars for pyridoxal). The black bars show the selectivity values expressed as the ratio 
HNE/pyridoxal Fig 2A: quenching activities of twenty ester dipeptides;  Fig 2B: quenching 
activities of twenty ester dipeptides towards pyridoxal;  Fig 2C:comparison of the 
diastereoisomeric pairs expressed as percentage differences of the quenching activities towards 
HNE (white bars) and pyridoxal (gray bars). The asterisks indicate the pairs showing statistically 
significant differences (i.e. p < 0.05).     
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4.2.e.  Discussion.  
 
 
 
4.2.e.1.  HNE quenching. 
 
Tab S1 and Fig 2 clearly show that cysteine-containing dipeptides possess an impressive 
scavenging activity since they completely quenched HNE during the incubation time regardless of 
their capping and configuration. These data suggest that cysteine-containing dipeptides do not 
follow the multistep mechanism involving the amino and imidazolyl moieties as seen for carnosine, 
while their high reactivity seems to be due almost exclusively to the marked nucleophilicity of the 
thiol group. Such a mechanism is indirectly confirmed by the virtually undetectable activity of the 
methionine-containing dipeptides. Although their favorable reactivity,  the Cys containing 
dipeptides cannot be considered as promising scaffolds in the design of improved carbonyl 
quenchers because the remarkable thiol nucleophilicity makes them prone to reacting unsafely via 
nonspecific mechanisms. The toxicity of thiol-containing drugs is mostly ascribable to their ability 
to react with cysteinyl residues to form protein-drug mixed disulfides[30]. Such adducts can impair 
the physiological functions of the modified proteins[31] and, more importantly, can behave as 
haptens triggering immune responses which can culminate in idiosyncratic reactions (IDRs) [32].  
Apart from the cysteine-containing dipeptides, all other derivatives are less active than carnosine 
whose quenching activity is reported in Tab S1 for easy comparison. In order to allow a more 
appropriate comparison, the quenching activity of the corresponding nor-analogue of carnosine (i.e. 
Gly-His, Tab S1) was also determined revealing that the shortening of the C-terminus induces a 
marked decrease of the activity toward HNE. Interestingly, Gly-His has been extensively studied 
for its ability to chelate transition metals[33] and for its oxidative reactions [34], but its quenching 
activity was never determined. The results reported here confirm the poor activity of the 
proteinogenic peptides, as already seen in GHK tripeptides[35]. This finding can be rationalized by 
their greater rigidity as reflected in weaker interactions between the frontier molecular orbitals of 
the imidazolyl ring and the unsaturated imino group, as well as in a greater instability of the 
resulting macrocyclic intermediates due to their hindered and constrained geometry[35].  
Nevertheless, some of the present dipeptides show remarkable quenching activities which deserve 
specific considerations. The significant activity of the NH2-L-Lys-L-His-X peptides can be 
explained considering that they possess two primary amino groups which favor the formation of the 
imino intermediate regardless of which amino group is the more reactive one. In general, dipeptides 
containing aromatic residues show marked quenching activities probably because the aromatic 
rings facilitate interactions between the imidazole ring and the acceptor β-carbon atom through π-π 
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stacking, with a beneficial effect already seen with β-aryl amino acids[36]. However, all NH2-L-
His-(L or D)-His-X dipeptides show modest activities suggesting that the interference between the 
two imidazolyl rings has a prevalently negative effect on scavenging activity. Finally, the poor 
quenching activity of the dipeptides containing hydroxyl functions (Ser- and Thr-containing 
peptides) indicates that the possibility to yield hemiacetal intermediates does not enhance 
scavenging activity, a result which resembles those reported by Guiotto et al. for dihydroxy 
carnosine derivatives[37]. 
Tab S1 and Fig 2 indicate that the amide derivatives (17.96 ± 28.24) are less active than the  methyl 
esters (20.31 ± 28.31) (Tab 1C), but the difference is a mere trend devoid of statistical significance. 
Nevertheless, the trend gains credibility when comparing the derivatives for which both esters and 
amides have been analyzed, as in the case of NH2-L-Lys-(L or D)-His-X and NH2-L-Trp-(L or D)-
His-X. As revealed by molecular modeling simulations, the trend is compatible with the 
interference of the terminal amido group which tends to interpose itself between the imidazolyl ring 
and the unsaturated imino group, thus stabilizing interactions and preventing their mutual approach. 
This observation is in line with recent studies emphasizing the strength of amide stacking and its 
heavy influence on the conformational profile of small peptides[38].  
As illustrated by Tab S1 and Fig 2C, the pairs of diastereoisomers show only marginal quenching 
differences since the heterochiral isomers (19.7 ± 28.1) are nearly equiactive with their respective 
homochiral diastereoisomer (18.6 ± 28.5), a result explainable by the heterogeneity of the 
examined dipeptides which prevents general trends to be uncovered. Nevertheless, several pairs of 
diastereoisomers exhibit statistically significant differences which may reflect the already 
investigated physicochemical differences (see below). As reported by Tab S1 and Fig 2C and , 11 
diastereoisomeric pairs out of 20 show statistically significant differences (i.e. p < 0.05) and for 7 
pairs out of 11 the heterochiral dipeptide is more active than the homochiral one thus substantiating 
the trend observed in the overall means.  
This result can be explained by the conformational differences between diastereoisomers evidenced 
by previous studies[39] which suggest that the favored conformations of the homochiral isomers 
are mainly characterized by intramolecular interactions between the side chains, while those of the 
heterochiral isomers show stabilizing contacts between the terminal groups. Consequently, the 
greater activity of heterochiral dipeptides is easily interpretable in terms of increased accessibility 
of the histidine side chain. This renders the imidazole ring more prone to Michael addition, while 
the intramolecular interactions which characterize the homochiral isomers shield the imidazolyl 
ring preventing its approach to the unsaturated imino group. 
For both lysine-containing pairs of diastereoisomers, the homochiral isomers are conversely more 
active than the corresponding heterochiral ones. This finding may suggest that here the imino 
intermediate is mostly derived not from the N-terminus but from the lysine‟s ε-amino group which 
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is stably closer to the imidazolyl ring in the homochiral dipeptides, a proximity that favors the key 
Michael addition. 
By supposing that C-terminal capping induces negligible effects on quenching activities, a 
consideration indirectly confirmed by the above-mentioned marginal differences between esters 
and amides, the comparison between the reported dipeptides and the corresponding unsubstituted 
Gly-His reference derivative allows the specific contribution of each N-terminal side-chain to be 
revealed. In detail (and excluding cysteine-containing dipeptides due to their different mechanism), 
Tab S1 and Fig 2 indicate that 11 dipeptides out of 36 have a significantly greater quenching 
activity compared to Gly-His. Furthermore, the N-terminal side-chain does not induce significant 
activity changes in 11 cases and 14 dipeptides possess lower activities than Gly-His, thus 
suggesting that the influence of the N-terminal side-chain on the scavenging activity strongly 
depends on its physicochemical properties. 
A closer analysis confirms that aromatic and positively charged side-chains have generally a 
significantly beneficial effect; aromatic residues promote contacts between the imidazolyl ring and 
the carbon atom as discussed above, while positively charged residues may promote the initial 
imino formation. In contrast, negatively charged and H-bonding side-chains show an overall 
negative effect on quenching activity: the former can stabilize ion-pairs with a primary amino 
group thus hampering imino formation, while H-bonding residues may engage the imidazolyl ring 
and the imino function in intramolecular H-bonds which shield their nucleophilicity or preclude 
their contacts. In general, hydrophobic residues have a modest effect on quenching activity when 
slightly hampering the approach of the reactive groups by steric hindrance. 
 
 
4.2.e.2.  Pyridoxal quenching and peptide selectivity. 
 
A bird‟s eye view of Tab S1 and Fig 2 show that all considered derivatives possess very modest 
quenching activities toward pyridoxal. Specifically, Tab S1 and Fig 2 reveal that cysteine-
containing dipeptides show the greatest quenching activity, a fact explainable by the marked 
nucleophilicity of their thiol group. As for the detectable activity of some hydroxy-containing 
dipeptides, it can be explained by their capacity to form hemiacetal adducts.  
Overall, the very poor activity toward PYR of the examined dipeptides confirms that they are 
unable to yield stable imino derivatives with physiological carbonyls. A similar result was already 
seen for carnosine, indicating that the basicity of the N-terminus of the present dipeptides, despite 
being on average weaker than that of carnosine (as experimentally determined, see ref. 39), is still 
too strong to yield stable imines. On average, all peptides show the same poor activity regardless of 
their capping and absolute configuration, which indeed have a limited impact on the reactivity of 
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the amino group. Similarly, all peptides show an activity roughly comparable with that of the 
reference compound Gly-His, thus suggesting that the N-terminal side chain has a marginal effect 
on the reactivity of the primary amine.  
As observed for HNE quenching, the pairs of diastereoisomers show, on average, only marginal 
quenching differences which are mostly ascribable to the markedly greater activity of the cysteine-
containing heterochiral dipeptide, probably due to a greater accessibility of its thiol group. When 
considering diastereoisomeric pairs individually (as illustrated by Fig 2C), their difference is 
statistically significant for 10 pairs out of 20. However, these statistically significant differences are 
equally distributed since in 5 cases the homochiral dipeptides are the more active ones, thus 
cancelling any overall significance.  
Concerning the HNE/PYR selectivity (as reported in Fig 2), all tested dipeptides show a marked 
selectivity for HNE given their very weak quenching activity toward pyridoxal. More importantly, 
such a remarkable selectivity emphasizes that the HNE quenching of these dipeptides cannot be 
restricted to the formation of a mere imino function but may also involve a crucial Michael 
addition.  
 
 
Fig 3.  Distribution of HNE quenching activities versus PYR quenching activities showing that 
there is no correlation between them. Due to their different mechanism, cysteine-containing 
dipeptides are not included. The straight lines passing through the average activities subdivide the 
plot into four fuzzy regions: (a) inactive dipeptides; (b) inactive and unselective dipeptides; (c) 
active and selective dipeptides; and (d) active but unselective dipeptides. 
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Fig 3 compares quenching activities toward HNE and PYR showing that there is no correlation at 
all between them. This result confirms the aforementioned selectivity of the tested compounds. It 
also emphasizes that, excluding the Cys-containing peptides, HNE and PYR are quenched through 
substantially different mechanisms. When subdividing the obtained plot by straight lines passing 
through the average values of the quenching activities (average HNE = 12.2; average PYR = 3.89), 
it is possible to recognize four fuzzy regions. Among these, the (c) region includes the most 
promising dipeptides, namely those endowed with both a high HNE quenching activity and a 
significant selectivity, while the other three regions comprise less interesting peptides which show 
either low quenching activities toward HNE [(a) and (b) regions] or unsatisfactory selectivity ratios  
[(d) region] even though this last region contains some remarkable peptides such as the tryptophan-
containing derivatives. 
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4.2.e.3.  Peptide Stability. 
 
 
Dipeptides 
Residual Amount (%) 
after 30 min. 
L-Lys-L-His-OMe  87.5   2.6 
L-Lys-D-His-OMe 90.5  1.3 
L-Tyr-D-His-OMe 40.5   3.1 
L-Lys-L-His-NH2 67.7  3.2 
L-Lys-D-His-NH2 68.0   1.4 
L-Gln-D-His-NH2 81.3   2.5 
 
Tab 1.   Plasma stability for some selected dipeptides. 
 
 
Although the considered dipeptides were capped at the C-terminus to reduce the effect of 
hydrolases and so improve their pharmacokinetic profile, the stability of selected representative 
dipeptides was experimentally investigated in human plasma. As reported in Table 1, the study 
involved the four lysine-containing dipeptides since they allow the role of capping and 
configuration to be comprehensively analyzed. Besides lysine-containing dipeptides, the study also 
involved two very active quenchers (namely L-Tyr-L-His-OMe and D-Gln-L-His-NH2). Overall, 
the measured residual amounts reveal that the reported dipeptides are significantly stable (mean 
residual amount is 72.6%) and only L-Tyr-L-His-OMe shows a residual amount smaller than 50%. 
More importantly, all the tested dipeptides are much more stable than L-carnosine which is totally 
consumed after 30 min of incubation[28]. A more in-depth analysis of the stability data suggest that 
the ester derivatives are on average more stable than the amides, the capping of which could be 
hydrolyzed by non-specific peptidases. As expected, heterochiral peptides are slightly more stable 
than homochiral ones even though the reported differences are very modest, suggesting their 
stability to be mostly influenced by capping. Finally, the instability of the L-Tyr-L-His-OMe could 
be ascribed to its lipophilicity which may make it a good substrate for serum esterases, thus 
confirming that stability of ester derivatives strongly depends on their polarity. 
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4.2.e.4.   Molecular modeling. 
 
As discussed in the Supplementary Material, a preliminary computational study analyzed the 
property space of the amide dipeptides, representing the extension of a previous study focused on 
the ester derivatives[39]. Such an analysis involved MD simulations in isotropic solvents of 
different polarity to investigate how the conformational profile of the dipeptides is influenced by 
their environment. The solvent‟s effect was examined by computing the property space of few 
representative physicochemical descriptors (namely, radius of gyration[40], logP_MLP[41] and 
polar surface area[42]) and parameterized by the corresponding property range values as proposed 
by us in previous studies.   
Afterward, the computed property space ranges plus some well-known 2D/3D molecular 
descriptors  were utilized to derive relationships able to rationalize quenching activities as later 
discussed. Specifically, the correlations were iteratively developed by maximizing their r
2
 value 
and including at most four independent non-interrelated variables. The molecular descriptors 
included in the presented equations are collected in Table S2. 
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Dipeptide Rotors HBtot Ovality Rings Volume (Å3) logP range PSA range (Å2) 
L-Asn-D-His-OMe 8 12 1.70 1 251.7 1.34 25.5 
L-Asn-L-His-OMe 8 12 1.67 1 253.0 1.31 20.8 
L-Cys-D-His-OMe 7 9 1.58 1 236.2 1.22 24.5 
L-Cys-L-His-OMe 7 9 1.58 1 238.4 1.07 28.1 
L-Glu-D-His-OMe 8 11 1.71 1 261.4 1.18 24.5 
L-Glu-L-His-OMe 8 11 1.71 1 263.8 1.09 26.5 
L-His-D-His-OMe 8 11 1.75 2 277.1 1.4 23.6 
L-His-L-His-OMe 8 11 1.73 2 275.1 1.48 23.9 
L-Lys-D-His-OMe 10 12 1.79 1 286.0 1.62 25.6 
L-Lys-L-His-OMe 10 12 1.80 1 286.9 1.65 28.7 
L-Met-D-His-OMe 8 10 1.73 1 254.8 1.42 16.5 
L-Met-L-His-OMe 8 10 1.75 1 255.0 1.46 16.2 
L-Ser-D-His-OMe 7 11 1.63 1 228.8 1.31 20.1 
L-Ser-L-His-OMe 7 11 1.65 1 228.6 1.07 19.6 
L-Trp-D-His-OMe 8 10 1.76 3 324.9 1.21 23.1 
L-Trp-L-His-OMe 8 10 1.79 3 327.3 1.48 22.9 
L-Tyr-D-His-OMe 8 11 1.72 2 299.9 1.37 22.3 
L-Tyr-L-His-OMe 8 11 1.63 2 289.9 1.55 21.6 
L-Val-D-His-OMe 6 9 1.69 1 260.6 1.2 28.5 
L-Val-L-His-OMe 6 9 1.72 1 255.8 1.46 24.6 
L-Gln-D-His-NH2 7 13 1.62 1 234.5 1.27 30.2 
L-Gln-L-His-NH2 7 13 1.60 1 233.5 1.35 28.5 
L-Cys-D-His-NH2 6 10 1.45 1 225.3 1.39 28.2 
L-Cys-L-His-NH2 6 10 1.45 1 221.7 1.65 27.8 
L-Asp-D-His-NH2 6 12 1.58 1 227.7 1.28 27.8 
L-Asp-L-His-NH2 6 12 1.60 1 225.2 1.2 33.2 
L-His-D-His-NH2 7 12 1.66 2 253.5 1.23 29.6 
L-His-L-His-NH2 7 12 1.62 2 253.0 1.1 21 
L-Lys-D-His-NH2 9 13 1.65 1 264.9 1.82 24 
L-Lys-L-His-NH2 9 13 1.70 1 266.2 1.9 22.8 
L-Trp-D-His-NH2 7 10 1.68 3 308.6 1.15 20.5 
L-Trp-L-His-NH2 7 10 1.69 3 308.9 1.36 19.1 
L-Thr-D-His-NH2 6 12 1.64 1 232.7 1.24 27.4 
L-Thr-L-His-NH2 6 12 1.58 1 231.6 1.4 29.2 
L-Arg-D-His-NH2 10 15 1.73 1 285.8 1.21 30.7 
L-Arg-L-His-NH2 10 15 1.72 1 282.2 1.73 26.4 
L-Phe-D-His-NH2 7 10 1.64 2 275.2 1.52 17.4 
L-Phe-L-His-NH2 7 10 1.67 2 277.0 1.03 16.4 
L-Ile-D-His-NH2 5 10 1.62 1 255.5 1.32 25.2 
L-Ile-L-His-NH2 5 10 1.69 1 259.6 1.34 25 
 
 
Tab S2.  Molecular descriptors included in the reported equations. 
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N Equation Statistics 
1
a 
Quenching HNE = 5.61 + 0.206 Rotors – 3.40 Ovality – 
0.174 HBTot + 0.0275 PSA_Range 
n = 40; r
2
 = 0.85; r
2
cv = 0.83;  
SE = 0.12; F = 44.4; p< 0.0001 
2
 b
 
Quenching HNE = 5.52 + 0.221 Rotors – 3.49 Ovality – 
0.174 HBTot + 0.0304 PSA_Range 
n = 25; r
2
 = 0.79; r
2
cv = 0.73;  
SE = 0.13; F = 17.1; p< 0.0001 
3
 b
 Quenching HNE = 0.911 Quenching HNEpred + 0.034 
n = 15; r
2
 = 0.83; r
2
cv = 0.77  
SE = 0.11; F = 16.8; p< 0.0001 
4 
Quenching PYR = 6.67 + 0.461 Rings – 3.97 Ovality     
– 0.0152 HBTot + 0.00559 PSA_Range 
n = 40; r
2
 = 0.66; r
2
cv = 0.62;  
SE = 0.19; F = 13.8; p< 0.0001 
5 
Selectivity ratio HNE/PYR = – 43.3 + 2.01 Rotors + 
0.156 Volume – 10.2 Rings + 9.71 log P_Range 
n = 40; r
2
 = 0.70; r
2
cv = 0.65; 
SE = 5.69; F = 19.6; p< 0.0001 
 
 
Tab 2.  Main predictive equations developed in the study. All included property space descriptors 
were obtained from MD runs in vacuo.  
 
Tab 2 reports the best relationship (Eq. 1) which correlates quenching activities with a set of 
computed descriptors. Specifically, Eq. 1 indicates that HNE quenching is favorably influenced by 
flexibility as encoded by both structural and property variability (namely, number of rotors and 
PSA range, respectively), whereas it is negatively affected by strong intramolecular interactions (as 
reflected by the number of H-bonding groups, HBTot) which shield the reactive groups and 
stabilize folded conformations (as parameterized by molecular ovality). These results imply that 
both flexibility and intramolecular contacts influence the ability of a given molecule to assume the 
conformations most suitable to the formation of the imino intermediate followed by the reaction of 
Michael addition. In other words, a too rigid molecule cannot undergo the necessary 
conformational transitions to bring in close vicinity the imidazole ring and the acceptor β-carbon 
atom. 
To assess the predictive power of Eq. 1, the set of forty dipeptides was randomly subdivided into a 
training (n = 25) and a test (n = 15) set. The correlation as computed for the training set only 
confirms the robustness of Eq. 1 since these two equations (Eqs. 1 and 2) have very similar 
coefficients. Eq. 1 thus appears to be reasonably independent of the number of ligands considered. 
The relation between experimental and predicted pKm values (Eq. 3, Table 4), as computed by Eq. 
2 for the external test set, affords an encouraging validation for the predictive power of Eq. 1. 
Equation 3 is indeed a satisfactory one given its statistics, its slope being close to 45° ( = 42.3°) 
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and the intercept close to zero. The analysis of residuals (results not shown) indicates that there is 
no correlation with quenching activities thus suggesting that Eq. 1 applies equally to good and poor 
HNE quenchers. 
Similarly, Tab 2 reports an interesting correlation (Eq. 4, somewhat poorer than the previous one) 
to predict the quenching of pyridoxal. The equation includes parameters which are related to the 
ability to expose the amino group (HBTot, ovality, and PSA_Range, already present in Eq. 1), as 
well as to stabilize the resulting imino adducts since aromatic rings can contribute to their 
formation by (1) attracting protonated amines; (2) stabilizing charged intermediates; and (3) 
shielding the imines from the water environment. Comparing Eqs. 1 and 4 reveals the 
disappearance in the latter of the flexibility descriptor (i.e. number of rotors), thus emphasizing that 
PYR quenching obeys a one-step mechanism and does not require significant conformational 
adaptation as previously discussed for HNE quenching. 
These considerations find confirmation when analyzing Eq. 5(Tab 2) meant to predict HNE/PYR 
selectivity ratios. Indeed, the number of rotatable bonds and the log P range (both of which 
describe molecular flexibility) favor selectivity, which in turn is influenced negatively by aromatic 
rings due to their stabilizing effect on imine formation. Taken together, these correlations 
emphasize the critical role played by flexibility in HNE quenching, presumably because it accounts 
for the ability of a given molecule to assume a conformation able to promote the crucial Michael 
addition.  Such a consideration is in line with what was previously investigated for some aryl 
derivatives of carnosine [36], the quenching activity of which was linearly related to their ability to 
assume folded and reactive conformations.  
 
4.2.e.5.  Conclusions.  
 
As a rule, the hitherto published carnosine derivatives are structurally quite similar to the parent 
compound[39]. Consequently, they are devoid of enough structural variability to deepen our 
understanding of the major molecular factors influencing quenching activity, except for 
straightforward deductions derived from a knowledge of the quenching mechanism (e.g., the 
nucleophilicity of the Michael donor moiety or the basicity of the primary amino group). As 
documented by the QSAR equations in Tab 2, the derivatives presented in this work, while having 
the same reactive groups and being, on average, less active than carnosine, possess a structural and 
configurational variability compatible with a broader structure-activity analysis. The latter concerns 
non only factors characterizing the reactive centers but also factors which pertain to a given 
molecule as a whole and contribute indirectly to the quenching activity (e.g., H-bonding capacity 
versus HNE quenching, and the presence of aromatic rings versus PYR quenching). 
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Such a detailed analysis provides a more precise picture of the entire quenching mechanism and 
could support the design of novel carbonyl quenchers featuring all the key properties able to 
maximize both activity and selectivity. In other words, an in-depth understanding of all relevant 
factors could permit to improve the quenching activity of a given compound without necessarily 
increasing the nucleophilicity of its reactive moieties, thus avoiding compounds of dangerously low 
selectivity.  
By considering the key contribution of both the N-terminal side-chains and configuration for the 
investigated dipeptides, the obtained results emphasize how reactivity of the imidazolyl ring 
heavily depends on both conformational properties and vicinal residues. This finding can explain 
the remarkable specificity with which histidine residues form covalent adducts with reactive 
carbonyl species and might provide useful clues to rationalize the different reactivity of histidine 
residues for a given protein. 
Finally, the present study reports some dipeptides  (namely L-Lys-L-His-OMe and L-Tyr-D-His-
OMe, see Fig 1) which show a quenching activity slightly weaker than that of carnosine, but are 
endowed by a markedly greater selectivity and can represent truly promising candidates for the 
design of improved carnosine derivatives. Also, the good quenching activity of tryptophan-
containing dipeptides deserves specific attention. Indeed, considering that (a) Trp-His is a 
vasodilating dipeptide which inhibits extracellular Ca
2+
 entry by blocking dihydropyridine-like L-
type channels[44], and (b) some carnosine derivatives show antihypertensive effects in animal 
models[45], Trp-His derivatives could become useful agents to treat dyslipidemia-induced 
hypertension. 
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5.  A new high resolution mass spectrometry application for the 
comprehensive analysis of the ligand-binding properties of RAGE. 
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5.1.  Introduction. 
 
 
 
The receptor for advanced glycation end products (RAGE) is a type I transmembrane glycoprotein 
of the immunoglobulin superfamily of cell surface receptors[1]. The engagement of RAGE by 
ligands triggers key signalling pathways resulting in oxidative damage and release of pro-
inflammatory and pro-fibrotic molecules[2]. RAGE is able to bind a class of heterogeneous 
compounds such as advanced glycation end products (AGEs) formed as a result of nonenzymatic 
biochemical reactions involving glucose and oxidative derived cheto-aldehydes.  
AGEs are involved in the onset and progression of different oxidative based diseases, including 
diabetic vascular complications and atherosclerosis. Hence, the inhibition of AGEs formation as 
well as the blockade of AGEs-RAGE interaction represents a promising drug target. 
The receptor can be inactivated by high-molecular substrate analogs, low-molecular weight 
inhibitors or by anti-RAGE antibodies, neutralizing the receptor. A set of compounds has been 
proposed as RAGE inhibitors and tested in animal models. 
 
Probably due to the complexity of the molecular interactions between AGEs-RAGE, only few 
studies on AGEs antagonists have so far been reported. A main limit in the discovery program of 
AGEs antagonists is the lack of reliable methods for studying AGEs-RAGE interaction. 
 
In order to exploit RAGE as a therapeutic target, a comprehensive analysis of the structure and 
ligand-binding properties of RAGE is required. For this purpose, aim of the present work was to 
set-up a MS method able to study the non covalent interactions between ligands and recombinant 
sRAGE (V1-C1), which represents the ligand binding domain of RAGE. The V1-C1 protein target 
was expressed in E. coli and the ligand-protein binding properties (stoichiometry and Kd values) 
were determined by a high resolution mass spectrometric (orbitrap) approach carried out in non 
denaturating conditions. 
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5.2.  Materials and methods. 
 
 
 
5.2.a.  Sterilization methods. 
 
In order to avoid contaminations by undesirable microorganism, sterilization has an important role 
for the microorganisms manipulation. Each equipment was sterilized on dry heat flow in an oven at 
a temperature of 150 °C for a minimum of 3 hours. Overall medium, solutions, buffers and other 
materials were sterilized at 110 °C at a pressure of 0.8 atmospheres for 30 minutes. 
Solutions containing heat-labile substances were sterilized by filtration through Millipore filters 
with a pore diameter of 0.22 µM or with Stericap (Millipore). 
 
 
5.2.b.  Strains preservation and E.coli strains growth conditions. 
 
With a view to preserve the strains for several months, the strains were propagated at 4 °C  in solid 
medium. The long-term storage was performed in glycerinate solution: E.coli cells were placed in a 
sterile solution of water mq/glycerol 50/50 (v/v) and store at -80 °C. 
 
 
E.coli strains and growth conditions: 
 
The strains of E.coli  used  are listed in Tab 1. 
Strains ORIGAMI B (DE3)-pET-15b-sRAGE and ORIGAMI B (DE3)-pET-15b-VC1 
were kindly provided by Dr. G. Fritz [Department of Neuropathology Albert-Ludwigs University 
of Freiburg (Germany)]. 
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Strain Genotype Provenance 
ORIGAMI B 
(DE3)-pET-15b-
sRAGE 
F
-
 ompThsdSB(rB
-
mB
-
) gal dcm lacY1 ahpC (DE3) 
gor522::Tn10trxB (Kan
R
, Tet
R
) 
Dattilo, B.M.,  
et al. 
 
ORIGAMI B 
(DE3)-pET-15b-
VC1 
F
-
 ompThsdSB(rB
-
mB
-
) gal dcm lacY1 ahpC (DE3) 
gor522::Tn10trxB (Kan
R
, Tet
R
) 
Dattilo, B.M., 
et al. 
ORIGAMI 2 
(DE3) 
Δ(ara-leu)7697 ΔlacX74ΔphoAPvuIIphoR araD139 
ahpCgalEgalKrpsL F [lac
+
lacI
q
 pro] (DE3) gor522:: 
Tn 10 trxB (Str
R
, Tet
R
) 
Novagen 
ORIGAMI 2 
(DE3)-pET-15b-V 
F
-
 ompThsdSB(rB
-
mB
-
) gal dcm lacY1 ahpC (DE3) 
gor522::Tn10trxB (Str
R
, Tet
R
) 
Collection from 
Professor 
Popolo 
DH5α 
F
-
 φ80lacZΔM15 Δ(lacZYA-argF) U169 recA1 
endA1 hsdR17(rk
-
, mk
+
) phoAsupE44 thi-1 gyrA96 
relA1 tonA 
Invitrogen 
DH5α-pET-15b-V 
F
-
 φ80lacZΔM15 Δ(lacZYA-argF) U169 recA1 
endA1 hsdR17(rk
-
, mk
+
) phoAsupE44 thi-1 gyrA96 
relA1 tonA 
Collection from 
Professor 
Popolo 
 
 
Tab 1.  E.coli strains used in this work. 
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The media for the growth of E.coli are listed in Tab 2. 
 
Medium 
 
Composition 
 
Usage 
LB 
1% triptone, 0,5% yeast estract, 
0,5% NaCl (2% agar for solid medium). 
E. coli growth 
LB-BUFFERED 
1% triptone, 0,5% yeast estract, 0,5% NaCl, 
0,2 M NaH2PO4, 0,2 M Na2HPO4. 
Induction  
of transformed 
E. coli  clones 
LB 1% NaCl 1% triptone, 0,5% yeast estract, 1% NaCl. 
Induction  
of transformed 
E. coli  clones 
DYT 
0,6% triptone, 1% yeast estract, 0,5% NaCl, 
50 Mm Na2HPO4, 0,2% glucose. 
Induction of 
transformed 
E. coli  clones 
AM 
0,5% triptone, 0,25% yeastestract, 25 mMNaH2PO4, 25 
mM KH2PO4, 50 mM NH4Cl, 5 mM Na2SO4, 50 µM 
FeCl3, 20 µM CaCl2, 10 µM MnCl2, 10 µM ZnSO4, 2 
µM CoCl2, 2 µM CuCl2, 2 µM NiCl2, 2 µM Na2MoO4, 2 
µM Na2SeO3, 2 µM H3BO3, 1 M MgCl2, 0,5% glycerol, 
0,05% glucose, 0,2% lactose. 
Induction through 
the autoinduction 
method of 
transformed 
clones of E. coli 
 
Tab 2.  Media for E.coli growth. 
 
The media were added with 100 µg/ml of ampicillin (from 1000X stock solution in ethanol, filtered 
and stored at -20 °C), or with 15 µg/ml of kanamycin (from 1000X stock solution in H2O, filtered 
and stored at 4 °C) or 12.5 µg/ml(from 1000X stock solution in ethanol, filtered and stored at -20 
°C), according to the experimental needs. 
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5.2.c.  Molecular biology techniques. 
 
 
5.2.c.1.  Plasmids and oligonucleotides. 
 
The expression of the V-C1 was performed by the vector pET-15b which includes ampicillin 
resistance as selective marker (fig. x). The employment of this vector in the presence of lactose or 
IPTG guarantees high levels of expression of recombinant proteins. In addiction the vector pET-
15b allows an easy purification step by affinity chromatography due to the pET-15b sequence 
encoding for an oligopeptide containing six histidine residues linked to the N-terminal portion of 
the recombinant protein. The high affinity of the histidine tag for divalent metals based affinity 
column allows the purification of the protein of interest. 
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Fig 1.  A)  pET15b vector map with highlighted the polylinker region.  B)  Cloning/expression 
pET15b vector sequence. 
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The oligonucleotides used in this work are listed in Tab  3. 
 
Name Sequence 5'-3' Use 
VNdeI-For 
AGCATATTCGACTGA
CATATGGCTCAAAAC
ATCACAGCCCG 
Amplification sequence encoding for V 
domain of RAGE to cloning into pET-
15b (in red: complementary region of 
the sequence encoding the V domain; 
stressed: sequence recognized by NdeI 
restriction enzyme). 
V223Xho-Rev 
ATCGTCGGGCTCACT
CGAGCTAAGGAATCT
GGTAGACACGGA 
Amplification sequence encoding for V-
C1 domain of RAGE to cloning into 
pET-15b (in red: complementary region 
of the sequence encoding the V-C1 
domain; stressed: sequence recognized 
by Xhol restriction enzyme; italics: 
STOP codon). 
T7 promoter 
TAATACGACTCACTA
TAGGG 
PCR performed on E. coli colony for the 
transformed clones verification. DNA 
sequencing. 
T7 terminator 
GCTAGTTATTGCTCA
GCGG 
PCR performed on E. coli colony for the 
transformed clones verification. DNA 
sequencing. 
5‟ AOX1 
GACTGGTTCCAATTG
ACAAGC 
PCR performed on E. coli colony for the 
transformed clones verification. DNA 
sequencing. 
3‟ AOX1 
GCAAATGGCATTCTG
ACATCC 
PCR performed on E. coli colony for the 
transformed clones verification. DNA 
sequencing. 
 
Tab  3.  List of  oligonucleotides used to revise pET15b vector and characterize E. coli . 
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The reaction was performed at 37 °C for one hour followed by an inactivation step at 65 °C for 20 
minutes. The dephosphorylation was carried out on agarose gel and the band corresponding to the 
dephosphorylated vector pHIL-S1 was eluted from the gel by using the QIAquick® Gel Extraction 
Kit (QIAGEN). 
After the vector quantification, it was set up the ligation reaction between the pET15b/XhoI vector 
and the two V-C1 inserts amplified by OCR and digested by Xhol enzyme. 
The ligation reaction consisted to incubate 12.47 ng of vector (for V-C1 domain), 10 µl of buffer, 1 
µl of NEB and Milli Q water to reach the final volume of 21µl. The reaction was incubated at 25 
°C for 10 minutes. 
The ligation mixture was used to transform DH5α E. coli cells, designed for the plasmid replication 
containing a high number of copies per cell and made competent by adding CaCl2. 
The correct inserts integration into the pHIL-S1 vector has been checked through screening; the 
protocol provided the screening of 10 clones for each construct, by PCR performed on E. coli 
colony using 5'AOX1 as primer (which appears on the vector pHIL-S1) and V223XHis -Rev for 
the domain V-C1 (Tab 3). 
The amplifications have required, in a final volume of 20 µl, primers in a final concentration of 5 
µM, dNTPs in a final concentration of 2.5 mM, MgCl2 in a final concentration of 50 mM and 1.25 
U of INVITROGEN Taq polymerase. 
 
The PCR program was the following: 
 
Temperature Time Cycles 
94 °C 4 min X1 
94 °C 1 min  
58 °C 1 min X35 
72 °C 45 sec  
72 °C 10 min X1 
Hold8 °C   
 
10 µl of the PCR mixture was uploaded on 0.9% agarose gel to check the sequence amplification of 
the target sequence in the vector pET-15b. From the positive colonies tested by PCR (2/10 for V-
C1 domain) recombinant plasmids were extracted using QIAprep ® Spin Miniprep Kit (QIAGEN) . 
In order to confirm the correct insertion of the target sequences encoding for V-C1 a control 
digestion was performed on the plasmids sequence through the restriction enzyme Xhol. 
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The reactions were carried out as well: 
 
Plasmidic DNA 300 ng 
BSA 1 mg/ml 2 µl 
Buffer 10x 2 µl 
XhoI (20 U/µl) 20 U 
Milli Q water 4 µl 
Final volume 20 µl 
 
In order to verify the absence of mutations, the recombinant plasmids resulted positive for the 
control digestion were sequenced at the BMR Genomics laboratories (University of Padua) by the 
Sanger method (1975). 
 
Achievement of the recombinant plasmid pET-15b-V for the expression of V-C1 domain  (23-233) 
in E. coli as host. 
 
The gene encoding the V-C1 domain of RAGE was amplified by PCR by using the 
oligonucleotides VNdeI-For e V223Xho-Rev (Tab.4) which contains the restriction sites for the 
enzymes NdeI and XhoI. The recombinant plasmid pET-15b-V-C1 (23-243) kindly provided by Dr. 
G. Fritzwas used as template for the PCR reaction 
The reaction was carried out by mixing 10 µl of template (pET-15b-VC1), 0.5µM (final 
concentration) of VNdeI-For e V223Xho-Revprimers, dNTPs (final concentration) 0.25 mM, 
MgCl2 (final concentration) 1mM and 1 U of Phusion High-Fidelity supplied by Finnzymes. 
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The  PCR reactions were the following: 
 
Temperature Time Cycles 
98 °C 2 min X1 
98 °C 30 sec  
58 °C 30 sec X30 
72 °C 30 sec  
72 °C 10 min X1 
Hold8 °C   
 
 
The PCR products were analyzed by electrophoresis in 1% agarose gel. 
GeneClean Turbo for PCR Kit (supplied by Q-Biogene) was applied for the PCR product 
purification. 
The PCR product was digested using the restriction enzyme and XhoI, both supplied by New 
England Biolabs, NEB. 
 
The digestion reaction was so prepared: 
  
PCR product ~480 ng 
BSA 1 mg/ml 4 µl 
Buffer 10x 4 µl 
XhoI (20 U/µl) 20 U 
Final volume 40 µl 
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The reaction was incubated at 37 °C for one hour and, at the end of this step the reaction was 
inactivated at 65 °C for 20 minutes. Also the vector pET-15b-V-C1, utilized for the cloning of the 
target sequence was digested by Xhol through the following reaction conditions: 
 
pET-15b-VC1 ~1,2 µg 
BSA 1 mg/ml 6 µl 
Buffer 10x 6 µl 
XhoI (20 U/µl) 60 U 
Final volume 60 µl 
 
The reaction was incubated at 37 °C for 45 minutes (the milli Q water was added to get a final 
volume of 70 µl): 
 
BSA 1 mg/ml 1 µl 
Buffer 10x 1 µl 
XhoI (20 U/µl) 10 U 
Milli Q water 7 µl 
 
The reaction was re-incubated at 37 °C for one hour and, at the end of this step, the reaction was 
inactivated at 65 °C for 20 minutes. With the purpose to evaluate the occurred protein digestion, 10 
µl of digestion reaction were run by gel electrophoresis on agarose gel. 0.7%. 
The remaining digestion reaction was loaded on a 0.6% agarose gel. In order to allow the DNA 
purification from salts and other digestion components that might inhibit the ligase enzyme, the 
band corresponding to the digested vector with XhoI was eluted from the gel by using the 
QIAquick ® Gel Extraction Kit (QIAGEN). 
This process allows to purify DNA from salts or other components undigested of the digestion 
reaction which can inhibit the ligase and eliminate Moreover, any molecules of undigested vector. 
The commercial kits are based on the DNA adsorption by silica membranes with the presence of 
high salt concentrations. Hence, after multiple final washing to remove the residual impurities the 
DNA was eluted by dH2O or by 10 mM Tris, pH 8. 
The eluted vector from gel was then quantified. 
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The ligation reaction was up in a final volume of 21 µl. The protocol involved the addition of  50ng 
of  pET-15b/NdeI/XhoI  vector, 8.98 ng of insert, 10 µl of buffer, 4.91 µl of Milli Q water  and 1 µl 
of NEB ligase. The reaction was incubated at 25 °C for 10 minutes. 
The ligation mixture was used to transform cells of E.coli DH5α, designed for the plasmids 
replication allow a high number of copies per cell and made them competent by treatment with 
CaCl2. 
Colony PCR screening of 17 clones was applied to check the correct integration into the vector 
pET-15b of the target insert.  As reported in figure x the gene amplification of the target region has 
been allowed by using 0.7 µM of T7 promoter and T7 terminator primers. 
For the reaction in a final volume of 20µl were used, T7 promoter and T7 terminator primers 
0.5µM (final concentration), dNTPs (final concentration) 0.25 mM, MgCl2 (final concentration) 
2.5mM and  0.5 U of INVITROGEN TAQ Polymerase. 
The PCR program was the following: 
 
Temperature Time Cycles 
94 °C 4 min X1 
94 °C 1 min  
52 °C 1 min X35 
72 °C 45 sec  
72 °C 10 min X1 
Hold 8° C   
 
10 µl of the PCR mixture was uploaded on 0.9% agarose gel to check the sequence amplification of 
the target sequence in the vector pET-15b. From the positive colonies tested by PCR (6/17 for V-
C1 domain) recombinant plasmids were extracted using QIAprep ® Spin Miniprep Kit (QIAGEN) . 
In order to confirm the correct insertion of the target sequences encoding for V-C1 a control 
digestion was performed on the plasmids sequence through the restriction by Xhol enzyme. 
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The reactions were carried out as well: 
 
DNA plasmidic 300 µg 
BSA 1 mg/ml 2 µl 
Buffer 10x 2 µl 
XhoI (20 U/µl) 20 U 
Milli Q water 4 µl 
Final volume 20 µl 
 
In order to verify the absence of mutations, the recombinant plasmids resulted positive for the 
control digestion were sequenced at the BMR Genomics laboratories (University of Padua) by the 
Sanger method (1975). 
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5.2.c.2.   E. coli transformation. 
 
With the purpose of transforming E. coli were exploited DH5α cells. For the expression strain was 
preferred to use ORIGAMI B (DE3), mutated in trxB/gor genes that consent to encode for thio 
redox in reductase and glutathione oxidoreductase that promotes the formation of disulfide bridges. 
 
The protocol to make competent E. coli cells is the following: 
• Inoculate 5 ml of LB medium (Tab. 2) with an unspecified number of E. coli cells; 
• incubate at 37 °C, overnight stirring; 
• dilute 0.5 ml of pre inoculum  in 20 ml of fresh medium, place at 37 °C on stirring; 
• stopped the cells growth until an OD600 value in a range between 0.3-0.5; 
• collect the cells and centrifuge for 5 minutes at 4000 rpm in a 50 ml tube; 
• discarded the supernatant and suspend the cell pellet in 1 ml of sterile solution A (10 mM 
MOPS pH 6,5, 10 mM RbCl); 
• make up to 10 ml with sterile solution A spin at 4000 rpm for 5 minutes; 
• discard the supernatant and suspend the cell pellet in 1 ml of sterile solution B(10 mM 
MOPS ph 6,5, 50 mM CaCl2, 10 mM RbCl); 
• make up to 10 ml with sterile solution B; 
• place the cells for 30 minutes on ice. Collect the cells by centrifugation and suspended  
them gently in 2 ml of solution B; 
• prepare 200 µm aliquots for further transformation. 
 
The DNA contained in the ligation buffer was spiked with 200 µl of competent cells for the 
transformation, while for internal control it was employed a cells line not loaded of DNA. 
After keeping the mixture on ice for 30 minutes, the cells were subjected to a thermic shock at 42 
°C for 2 minutes in order to promote the DNA incorporation. Each aliquot was spiked with 1 ml of 
LB medium and after at least one hour of incubation, the cells were collected by centrifugation, 
suspended in 100 µl of LB medium and then plated on selective medium. The last step was to 
incubate for 12-14 hours at 37 °C. 
 
 
 
 
 
 
 
212 
 
5.2.c.3.  Expression and purification from E. coli. 
 
 
5.2.c.3.1.  E. coli  transformed clones induction. 
 
E. coli growth and induction were promoted using different media and two different methods of 
induction: 
1) Induction by IPTG: the transformed cells were grown in LB medium 1% NaCl (Tab 2), 
implemented with 50 µg/ml of ampicillin, 15 µg/ml of tetracycline and 12.5 µg/ml of kanamycin, 
O.N. at 37 ° C.At the end of incubation, the sample was centrifuged and resuspended in LB 
medium buffered (Tab 2), and the cells growth at 25 °C. When the optical density at 600 nm was 
between 0.4 and 0.6, the cells were induced by adding IPTG (0.5 mM, 0.75mM, 1mM) and kept 
growing O.N. at the same temperature. 
2) Self-induction: the transformed cells were grown by the implementation of DYT medium (Tab. 
2) and by supplementing ampicillin, O.N. at 37 °C. 
At the end of incubation, the sample was centrifuged and resuspended in AM medium (Tab 2) and 
then the cells were growth at 37 °C. When the optical density at 600 nm was between 0.4 and 0.6, 
the flasks were transferred and kept growing O.N. at 21 °C. 
In both the methods above reported, the cells were kept on ice and stirred  for 10 minutes to avoid 
the  proteases, afterwards they were collected by centrifugation using a Sorvall centrifuge  at 8000 
rpm for 30 minutes at 4 ° C. The pellet was weighed (wet weight), frozen in liquid nitrogen and 
stored at -80 ° C. 
 
  
5.2.c.3.2.  Total extracts of E. coli protein preparation. 
 
The E. coli cells were broken down through two physical mechanisms. 
 
1) Sonication: This method, based on mechanical breakage, because develops a high heat stress, 
was carried out maintaining the cells on ice. The cells were subjected to 5 rupture cycles, each 
cycle consisting of 30 seconds of sonication and 30 seconds on ice. 
 
2) Liquid extrusion: Also this method is based on mechanical breakage, and involves the use of a 
steel cell fitted with a piston closed by a valve (French Press) in which the cell suspension is 
inserted. 
At the end of the slow thawing of the bacterial pellet, the cells were resuspended  in a lysis  buffer 
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solution (about 2-3 ml of buffer per grams of cell) containing complete protease inhibitor cocktail 
(EDTA-free Roche Applied Science), DNasi I, 0,5 mM MgCl2, 20 mM HEPES, 300 mM NaCl, pH 
7,4. 
The liquid extrusion proceeds with the breaking of the cells by the application of a pressure of 1000 
psi. Isolation of the soluble fraction from the cellular debris was carried out by apply in an ultra 
centrifuge cycle at 4 ° C for one hour at 100,000 rpm and then the supernatant was collected. 
 
 
5.2.c.3.3.  Scale-up purification of V-C1 domain from E. coli cells. 
 
The soluble fraction obtained from ultracentrifugation was loaded on Ni-Sepharose column (26 mm 
of diameter, loading volume 50 ml, GE healthcare) previously equilibrated with Lysis buffer (50 
mM NaH2PO4, 300 mM NaCl) and uploaded with imidazole 30mMuntil the signal was stable at 
A280 (baseline). 
The elution was performed by using a buffer containing 50 mM NaH2PO4, 300 mM NaCl and 500 
mM imidazole. The different elution fractions were collected in separate tubes. 
The second step consisted in the removal of the His-tag fusion proteins which was carried out by 
incubating the purified proteins for 3 hours at 25 °C with thrombin enzyme (GE Healthcare), in the 
presence of CaCl2 as cofactor. 
In order to remove the protein precipitate the incubation mixture was centrifuged in a Sorvall 
centrifuge at 10000 rpm for 4 °C. 
A further passage on Ni-Sepharose column allowed the separation of the V-C1 portion from the 
VC-1-His-tag moiety not correctly digested. 
At the end of the separation the Flow-through was collected, containing the not bound proteins. 
The last of the purification protocol consisted in a Size Exclusion Chromatography using Superdex 
75 (26/60) previously equilibrated with 20 mM Na acetate, 150 mM NaCl, pH 5.2. 
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5.2.d.  Biochemical techniques. 
 
  
5.2.d.1.  SDS-PAGE. 
 
SDS-PAGE technique allows the individual protein separation in function of the molecular weight 
from a complex mixture of proteins. The separating gel is composed of two different parts that 
allow the simultaneously separation in based on porosity and the buffer pH. The high porosity 
STAKING GEL permit the protein concentration on the surface of the low porosity RUNNING 
GEL, that allows the effective protein separation; and going into detail the system resolution can be 
increased in case of excessive protein concentration by varying the acrylamide concentration. 
Both minigels (9x7 cm) and slab gels (14x13 cm) at 16% of polyacrylamide were used in the 
present work 
 
Running Gel 16%  
Lower gel buffer (1.5 M Tris-HCl pH 8.8, 0.4% SDS) 0.250 vol 
Acrilammide stock II 30% 0.215 vol 
H2O 0.532 vol 
Ammoniumpersulfate 10% 0.003 vol 
TEMED 0.001 vol 
 
 
Stacking Gel  
Upper gel buffer (0.5 M Tris-HCl pH 6.8, 0.4% SDS) 0.250 vol 
Acrylamide stock II 30% 0.150 vol 
H2O 0.600 vol 
Ammoniumpersulfate 10% 0.003 vol 
TEMED 0.001 vol 
 
The composition of the electrophoresis buffer was as follows: 0.025 M Tris-HCl, 0.192 M glycine, 
0.1% SDS, pH 8.3. 
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5.2.d.1.1.  Coomassie and Silver staining assays. 
 
Staining was performed by incubating the gel with the Coomassie brilliant blue R-250 for 30 
minutes at room temperature on mild stirring. The solution was then removed and the gel washed 
up with the destaining solution (40% ethanol,55% H2O, 5% acetic acid) to allow the removal of the 
stain in excess. 
Silver staining was carried out using the commercial kit ProteoSilver ™ Silver Stain (SIGMA) and 
following the protocol of the supplier. 
 
 
5.2.d.1.2.  Immunoblotting. 
 
The immunoblotting consists of the proteins transfer from the gel to a nitrocellulose membrane by 
the direct contact through the two surfaces. 
The transfer buffer composition was as follows: 0.025 M Tris-HCl, 0.192 M glycine, 20% 
methanol, pH 8.3. The protein transfer was carried out by applying an electric current of 500 mA 
for two hours or 250 mA O.N. After the protein transfer, the membrane was stained for 1 minute 
ina red Ponceau S (Sigma) solution in order to check the electrophoretic run, the separation, 
uploads and also to identify the known molecular weight markers. Before the next step consisting 
in the immuno-decoration, the red Ponceau was removed by washing the membrane for 5 minutes 
in TBS(0.01 M Tris-HCl pH 7.4, 0.166 M NaCl). The protocol for the immuno-decoration provides 
one hour gel saturation by milk in TBS-5% w / v, 0.1% Tween20 at room temperature. 
Alternatively, the saturation was performed over night at 4 ° C. After 5 minutes of washing by 
using TBS-0.3% Tween 20, the membrane was incubated for 2 hours with the primary antibody 
[mouse anti-polyHIS (ROCHE)]  on mild stirring followed by 4 washes in TBS-Tween 20 0.3% of 
15 minutes each. Membranes were then incubated with the secondary antibody at least for one hour 
(anti-mouse antibody provided by Jackson Laboratories and diluted 1:10000)and after 3 washes of 
three minutes each in TBS-Tween 20 0.3%, the membrane was covered by ECL (luminol, Thermo 
Scientific) for 1 min. As a last step, the membrane was placed between two sheets of tracing paper 
and exposed, in dark boxes, to autoradiographic plate. 
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5.2.d.2.3.  Mass spectrometry analysis. 
 
Direct infusion of  VC1 by ESI-MS spectrometer in denaturing and native conditions. 
 
V-C1 protein was stored at -80 °C in 20 mM sodium acetate pH 5.2 150 mM NaCl until the MS 
analysis. In order to desalt and concentrate the protein, allowing mass spectrometric analysis, the 
sample was centrifuged by Amicon Ultra-0,5 ml Filter (Millipore). This step also enables the buffer 
exchange  with a volatile buffer for a suitable mass spectrometry analysis. For the denaturing 
analysis conditions the proteins were mixed (in a of 1:1 ratio) with a denaturaing buffer composed 
by ammonium acetate, acetonitrile, formic acid (25/30/0.1 v/v/v). MS analysis in native conditions 
were carried out using the following conditions:  proteins at 10µM concentration in 1 mM 
ammonium acetate pH 7.4. 
Mass spectra were acquired by direct infusion (10 µl/min) by usingan LTQ XL-Orbitrap mass 
spectrometer (Thermo Scientific, Milan, Italy) equipped with a ESI  source (Thermo Scientific, 
Milan, Italy) set as follows: spray voltage 4.0 kV; capillary temperature 150 °C, capillary voltage 
41 V; tube lens offset 100 V, no sheath gas flow, 20 arbitrary units  auxiliary gas flow. The 
Orbitrap mass spectrometer continuously performed scan cycles at high-resolution (resolving 
power 60,000,FWHM at m/z 400) in full scan (500–3500m/z) and in profile mode. 
Protonated phthlates [dibutylphthlate (plasticizer), m/z 279.159086; bis(2-ethylhexyl)phthalate, 
m/z391.284286] and polydimethylcyclosiloxaneions ([(Si(CH3)2O)6+H]+, m/z 445.120025) were 
used for real time internal mass calibration. 
For the acquisition has been used Xcalibur software (Thermo). 
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5.3.  Results. 
 
 
 
 
5.3.a.  Expression and purification of  V, V-C1 human s-RAGE by E. coli. 
 
 
5.3.a.1.  Cloning of the V-domain in E. coli. 
 
The V-domain of RAGE receptor was produced exploiting the E. coli Origami B (DE3) strain as 
intracellular recombinant protein by using the bacterial expression vector pET-15b. 
With the aim to develop the recombinant vector, the DNA fragment encoding the V domain was 
amplified by PCR and then cloned into the target vector. To do this the DNA fragment encoding for 
the V domain was amplified by PCR and cloned in frame into the vector pET-15b containing the 
sequence coding for the tag of 6 histidines (His-Tag) and the site cutting for Thrombin (LVPRGS), 
located on the N-terminus. The protein expression is controlled by the lac promoter. 
The recombinant vector pET-15b-V was used to transform the strain of E. coli Origami B (DE3). 
The strain E. coli Origami B (DE3) represents one of the most used expression host  strains to 
synthesize recombinant proteins in which disulfide bridges are present due too the fatc that 
mutations in the trxB/gor genes create an oxidant microenvironment leading the formation of 
disulfide bridges. 
The expression of the V-domain has been tested together with that of the domains V-C1 and 
sRAGE (V-C1-C2).The strains of E. coli Origami B (DE3) employed in this work and transformed 
with vectors pET-15b and pET-15b-VC1-sRAGE were kindly provided by Dr. G. Fritz. 
Here below is shown a schematic representation of the constructs used for the recombinant proteins 
production. 
 
 
 
 
 
218 
 
 
 
Fig 2.  Schematic representation of the fusion proteins constructs sRAGE, V-C1 and V obtained 
from the recombinant vectors. 
 
 
5.3.a.2.  Small-scale V-C1 expression and purification from E. Coli. 
 
E. coli cells were grown at 37 °C O.N. in LB 1% NaCl medium (Tab 2) and the following day the 
exhausted medium was replaced with LB-BUFFERED (Tab 2) and the temperature lowered at 25 
°C. When the optical density at 600 nm reached a value of 0.6 a.u., the protein expression was 
induced by adding IPTG to the medium culture at a final concentration of 0.5 mM. After 16 hours 
from the induction, the cells where broken down by ultrasonication and the protein purified. In 
order to obtain a soluble fraction containing all the soluble proteins of the E. coli, the total extract 
was centrifuged at 100.000 g for one hour at 4 °C. The purification was performed  by using the 
protocol previous reported in the section “Materials and Methods”. 
The purification of V-C1 was found very difficult to achieve due to the ability of the protein to bind 
DNA fragments as reported by the UV spectrum of the protein where the characteristic peak at 280 
nm referred to proteins was masked by a much wider peak with a maximum of absorption at 260 
nm  representing the characteristic peak of nucleic acids. This feature, combined with the 
considerable degree of protein precipitation,  make the purification of the V-C1-His domain very 
difficult to be achieve. 
The Fig 3 displays the SDS-PAGE analysis performed to verify the V-C1 expression. The protein 
expression was verified and compared with the total extract sample of E. coli cells. 
The SDS-PAGE analysis carried out by a 16% polyacrylamide gel shows that the addiction of 
IPTG has effectively favored the protein expression. In fact, while the lane 2 doesn‟t display any 
visible band at the molecular weight relative to the V-C1 domain, lane3 which is relative to the 
cells added with IPTG shows the expected band. A further confirmation of the protein expression is 
the presence of the protein in the soluble fraction from the total extract (lane 4). 
Purification of the protein by Ni-NTA resin was found effective as shown by the lanes in the SDS 
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PAGE which show the purified protein and the removal of cell proteins. 
 
 
 
Fig 3.   SDS-PAGE stained with Coomassie to verify V-C1-his domain from E. Coli expression and 
purification. The arrow indicates the VC1-His (26 kDa) position. -IPTG and + IPTG indicate the 
absence or presence of the inductor IPTG, SOL: soluble fraction, Ni-NTA ELUTION FRACTION: 
fractions eluting from the resin by adding imidazole 250 mM. 
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The data of V-C1-His yield after column passage showing high levels of purification, are reported 
in Tab 4. 
 
 OD600 ml culture OD total Mg protein Mg protein/OD600 
VC1-HIS 1,4 500 700 3,9 0,0055 
 
Tab 4.  V-C1-His protein purification yield. 
 
The second part of the protein purification process was focused on the His-Tag  removal from V-
C1 fusion protein. The protein purified by the Ni-NTA resin underwent a thrombin treatment at 25 
°C for 3 hours. At the end of this step, with the purpose of verify the correct protease cut, an 
Immunoblotting analysis was performed by using an Anti-polyHis monoclonal antibody which is 
selective towards the 6 polyhistidines tag linked to the fusion protein. 
Fig 4 shows a direct comparison between the protein before and after the treatment with thrombin. 
The Ponceau staining shows the protein in both the lanes while the Western blot analysis reveals 
the spot only in the lane relative to the His tag protein but not after trombin treatment thus 
confirming the enzymatic cut of the polyhistidin moiety 
 
 
 
Fig 4. VC1 and VC1-His Western blot analysis performed to verify the thrombin photolytic cut. 
The staining with Ponceau, in the bottom panel, confirms the presence of the VC1 protein 
characterize by  a lower molecular weight in respect with the corresponding His-Tag fusion 
protein. 
 
The protein fraction resulting from the enzymatic cut of the polyhistidin moiety was reloaded on a 
Ni-NTA resin for a second step in batch purification in order to separate the V-C1 fraction from the 
VC1-His-Tag fraction not  properly digested. 
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5.3.a.3.  Large-scale V-C1 expression and purification from E. Coli. 
 
E. coli cells were inoculated into DYT medium (Tab 2) at 37 °C O.N. and the following morning 
the exhausted medium replaced with AM (Tab 2) lowering the temperature at 21 °C. After about 16 
hours of medium exchange, the cells were broken in the presence of DNase I. In order to obtain the 
soluble fraction containing all the soluble protein of the E. coli, the total extract was centrifuged at 
100.000 g for one hour at 4 °C. The purification was performed  by using the protocol previous 
reported in the section “Materials and Methods”. 
The pellet (insoluble fraction) and the supernatant (soluble fraction) were analyzed by SDS-PAGE 
(data not shown). The first part of the protein purification process was focused on the His-Tag  
removal from V-C1 fusion protein soluble fraction. Hence, after having joined the purified proteins 
collected from the Ni-NTA (about 70 mg) resin column, the fractions underwent to the thrombin 
treatment at 25 °C for 3 hours and reloaded on the nickel column to a collect the HIs-Tag protein 
free. 
A final purification using a a size exclusion chromatography was then performed. 
The yield of the process is quite low due to the abundant protein precipitation. Starting from an 
amount of purified VC1-His of almost 70 mg of fusion protein, 5 mg of purified protein was 
obtained in the last purification step. 
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5.3.b.  Mass spectrometry analysis focused on RAGE-ligand interactions. 
 
 
5.3.b.1.  V-C1 domain and known ligands ESI-MS analysis. 
 
The first step of the MS analysis of the recombinant RAGE was addreesed to determine the MW 
and the primary sequence of the protein. The MW of the protein was determined in top-down mode 
and in denaturating conditions. Fig 6 shows the typical multicharged ion spectrum of RAGE and 
Fig 5 the deconvoluted spectrum. The MW of 24580 Da as well as the isotopic pattern well match 
the simulated ones thus confirming the identity of the protein. 
 
 
 
Fig 5.  A) Deconvoluted spectrum of V-C1 from experimental analysis.  B) Theoretical 
deconvoluted spectrum of V-C1 calculated from the amino acidic structure. 
 
 
 
 
A 
B 
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The sequence of the protein was then determined by a bottom-up approach which consists in the 
enzymatic digestion of the protein following by the separation of the resulting peptides through a 
reverse phase chromatography. The eluted peptides were sequenced by a nano LC-ESI MS/MS. 
The primary sequence of VC1 was in agreement with the nucleotide sequence of the protein with a 
coverage of the sequence higher than 85%. 
 
 
 
 
Fig 6.  A) LC-MS/MS chromatogram trace of V-C1 protein. B)V-C1 amino acids sequence. In red 
are reported the peptides mapped on the amino acids sequence deduced from the V-C1 nucleotide 
sequence. 
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5.3.b.2.  RAGE-ligand interaction study by native ESI-MS: set-up of the method. 
 
MS analysis in native conditions was used to study the protein–ligand interaction. The first step 
was to optimize the experimental conditions and the mass spectrometer source parameters in order 
to maintain the protein in the native state during the ESI source ionization, a condition that is 
required in order to maintain the protein in a proper conformation state required for the ligand 
engagement and to maintain stable the protein-ligand complex. 
 
Besides MS and ESI optimization, a further  key factor for obtaining a suitable mass spectrum 
characterized by a suitable signal/noise ratio regards the buffer selection, the desalting step and the 
protein concentration. 
Unfortunately, most of the common buffers used for protein purification and storage are not 
compatible with ESI-MS techniques due to the presence of not-volatile salts; in particular the salts 
represent the major problem in mass spectrometry, causing instrument sedimentation, that occur 
during the sample desolvation which is require for the entire molecule transfer to the gas phase. 
Furthermore, the proteins tend to form electrostatic complexes with several cations derived from 
alkali metals, causing the appearance of high molecular weight cluster larger than the free protein, 
thereby reducing the intensity of signal. Moreover, the presence of salts and impurities can lead to 
the ion suppression and thus to a further signal reduction. 
Hence, to allow the data acquisition the buffer exchange was required as initial step and therefore, 
the protein was exchanged in ammonium acetate which is a volatile buffer very common in ESI-
MS experiments. Ammonium acetate permits that the adduct formed between protein and ions such 
as sodium and potassium are readily exchanged by ammonium ions, which evaporate during the 
ESI process leaving the protein without saline adducts. The buffer exchange allowed obtaining not 
only a more intense signal, but also a more simplified mass spectrum which is  therefore better 
interpretable. Nevertheless, the ammonium acetate buffer concentration was required to be 
carefully balanced according to the target protein. 
In this respect different ammonium acetate concentrations were tested and in particular: 100 mM, 
75 mM, 50 mM, 25 mM and 10 mM. The effects of buffer concentration on the mass spectra of 
VC1 domains are in figure x shown. 
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Fig 7. Effects of ammonium acetate concentrations on the VC1 mass spectra. The protein 
concentration was maintained constant and equal to10uM.. 
 
As shown by the ESI-MS spectra reported in Fig 7, the buffer concentration affected both the signal 
intensity and the peaks broadening and the ammonium acetate concentration of 50 mM was found 
the most suitable concentration in regards to both the two parameters. 
The second step consisted to optimize the protein concentration and the effect of this parameter on 
the signal intensity is shown in Fig 8.  
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Fig 8.  Effect of protein concentration on the signal intensity of V-C1. 
 
A quite linear correlation was found between the protein concentration and the signal intensity and 
the concentration of 10 µM was found a good choice in order to get a suitable signal/noise ratio 
with the lowest protein consumption. 
The next step was to optimize the ESI parameters and in particular the temperature and the 
ionization voltage. Fig 9 shows the effect of the temperature on VC1 spectra. 
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Fig 9.  Effect of ESI source temperature on the V-C1 spectra acquisition.. 
 
As a general aspect the optimization of the temperature represents a critical step in native ESI-MS 
experiments since it should remain as low as possible in order to maintain the protein in a native 
condition but at the same time it should be able to suitable desolve the protein. As shown in Fig 9, 
at low temperatures, below 100 ° C, the peak ions resulted particularly broad, due to the fact that 
the molecules are in a solvated form. A satisfactory desolvation was reached setting the ESI 
temperature at 150 ° C. 
Fig 10 shows the ESI-MS spectra of RAGE recorded in denaturating and non-denaturating 
conditions. It is quite clear that in denaturating conditions, the peak ions are characterized by lower 
m/z values and hence by a higher charges state in respect to the peak ions recorded in non-
denaturating conditions. This is due to the fact that in denaturating conditions the protein is in a 
unfolded state and hence the basic residues, which are more exposed to the solvents, are easily 
protonated, leading the formation of high charge state ions. By contrast, when the protein is in a 
native state it is folded and the basic residues are not exposed to the solvents and this leads to less 
charge state ions. 
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Fig 10.  A) V-C1 ESI-MS spectrum recorded in denaturing conditions.  B) V-C1 ESI-MS spectrum 
recorded in native conditions after the parameters set-up. 
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5.3.b.3.  Set-up of an automated output screening ESI-MS method for V-C1-ligand 
binding. 
 
The next step was to set-up and validate an ESI-MS method for studying the VC-1 ligand 
interaction and to calculate the dissociation constant. 
The carboxymethylated and carboxyethylated derivatives of the peptides DEFKADE and 
FKDLGEE, in which the lysine residues are modified by the addition of carboxymethyl and 
carboxyethyl moiety, previously reported to act as RAGE ligands,were used as known ligands for 
the binding studies and to validate the approach. The amino acid sequence of the peptides was 
derived from the primary glycation sites of human serum albumin (HSA).  
The peptides with the same amino acid sequence but containing the lysine residue is unmodified 
state were used as negative control. 
 
The spectra of the two series of modified peptides recorded in denaturing experimental conditions 
are reported here below. 
 
 
 
Fig 11.  MS Spectra of DEFKADE series recorded in denaturating conditions:  the upper spectrum 
is relative to theCML-modified peptide, below that relative to the CEL-modified peptide and in the 
bottom  the spectrum relative to the unmodified peptide. 
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Fig 12.  Spectra of FKDLGEE series in denaturation conditions: the upper spectrum is relative to 
the CML-modified peptide, below that relative to the CEL-modified peptide and in the bottom  the 
spectrum relative to the unmodified peptide. 
 
 
The complete automation of the method for the sample injection associated with the mass spectra 
acquisition was needed to allow in a short time a quick spectra acquisition. To get this goal it was, 
therefore, set up a 96-well plate in which, after having been allocated the same amount of VC1 (10 
mM) in each well, were added the different peptides species by keeping different stoichiometric 
ratios with respect to VC1. The experimental procedure just described allowed to calculate the Kd 
values derived from the V-C1-ligands binding. 
After the sample incubation, performed at 25 °C and directly managed into the thermostated 
autosampler, 10 µl of  each reaction was withdrawn from each well at established time by the 
operator with a gap of 6 minutes and injected into the mass spectrometer to be analyzed. 
The mass spectra related to the V-C1 incubation with the DEFKADE series peptides in a 1:10 ratio 
are here below reported (Fig 13, 14, 15). 
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Fig 13.  A) Multicharged spectrum relative to the V-C1-DEFKADE CML-modified bond incubated 
at t=0. B) Deconvoluted zoom spectrum of A (calculated by the Xtract software). 
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Fig 13 panel A shows the MS spectrum of the reaction mixture containing VC-1 incubated in the 
presence of DEFKADE CML-modified peptide at a 10:1 molar ratio. The peak ion series relative to 
the VC-1 and to the peptide are well evident. Fig. 13 panel b shows the deconvoluted spectrum 
reporting a peak cluster relative to the free VC-1 as well as a cluster at higher MW and shifted by 
almost 910 Da which can be attributed to the non-covalent complex between VC-1 and the 
modified peptide. The MS spectrum was acquired immediately after mixing the protein with the 
ligand indicating that the complex forms immediately and did not increase in respect to time. 
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Fig 14.  A) Multicharged spectrum relative to the V-C1-DEFKADE CEL-modified bond incubated 
at t=0. B) Deconvoluted zoom spectrum of A (calculated by the Xtract software). 
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Also in the case of the MS spectrum relative to the mixture containing V-C1 and DEFKADE CEL-
the clusters relative to the protein and peptide in free form can be observed. The deconvoluted 
spectrum shows the peak ion relative to the free protein as well as that attributed to the non-
covalent complex and with a relative intensity below 5%. 
 
 
Fig 15.  A)Multicharged spectrum relative to the V-C1-DEFKADE unmodified bond incubated at 
t=0  B) Zoomed  spectrum of A relative to the ion z= 12 (calculated by the Xtract software). 
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Fig. 15 shows the MS spectrum of VC-1 incubated in the presence of the native peptide. Besides 
the clusters relative to the protein and peptide, also in this case the deconvoluted spectrum shows a 
cluster ion attributed to the non covalent complex but characterized by a lower relative intensity in 
respect to that observed when the CEL or CML peptides were used. The data indicate that the 
peptide as such binds to the VC-1 and that the CML and CEL modification significant increases the 
affinity. 
 
Dissociation constant (Kd) of the complexes were then determined by titration experiments, 
consisting to calculate the relative abundance of the complex in respect to the different 
concentrations of the ligands and maintaining the concentration of the protein at a constant level. 
The following equations were used for the Kd calculation: 
 
 
 
As an example Fig 16 shows the titration experiments of the peptide DEFKADE-CEL incubated 
with the protein at the following molar ratio (protein:peptide):1:1, 1:5, 1:50, 1:100 (Fig 16). 
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Fig 16.  Monocharged deconvoluted spectra relative to the V-C1 incubated with DEFKADE-CEL 
modified peptide  incubated at different stoichiometric ratios. 
 
It is well evident a dose-dependent increase of the relative concentration of the non-covalent 
complex. 
The values of Kd obtained by using the titration experiments are shown in table 17 and well 
indicate that for both the peptides, those characterized by the CML and CEL moiety have greater 
affinity in respect to the native ones. Moreover the Kd were found not significantly different in 
respect to those determined by quenching fluorescence experiments thus indicating that the MS 
method is a reliable approach for studying RAGE-AGEs interaction. 
 
 
 
 
 
 
 
 
 
237 
 
Binding affinities of the CML/CEL peptides for 
the wild type and mutants of V domain.
Dissociation constant was obtained by fitting 
fluorescence titration data with a single site 
binding isotherm.
Xie et al. Structure 2011
Method validation by determining the Kd of known ligands
 
 
Tab 17.  Kd values related to the binding activity of V-C1 incubated in the presence of DEFKADE 
and FDKLGEE series. 
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5.4.  Conclusion. 
 
 
In conclusion the high resolution ESI-MS method here reported is suitable to detect V1-C1 RAGE 
portion-ligand complexes and to determine accurate Kd. The method we set up is suitable to test a 
library of peptides bearing a variety of AGEs modifications including imidazolinone, methyl-
imidazolinone, and the Michael adducts with alfa,beta-unsaturated aldehydes, in order to 
understand the structure requirements for RAGE recognition. 
Furthermore, in view to a drug discovery approach aimed to identify RAGE antagonist, the method 
here proposed is suitable to screen libraries in order to identify RAGE ligands. 
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